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P R E F A C E  
This cumulative dissertation comprises four studies investigating pain processing within the 
human brain. A short overview of these studies is provided on page 7. From here on, the four 
studies are referred to as Studies 1, 2, 3 and 4 in chronological order, starting with the latest. All 
studies have been published in peer-reviewed journals within the last four years. All manuscripts 
are reproduced in their last pre-print version with permission from the publishers. All 
manuscripts were adapted to the formatting and orthography recommended by the Publication 
Manual of the American Psychological Association (2010) for consistency. 
The four separate reference sections were integrated into one bibliography at the end of the 
thesis. Tables, figures and appendices were renumbered. Otherwise the manuscripts were not 
changed. 
A number of people have made this work possible. They are given due credit on page 5. The 
contributions of co-authors to the four studies are further detailed on page 8. My colleagues and 
I have completed a number of related studies during my doctoral studies, which are not included 
in this dissertation, but worth mentioning: 
• In parallel with Study 1, we investigated the effects of oxytocin on emotional pain 
modulation and its brain correlates. The study is currently in preparation for publication. 
• In parallel with Study 2, we assessed the effects of exam stress on sleep and legal drug 
consumption. The results have been submitted for publication, but do not match the 
topic of this dissertation and were therefore not included. 
• Before Study 3, we completed and published an experiment testing the effects of 
acupuncture on motor system excitability (Zunhammer, Eichhammer, Franz, Hajak, & 
Busch, 2012). Main contributor was Dr. med. Johanna Franz, who also wrote her 
doctoral thesis on the topic. 
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Ich erkläre hiermit an Eides Statt, dass ich die vorliegende Arbeit ohne unzulässige Hilfe Dritter 
und ohne Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Die aus anderen 
Quellen direkt oder indirekt übernommenen Daten und Konzepte sind unter Angabe der Quelle 
gekennzeichnet.  
Bei der Auswahl und Auswertung des Materials haben mir die auf der Seite 8 aufgeführten 
Personen in der jeweils detaillierten Weise unentgeltlich geholfen. Weitere Personen waren an der 
inhaltlich-materiellen Erstellung der vorliegenden Arbeit nicht beteiligt. Insbesondere habe ich 
hierfür nicht die entgeltliche Hilfe von Vermittlungs- beziehungsweise Beratungsdiensten 
(Promotionsberater oder anderer Personen) in Anspruch genommen. Niemand hat von mir 
unmittelbar oder mittelbar geldwerte Leistungen für Arbeiten erhalten, die im Zusammenhang 
mit dem Inhalt der vorgelegten Dissertation stehen. 
Die Arbeit wurde bisher weder im In- noch im Ausland in gleicher oder ähnlicher Form einer 
anderen Prüfungsbehörde vorgelegt.  
Ich versichere an Eides Statt, dass ich nach bestem Wissen die reine Wahrheit gesagt und nichts 
verschwiegen habe. Vor Aufnahme der obigen Versicherung an Eides Statt wurde ich über die 
Bedeutung der eidesstattlichen Versicherung und die strafrechtlichen Folgen einer unrichtigen 
oder unvollständigen eidesstattlichen Versicherung belehrt. 
 
Die Eidesstattliche Erklärung zu dieser Dissertation wurde in Regensburg am 14.05.2014 von 
Matthias Zunhammer gegeben und vom Fakultätsverwalter Peter Grimm aufgenommen. Die 
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A B S T R A C T  
The available means to control human pain are insufficient, novel mechanisms of pain 
modulation must be explored and understood. This cumulative dissertation comprises four 
studies, which explored potential means to modulate pain in the central nervous system. An 
overview on the current understanding of pain, its basic mechanisms, and its known modulators 
is provided. 
Study 1 tested if a high intranasal dose of the neuro-hypophyseal hormone oxytocin affected 
perception and processing of thermal pain in 36 healthy male volunteers. Experimental pain 
thresholds were obtained and a functional Magnetic Resonance Imaging experiment with ratings 
of noxious heat was conducted. Oxytocin was found to reduce ratings of perceived heat intensity 
and amygdala activity. Both effects were small and independent of temperature. Although the 
hypothesis of an antinociceptive effect of oxytocin could not be confirmed, the study provides 
first evidence for effects of oxytocin on thermal stimulus processing. 
Study 2, a longitudinal questionnaire study, examined the effects of a period of academic exam 
stress on bodily symptoms in 150 students. Various symptoms of pain, as well as gastro-intestinal 
and autonomic complaints were found to increase during exam stress. Neuroticism, but not 
alexithymia, trait anxiety, or depression explained symptom increases under exam stress. Study 
two offers the first comprehensive, quantitative description of bodily symptoms under exam 
stress. Neuroticism was identified as a potential predisposing personality factor for the 
occurrence of bodily symptoms under stress. 
Study 3 aimed at elucidating physiological mechanisms behind the proposed antinociceptive 
effects of slow breathing exercises in 20 healthy participants. Breathing frequency, heart rate 
variability, and hyperventilation were not found to predict changes in experimental pain 
thresholds or heat pain ratings. A correlation between heart rate at baseline and pain ratings 
could be observed, confirming that autonomic nervous system function and pain are intertwined. 
Study 4 explored and tested if and how repetitive transcranial magnetic stimulation (rTMS) over 
the cerebellum affected thermal pain thresholds in two separate experiments. Although pain-
relieving effects of cerebellar rTMS could be found in a first experiment, the second experiment 
showed that these effects were driven by peripheral mechanisms and/or the placebo effect. The 
study highlights the importance of proper experimental control conditions when investigating 
central modulators of pain. 
In a concluding discussion, the current methodology of pain research is reviewed. The methods 
used for this dissertation are discussed and limitations are identified; findings are summarized and 
further directions of research are highlighted. 
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I N T R O D U C T I O N  
Rationale, aims and hypotheses 
All studies of this thesis have a common motivation: The World Health Organization (2011) 
ranks “back and neck pain” as the 4th leading cause of disability adjusted life years in Europe. 
Chronic pain is a burden for the individual sufferer and the social welfare systems. Most patients 
are diagnosed with idiopathic pain, i.e. pain of unknown physiological cause (McMahon & Wall, 
2013, pp. 233–247). A considerable proportion of surgery patients suffer from chronic pain long 
after the acute recovery phase (Perkins & Kehlet, 2000). The available pharmacological and non-
pharmacological treatments are limited in their effectiveness and leave many non-responders with 
insufficient relief of pain (Moore, Derry, & Wiffen, 2013). Despite evidence suggesting that 
chronic pain is influenced by behavior, beliefs, emotions, motivation, and stress (Gatchel, 
Polatin, & Kinney, 1995; Wiech & Tracey, 2013) the psychological aspects of pain are complex 
and insufficiently understood. In this situation the study of central pain modulators can help to 
comprehend the mechanisms of pain and thus help to develop new and better treatments. The 
present dissertation is concerned with mechanisms of pain modulation from a neuropsychiatric 
perspective and a focus on stress-related phenomena. Four means of pain modulation were 
investigated: 
• Study 1, the main study of this thesis, was employed to test a novel pharmacological 
approach: Intranasal oxytocin has been shown to modulate stress, anxiety, and social 
cognition in a multitude of studies (Guastella & MacLeod, 2012; Kubzansky, Mendes, 
Appleton, Block, & Adler, 2012). Oxytocin was repeatedly found to affect amygdala activity 
(Bethlehem et al., 2013). Moreover, Rash, Aguirre-Camacho, & Campbell, (2013) recently 
suggested that oxytocin might have antinociceptive actions, based on a review of animal and 
human results. 
Study 1 tested if the hormone oxytocin, given as a nasal spray has antinociceptive effects. 
Effects of oxytocin within the brain were investigated by functional magnetic resonance 
imaging (fMRI). We hypothesized that intranasal oxytocin should: 
a) increase noxious thermal pain thresholds; 
b) decrease ratings of noxious heat intensity and/or unpleasantness; 
c) alter blood oxygen dependent (BOLD) signal changes related to the processing of the 
thermal stimulus on whole brain level; 
d) alter stimulus processing in the amygdala. 
• Study 2 focused on the phenomenon of somatization, i.e. bodily complaints in response to 
psychosocial stress: This questionnaire survey investigated how academic exam stress impacts 
on reports of pain and other everyday symptoms in university students. In addition, 
personality factors contributing to the development of symptoms were assessed. 
Our aim was to provide a detailed quantitative description of somatic symptom increases 
under exam stress. We hypothesized that symptoms of pain and other bodily complaints 
would increase during an exam period and return to baseline after a period without exams. 
We further aimed to compare the personality traits alexithymia, neuroticism, trait anxiety and 
depression with respect to their ability to explain increases in somatization under exam stress. 
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According to the stress-alexithymia hypothesis, a stronger association of somatization 
symptoms with alexithymia than with neuroticism, trait anxiety and depression was expected. 
• Study 3 followed up hypotheses on the mechanisms of slow breathing, a widespread 
alternative treatment for stress and pain control (Martin et al., 2012; Zautra et al., 2010): It 
was experimentally tested if breathing exercises modulate pain perception via breathing 
frequency, hyperventilation, or cardiac autonomic control, as suggested by Chalaye, Goffaux, 
Lafrenaye, & Marchand (2009). According to this hypothesis, measures of heart rate 
variability, such as the standard deviation of heart rate, were expected to explain a significant 
amount of variance in thermal pain thresholds and/or pain ratings. 
• Study 4 aimed to modulate pain perception experimentally by stimulating the cerebellum 
with repetitive Transcranial Magnetic Stimulation (rTMS). This non-invasive brain 
stimulation technique was previously shown to modulate thalamo-cortical excitability (Fierro 
et al., 2007). 
A two-step study was performed: Cerebellar target regions and frequencies of rTMS were 
explored for potential antinociceptive effects in a first experiment. Based on the results of the 
first experiment, it was hypothesized that 1 Hz stimulation over the lateral cerebellum would 
significantly decrease thermal detection and pain thresholds, compared to sham stimulation 
over the cerebellum and 1 Hz verum stimulation over the peripheral neck. A second 
experiment was then performed to test this hypothesis. 
Before these four studies are presented in detail, background information on the current 
knowledge on the processing of acute pain is provided. Information with relevance to the four 
studies of this dissertation will be highlighted in grey boxes. 
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Background 
The concept of pain anno 2014 
Pain is defined as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (International Association for the 
Study of Pain, 2002, p. 210). This definition implies that pain is not only a sensory but also an 
affective phenomenon with multiple dimensions, to which motivation, memory, and other 
cognitive processes must be added (Wiech & Tracey, 2013). The definition further underscores 
the subjective nature of pain, “which is always a psychological state, even though we may well 
appreciate that pain most often has a proximate physical cause” (International Association for the 
Study of Pain, 2002, p. 210). This definition pays regard to the fact that many disorders of pain 
are characterized by the lack of a detectable physiological cause and that “resultant pain is not 
necessarily related linearly to the nociceptive drive or input” (Tracey & Mantyh, 2007). Pain 
ultimately is a product of the brain and its function. 
Peripheral nociception 
The current definition of pain emphasizes the psychological nature of pain, but also 
acknowledges its usual bottom-up causes. Especially the understanding of the latter has advanced 
within the last decade: 
Transducer proteins are the sensors detecting harmful mechanical, thermal, and chemical signals 
on cellular level (for review see: Dubin & Patapoutian, 2010). These proteins are ion channels, 
located in the cellular membranes of so-called nociceptors, i.e. neurons dedicated to the 
perception of pain (for review see: Woolf & Ma, 2007). Transducer proteins are specifically 
located in the highly branched unmyelinated endings of nociceptors (Dubin & Patapoutian, 
2010). When activated, transducer proteins generate transient membrane potentials, which can 
cause neuronal discharge of the nociceptor (Dubin & Patapoutian, 2010). Accordingly, the main 
family of pain transducers was named “transient receptor potential” (TRP) channel family (Julius, 
2013). The existence of a machinery specific to pain detection rebuts the historical “intensity 
theory of pain” (Prescott & Ratté, 2012), which claimed that pain results from an 
“overstimulation” of somatosensory neurons rather than a distinct sensory machinery (e.g. 
Darwin, 1796; for review see: Mendell, 2013). 
 
Studies 1, 3 and 4 involved experimental heat and cold stimulation in the painful range. While 
the stimulation procedures were used to examine central pain processes, the following known 
TRP-family members were likely involved in mediating the observed effects in the periphery (for 
review see: McMahon & Wall, 2013, pp. 1–47): 
The “vanilloid” TRP channel subtypes TRPV3 and TRPV4 show optimal response 
characteristics below 43 °C and therefore might be responsible for the detection of non-noxious 
heat (Schepers & Ringkamp, 2010). Heat above this temperature is known to activate the 
subtypes TRPV1 and TRPV2, which are acknowledged transducers of heat pain (Julius, 2013; 
McMahon & Wall, 2013, pp. 1–47). For non-noxious cold the candidate transducers are the 
TRPV4 (again), and the “melastatin” TRP subtype TRPM8 (Schepers & Ringkamp, 2010). The 
“ankyrin” subtype TRPA1 has been suggested as the transducer for cold pain temperatures 
below 17 °C (Schepers & Ringkamp, 2010). Other proteins may play a role in noxious hot and 
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cold transduction as well, but are less understood, e.g. the transducer proteins of the potassium 
channel subfamily K (KCNK, also known as TREK/TRAAK), who have been shown to 
contribute to thermal pain perception, (Dubin & Patapoutian, 2010). 
Injuries and burns induce local sensitization within the skin. Immune cells, mast cells, 
keratinocytes, as well as nociceptors (Dubin & Patapoutian, 2010) of affected tissues release a 
noxious “soup” (Woolf & Ma, 2007), consisting of substances such as: hydroxonium ions (low 
pH), Adenosine triphosphate (ATP), glutamate, serotonin, bradykinin, interleukins, 
neurotrophins and prostaglandins (Mense, 2009). While some of these chemicals can directly 
activate transducers proteins and elicit nociceptor activation, most of them have a local 
sensitizing effect, especially when acting in combination (Julius, 2013; McMahon & Wall, 2013, 
pp. 1–47). The repeated and prolonged experimental thermal stimulation in Studies 1, 3 and 4 
might have caused such sensitization.  
Primary nociceptive neurons 
Nociceptors are pseudo-unipolar afferent neurons with soma located in the dorsal-root ganglia of 
the spinal cord that detect noxious signals within their receptive field and convey them to the 
central nervous system (CNS, Dubin & Patapoutian, 2010; McMahon & Wall, 2013, pp. 2–11). 
Two morphologically different nociceptive fiber classes can be found in humans: Small, 
myelinated nociceptive axons are classified as “Aδ-type”; they have conduction velocities 
between 5 and 30 m/s. Nociceptors with unmyelinated axons are classified as “C-type” and have 
relatively slow conduction velocities between 0.4 and 1.4 m/s (Dubin & Patapoutian, 2010). Both 
fiber types have been subject to several sub-classifications by researchers, according to target, 
function, and molecular features (McMahon & Wall, 2013, pp. 2–11). For brevity only the most 
prevalent sub-classifications are presented: Cutaneous nociceptors innervating the skin and 
visceral nociceptors innervating internal organs are target-specific sub-classifications (McMahon 
& Wall, 2013, pp. 2–11). Examples of function-specific sub-classifications are “mechano-
insensitive”, “heat-sensitive”, “heat-insensitive”, “cold-sensitive”, “cold-insensitive” and 
“polymodal” Aδ- and C-nociceptors (Ringkamp et al., 2001; Schepers & Ringkamp, 2010). 
Importantly, a mechano-sensitive C-fiber subtype not involved in nociception, but in the 
detection of gentle/social touch has been described (Olausson, Wessberg, Morrison, McGlone, 
& Vallbo, 2010). The main molecular classification divides Aδ-, as well as C-fibers, into 
“peptidergic” and “non-peptidergic” subgroups (Woolf & Ma, 2007). The peptidergic neurons 
contain neuropeptides like Substance P, calcitonin gene-related peptide (CGRP), and 
somatostatin; they are ontogenetically dependent of the Tropomyosin related kinase A (TrkA) 
pathway (Woolf & Ma, 2007). The non-peptidergic neurons do not produce neuromodulatory 
signaling-peptides in significant amounts and are ontogenetically dependent on the expression of 
a receptor tyrosine kinase “Ret” (Woolf & Ma, 2007). Differences of peptidergic and non-
peptidergic nociceptors in terms of target tissue innervation, signal relay in the spine, and 
transducer protein expression have been described, but are still a matter of ongoing research. 
(McMahon & Wall, 2013, pp. 6–7; Woolf & Ma, 2007) The fact that these classifications overlap 
and that these overlaps differ between model organisms (mouse, rat, cell culture, human), tissue 
types (glabrous skin, hairy skin, muscles vessels, viscerae), and even stimulation protocols (fast 
and slow ramping stimuli, high and low stimulus intensities) leads to a confusing picture 
(McMahon & Wall, 2013, pp. 2–11). An illustrative example is the often cited notion that Aδ-
fibers convey the “fast and sharp early pain” and C-fibers convey the “slow and burning pain” 
(Campbell & LaMotte, 1983): It is much less noted that the original report found this distinction 
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only for the hairy skin of the lower arm, but not for the glabrous skin of the hand (Campbell & 
LaMotte, 1983). Further, the distinction of “fast and early” and “slow and burning” was based on 
the transduction velocity of the fibers (Campbell & LaMotte, 1983). However, there are both 
slow- and fast-adapting C-fibers and Aδ-fibers, as well as Aδ-fibers with delayed-onset. 
(McMahon & Wall, 2013, pp. 2–11; Schepers & Ringkamp, 2010; Treede, Meyer, Raja, & 
Campbell, 1995) 
 
The experimental thermal stimulation in Studies 1, 3 and 4 most likely activated both Aδ- and 
C-fibers. Nociceptive signaling during the thresholding procedures may have been dominated by 
fibers with no latency, and low activation thresholds, since the stimuli involved were of short 
duration and low intensity. Slow-adapting, late onset fibers might have contributed to the pain 
rating procedures used in Studies 1 and 3, which involved prolonged stimulation. As discussed 
above, the relative contributions of Aδ- and C-fiber (sub-)types to the observed effects are 
difficult to judge. However, the use of repeated stimuli and of pre-conditioning stimuli for the 
pain rating procedures might have promoted C-fiber signaling over Aδ-fiber signaling according 
to Hashmi & Davis (2008). 
Spinal pain processing and descending brainstem control 
Aδ-fibers and C-fibers from the periphery do not project directly to the brain via axonal 
collaterals, like non-nociceptive afferents (McMahon & Wall, 2013, pp. 77–84), but connect with 
neurons in the dorsal horn of the spine 1 : Nociceptive C-fibers mainly terminate in 
laminae I and II of the dorsal horn, while nociceptive Aδ-fibers mainly terminate in 
laminae I, II and V; visceral nociceptors tend to connect to deeper laminae (McMahon & Wall, 
2013, pp. 77–84). Within the dorsal horn, primary nociceptors pass their signals on to 
interneurons and/or projection neurons (secondary nociceptive neurons) by releasing the 
excitatory neurotransmitter glutamate and signaling peptides such as Substance P (Millan, 2002; 
Todd, 2010). The interneurons accomplish an immediate, spinal-level pre-processing of the 
incoming nociceptive information (Todd, 2010). Around 30 % of them release inhibitory 
(GABA, glycine) neurotransmitters, while the others are thought to release excitatory (glutamate) 
neurotransmitters (Todd, 2010). The interneurons modulate the activity of primary nociceptive 
neurons, projection neurons, and other interneurons (McMahon & Wall, 2013, pp. 87–88). The 
axons of the projection neurons decussate to the contralateral spinal hemisphere and then project 
to the brain via the anterolateral system (Kandel, Schwartz, Jessell, Siegelbaum, & Hudspeth, 
2013, pp. 493–495). It is still a matter of dispute if the information from different nociceptor 
subtypes is relayed to the brain in a “labeled lines” fashion (specificity theory), or if information 
from different nociceptors is combined at spinal level first (combinatory theory, for a discussion 
see: Prescott & Ratté, 2012) 
A number of brainstem nuclei, such as the periaqueductal gray (PAG), the nucleus of the solitary 
tract (NTS), and the nucleus cuneiformis receive direct input from secondary nociceptive 
neurons (for review see: Todd, 2010; Tracey & Mantyh, 2007). These and other brainstem 
regions can provide modulatory feedback to the spinal level, e.g. modulation of spinal presynaptic 
primary and postsynaptic secondary nociceptor activity can be achieved by descending 
                                                
1 Cranial nerves terminate in homologous regions of the trigeminal nucleus of the brainstem. 
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projections from the nucleus raphe (serotonin), the locus coeruleus (norepinephrine), and most 
importantly the rostral ventro-medial medulla (GABA, for review see: Millan, 2002). 
The majority of projection neurons relay their information to the ventral posterio-lateral 
thalamus and other posterior thalamic nuclei (Millan, 2002; Gauriau & Bernard, 2004). These 
thalamic nuclei have been suggested to convey the sensory-discriminative domain of pain 
(Gauriau & Bernard, 2004). Further, intra-laminar nuclei of the thalamus receive nociceptive 
input and were suggested to mediate arousal and motivation (Gauriau & Bernard, 2004). Besides 
the thalamus, two other forebrain structures receive direct input from secondary nociceptive 
neurons: The amygdala and hypothalamus (Millan, 2002). These connections are thought to 
mediate pain-related emotional and autonomic reactions, consistent with the central roles of 
these regions in anxiety and bodily homeostasis (Millan, 2002). 
 
The magno- and parvo-cellular nuclei of the paraventricular hypothalamus are the main source 
of oxytocin in the body (Lee, Macbeth, Pagani, & Young, 2009). From here, oxytocinergic 
neurites project to the posterior pituitary gland, diverse brain regions and the spinal cord (Lee, 
Macbeth, Pagani, & Young, 2009). The projections to the spinal cord have been suggested to be 
involved in anti-nociception in animal studies (Millan, 2002; Rash et al., 2013). Following 
intranasal application, oxytocin and other neuropeptides were found in increased amounts 
within the cerebrospinal fluid at spinal level (Born et al., 2002; Striepens et al., 2013). The 
modulation of spinal nociceptive signalling therefore poses one potential mechanism of action 
of intranasal oxytocin in Study 1. 
Stress is partly mediated by the autonomic nervous system (ANS), with its antagonistic 
sympathetic and parasympathetic branches. Especially the sympathetic branch is known as a 
potent modulator of pain perception (Millan, 2002). Of the brain regions known to control the 
sympathetic branch, almost all receive direct or indirect nociceptive input from spinal levels: The 
hypothalamus, the NST, the parabranchial nucleus, the locus coeruleus, and the ventrolateral 
medulla (compare: Kandel, Schwartz, Jessell, Siegelbaum, & Hudspeth, 2013, pp. 1069–1076 and 
Millan, 2002). These regions can directly modulate pain perception via descending noradrenergic 
fibers (locus coeruleus) and via controlling the spinal intero-mediolateral cell column, which in 
turn modulates spinal pain processing via noradrenergic signaling (Millan, 2002). Further, 
sympathetic effectors can impact on pain via systemic effectors, e.g. epinephrine release from 
the adrenal medulla, which can modulate inflammatory processes at peripheral and visceral sites 
(Dhabhar, 2009). These and other interactions of ANS control and pain processing might 
underlie the symptoms reported by our participants in Study 2. 
The nervus vagus is a main source of pre-ganglionic parasympathetic effector neurons (Kandel, 
Schwartz, Jessell, Siegelbaum, & Hudspeth, 2013, pp. 1069–1076). Its pre-ganglionic axons 
originate from a system of brainstem nuclei: (1) the dorsal vagal motor nucleus (2) the nucleus 
ambiguus, (3) the NTS, and (4) the spinal part of the trigeminal nucleus (Kandel et al., 2013, 
p 1025). The NTS not only receives secondary nociceptor input, but is also part of the dorsal 
respiratory group and gathers information from pulmonary stretch receptors (Kandel et al., 
2013, p 1032). Due to the anatomical co-localization a modulatory effect of breathing on pain-
related processes in the NTS seems plausible. Moreover, breathing exercises were hypothesized 
to modulate ANS activity through cardiac vagal control (Chalaye et al., 2009), which is 
coordinated centrally in the dorsal vagal motor nucleus and the nucleus ambiguus. Study 3 was 
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designed to test whether breathing frequency, or autonomic cardiac control are related to the 
proposed efficacy of breathing exercises as a behavioral intervention for pain relief. 
Pain processing in the forebrain 
Corresponding to the multidimensional nature of pain, not one, but several cerebral regions are 
thought to underlie pain processing (Tracey, 2008). The thalamus distributes nociceptive 
information to the cortex. Main targets of nociceptive input from the thalamus are the insula, the 
somatosensory cortices I and II (SI, SII), as well as the cingulate cortex (McMahon & Wall, 2013, 
pp. 111–128). Further, prefrontal areas–e.g. the dorsolateral prefrontal cortex (DLPFC)–
supplementary motor areas, basal ganglia, and the cerebellum (Duerden & Albanese, 2013) are 
thought to play a role in pain processing. All of these regions could be identified by neuroimaging 
studies (for review see: Apkarian, Bushnell, Treede, & Zubieta, 2005; Duerden & Albanese, 2013) 
and were termed in the past as the “pain matrix” (May, 2007). Attempts have been made to 
establish functional subdivisions of the pain matrix (May, 2007; Iannetti & Mouraux, 2010): e.g. 
brain regions have been divided into a “medial pain system” (medial/intralaminar thalamic nuclei, 
anterior cingulate cortex, amygdala, and hypothalamus) and a “lateral pain system” (ventral 
posterolateral thalamus, SI, and SII). The medial system has been suggested to mediate affective, 
motivational and somatic aspects of pain, while the lateral system has been suggested to process 
discriminative and sensory aspects of pain (May, 2007; Iannetti & Mouraux, 2010). The insula 
was proposed to be part of both systems (May, 2007). However, the term pain matrix has been 
criticized: According to Iannetti & Mouraux (2010) the concept is ill defined and has been 
interpreted differently by different authors. Iannetti & Mouraux (2010) particularly question if all 
brain regions identified in neuroimaging studies are pain-specific and necessary for the pain 
experience, as implied by the term “pain matrix”. This view is supported by a meta-analysis of 
Cauda et al. (2012). 
Nevertheless, for most regions commonly associated with pain in neuroimaging studies specific 
functional hypotheses have been proposed: SI and SII are thought to process location, 
controllability, and intensity of painful and non-painful somatosensation (Helmchen, Mohr, 
Erdmann, Binkofski, & Büchel, 2006; Mazzola, Isnard, & Mauguière, 2006; McMahon & Wall, 
2013, pp. 112-118). The insula has been suggested to serve as a monitor of bodily states and to be 
involved in magnitude estimation per se (Sterzer & Kleinschmidt, 2010). The insula has also been 
suggested to specifically code pain intensity and contribute to affective pain processing (Baliki, 
Geha, & Apkarian, 2009). The posterior cingulate cortex has been suggested to coordinate 
immediate motoric responses to pain via the supplementary motor area, whereas the anterior 
cingulate cortex is thought to be involved in affective pain processing and pain-related decisions 
(McMahon & Wall, 2013, pp. 112-118). Finally, higher cognitive modulation of the pain 
experience has been located in the DLPFC and the orbitofrontal cortex (Krummenacher et al., 
2010; Wiech & Tracey, 2013). 
Modulators of central pain processing 
“Central pain modulation”, in the sense of this thesis, is an umbrella term covering any internal 
and external mechanism affecting the processing of pain in the CNS. The term includes external 
and internal pharmacological, as well as cognitive, affective, and autonomic mechanisms. Since 
the means of central pain modulation are tantamount, only a few examples for established 
effectors on central pain processing are provided here. 
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The most prominent pharmacological modulators of central pain may be opiates, cannabinoids 
and substance P, which have been shown to play a relatively specific role in pain processing 
(McMahon & Wall, 2013, pp. 375–401). However, many “classic” neurotransmitters, like 
glutamate, GABA, glycine, dopamine, serotonin, and acetylcholine are also an integral part of the 
pain signaling pathways (McMahon & Wall, 2013, pp. 375–401). Further, hormones, 
neuromodulators and immune signals, such as vasopressin, oxytocin, cholecystokinin (CCK), 
TGF-beta, and histamine have been shown to have a modulatory effect on pain (Millan, 2002). 
Most of the substances have been found to influence pain processing at multiple levels of the 
nociceptive pathway: the periphery, the spine, the brainstem, and/or the forebrain (McMahon & 
Wall, 2013, pp. 375–401; Millan, 2002). 
Examples for cognitive modulators of pain experience are attention, expectation (Buhle, Stevens, 
Friedman, & Wager, 2012), the placebo effect (Krummenacher, Candia, Folkers, Schedlowski, & 
Schönbächler, 2010), hypnotic suggestions (Rainville, Carrier, Hofbauer, Bushnell, & Duncan, 
1999), (perceived) control over pain (Helmchen, Mohr, Erdmann, Binkofski, & Büchel, 2006; 
Salomons, Johnstone, Backonja, Shackman, & Davidson, 2007), social context (Aslaksen, 
Myrbakk, Høifødt, & Flaten, 2007; Jackson, Iezzi, Chen, Ebnet, & Eglitis, 2005), catastrophizing, 
memory, motivations, and goals (Read & Loewenstein, 1999). Prefrontal areas, especially the 
anterior cingulate cortex, DLPFC (Krummenacher et al., 2010), and the orbitofrontal cortex are 
considered to be involved in these higher order, top-down modulatory influences on pain (for 
review see: Wiech & Tracey, 2013). 
The affective modulation of pain has been extensively studied, e.g. by using facial pictures 
(Heckel et al., 2011), scenes (Meagher, Arnau, & Rhudy, 2001), film sequences (Loggia, Mogil, & 
Bushnell, 2008), odors (Villemure & Bushnell, 2009), music (Roy, Peretz, & Rainville, 2008), and 
emotional narratives (Mayer, Allen, & Beauregard, 1995). Generally emotional content of 
negative valence has been found to increase pain, while positive emotional material has been 
found to decreased pain (Wiech & Tracey, 2009). However, when occurring in high intensities, 
negative emotions, anxiety, and stress have also been reported to exert an antinociceptive effect, 
which might be an advantageous adaption for fight-or-flight situations (Wiech & Tracey, 2009). 
 
Oxytocin has been shown to modulate emotional processing (Di Simplicio, Massey-Chase, 
Cowen, & Harmer, 2009; Domes et al., 2009) and emotional processing is known to be a central 
component of pain (Wiech & Tracey, 2009). Oxytocin has repeatedly been shown to be a 
modulator of pain in animals (Rash et al., 2013). Spinal mechanisms, as well as opioid effects, 
have been hypothesized (Rash et al., 2013). Interestingly, oxytocin receptors are found in high 
densities within several pain processing regions in human brain samples (compare: Duerden & 
Albanese, 2013 and: http://human.brain-map.org, last seen: 01.03.2014, for reference see: 
Hawrylycz et al. 2012). Main motivation for Study 1 was that more controlled human trials 
investigating the role of oxytocin in pain are necessary, since there are only a few preliminary 
human studies on the topic (for review see: Rash et al., 2013). 
Psychosocial stress has been shown to exacerbate experimental pain (Crettaz et al., 2013) and 
might be an important factor in the development of chronic pain (Van Houdenhove, 2000). 
Besides the effects of stress on the ANS, higher brain functions like stress coping (Koh, Choe, 
Song, & Lee, 2006), attention to bodily states (for review see: Van Damme, Legrain, Vogt, & 
Crombez, 2010), and personality traits (Pud, Eisenberg, Sprecher, Rogowski, & Yarnitsky, 2004) 
might be involved. Therefore one aim of Study 2 was to identify personality traits predicting the 
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occurrence of symptoms under stress. 
Study 3 aimed to determine if and how breathing exercises affect pain processing at brainstem 
level. However, alternative hypotheses had to be considered, which involved higher brain 
function: Distraction and attention-related processes, the placebo effect (Buhle et al., 2012), and 
relaxation (Busch et al., 2012) had to be considered as alternative explanations for the effects of 
breathing exercises on pain perception. 
The cerebellum has been found to be involved in pain processing, but its exact role is still 
cryptic (Moulton, Schmahmann, Becerra, & Borsook, 2010). Study 4 explored whether 
repetitive rTMS over the cerebellum could modulate experimental pain thresholds. A preceding 
study showed that cerebellar rTMS affects measures of thalamo-cortical excitability (Langguth et 
al., 2008). As the thalamo-cortical connections are an integral part of the pathway for pain, it was 
hypothesized that rTMS over the cerebellum might influence pain perception. 
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This is a pre-copy-editing, author-produced version of an article accepted for publication in Psychosomatic Medicine 
(16.10.2014) after peer review. © 2014 American Psychosomatic Society, Lippincott Williams & Wilkins. 
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Abstract 
OBJECTIVE: Intranasal oxytocin has been shown to affect human social and emotional 
processing, but its potential to affect pain remains elusive. This randomized, placebo-controlled, 
double-blind, crossover trial investigated the effect of intranasal oxytocin on the perception and 
processing of noxious experimental heat in 36 healthy male volunteers. 
METHODS: Thermal thresholds were determined according to the Quantitative Sensory 
Testing (QST) protocol. A functional Magnetic Resonance Imaging (fMRI) experiment including 
intensity and unpleasantness ratings of tonic heat was used to investigate the effects of oxytocin 
within the brain.  
RESULTS: Thirty participants entered analysis. Intranasal oxytocin had no significant effect on 
thermal thresholds, but significantly (t = -2.06, p = .046) reduced heat intensity ratings during 
fMRI. The effect on intensity ratings was small (-3.46 points on a 100-point visual analog scale, 
95% CI [-6.86; -0.07]) and independent of temperature. No effects of oxytocin on stimulus- or 
temperature-related processing were found at the whole-brain level at a robust statistical 
threshold. A ROI analysis indicated that oxytocin caused small but significant decreases in left 
(-0.045 %, 95% CI [-0.087, -0.003], t = -2.19, p = .037) and right (-0.051 %, 
95% CI [-0.088,  -0.014], t = -2.82, p = .008) amygdala activity across all temperatures. 
CONCLUSIONS: The present study provides evidence for a significant, but subtle inhibitory effect 
of oxytocin on thermal stimulus ratings and concurrent amygdala activity. Neither of the two 
effects significantly depended of temperature, therefore the hypothesis of a pain-specific effect of 
oxytocin could not be confirmed. 
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Introduction 
Anti-nociceptive effects of oxytocin have been reported by nearly 30 non-human, but only a few 
human studies (Rash, Aguirre-Camacho, & Campbell, 2013). Only four studies have investigated 
the effects of oxytocin on human pain using the convenient nasal application route, which has 
been established as a safe (MacDonald et al., 2011) and effective method to increase oxytocin 
concentrations in the central nervous system (Born et al., 2002; Neumann, Maloumby, 
Beiderbeck, Lukas, & Landgraf, 2013; Striepens et al., 2013). Singer et al. (2008) were the first to 
test the potential of intranasal oxytocin to alter empathic responses to pain. Although this 
hypothesis could not be confirmed, they found that oxytocin reduced amygdala reactivity in 
response to pain in a small sub-sample. Using an experimental model of placebo analgesia, 
Kessner et al. (2013) showed that intranasal oxytocin enhances the placebo effect. However, no 
general anti-nociceptive effect of intranasal oxytocin was evident within their large healthy 
sample. Mameli et al. (2014) explored the potential of oxytocin as an adjunctive analgesic in a 
small sample of fibromyalgia patients with negative results. Rash & Campbell (2014) recently 
found that intranasal oxytocin reduces behavioral and physiological reactions in response to cold-
pressor pain. 
Various effects and neural correlates of intranasal oxytocin on the processing of stress and 
emotion have been identified, yet most neuroimaging studies reported oxytocin effects on the 
amygdala, a key region for anxiety processing (Bethlehem, Baron-Cohen, van Honk, Auyeung, & 
Bos, 2014; Bethlehem, van Honk, Auyeung, & Baron-Cohen, 2013). For example, intranasal 
oxytocin was found to attenuate amygdala responses related to threatening scenes (Kirsch et al., 
2005) and to conditioned fear of faces (Petrovic, Kalisch, Singer, & Dolan, 2008). Interestingly, a 
recent meta-analysis found 17 neuroimaging studies that report increased amygdala activity in 
response to experimental pain, which suggests that the amygdala plays a role in acute pain 
processing (Simons et al., 2014). 
The potential of neuropeptides such as oxytocin as an adjunctive treatment of chronic pain is of 
considerable interest. Nevertheless, the potential of intranasal oxytocin to affect pain processing 
is understudied (Rash et al., 2013). The present trial aimed to investigate the effect of oxytocin on 
experimental pain perception and processing. The established Quantitative Sensory Testing 
(QST) protocol was used to test effects of oxytocin on noxious and non-noxious thermal 
thresholds. Further, a functional Magnetic Resonance Imaging (fMRI) experiment with tonic heat 
pain stimulation and Visual Analog Scale (VAS) ratings of heat intensity and unpleasantness was 
employed to measure oxytocin effects on experimental pain perception and processing. 
Based on the above-mentioned studies we hypothesized that intranasal oxytocin should 
A)  increase noxious thermal pain thresholds; 
B)  decrease VAS ratings of noxious heat intensity and/or unpleasantness; 
C)  cause detectable blood oxygen level dependent (BOLD) signal changes related to 
thermal stimulus processing on whole brain level; 
D)  alter painful stimulus processing in the amygdala. 
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Methods 
Trial information 
The present study was approved by the ethics committee of the University of Regensburg 
(Approval Number: 11-111-0322) and the responsible federal medical agency. It was registered in 
a clinical trial registry (EUDRA-CT Number: 2009-015115-40) and conforms to the Declaration 
of Helsinki (59th WMA General Assembly, 2009). Written informed consent was obtained from 
every participant. All measures took place at the MRI facilities of the University of Regensburg at 
the Bezirksklinikum Regensburg between November 2012 and April 2013.  
Study design 
This is a placebo-controlled, double-blind, crossover trial. The random allocation sequence was 
generated by the Center for Clinical Trials at the University of Regensburg. According to this 
sequence, the Hospital Pharmacy of the University of Erlangen labeled and numbered the nasal 
sprays and corresponding emergency wrappers. At study inclusion, participant were assigned 
sequential participant numbers by author PE and hereby allocated to Group A or B at random. 
Group A received placebo and Group B received oxytocin at Visit 1; Group A received oxytocin 
and Group B received placebo at Visit 2. Both groups completed an additional training visit 
(Visit 0) at study inclusion. A period of ≥ 7 days between all visits was observed to minimize 
carry-over effects. 
Participants 
Healthy right-handed male volunteers between 18 to 50 years of age were eligible for trial 
participation. Participants were recruited by advertisement at the University of Regensburg, 
aiming at a sample size of 36. The sample size was chosen to optimize statistical power within the 
limits of the devoted resources. Participants received a compensation of 10 Euros per hour. 
Exclusion criteria were surveyed in a structured interview at inclusion. Exclusion criteria were: 
Allergies against any ingredients of the trial medication; past or present cardiac, major internal, 
neurological, psychiatric, hormonal, or chronic conditions; acute infections; recent surgery; recent 
use of illicit drugs, psychotropics, or analgesics; alcohol addiction; conditions incompatible with 
fMRI safety. Participants were required to abstain from alcohol and caffeinated beverages at least 
24 hours and 12 hours before visits, respectively. 
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Procedure 
 
 
Figure 1.1: Time schedule of experimental procedures (upper row) and schematic overview of a typical 
trial within the fMRI block design (lower row). The temperature applied during the 14-second heat plateau 
ranged from 44.7 °C to 47.5° C in steps of 0.4 °C. Abbreviations: fMRI: functional Magnetic Resonance 
Imaging, QST: Quantitative Sensory Testing. 
An overview of the experimental procedures is provided in Figure 1.1. Visits were scheduled 
between 8:00 h and 20:00 h, always at the same time of day (± 1h) within participants. Each visit 
started with a medical examination and a re-evaluation of inclusion and exclusion criteria. 
Subsequently, participants received a dose of 32 IU oxytocin, or placebo, applied as four puffs 
of 0.1 ml per nostril. The dose was chosen according to Singer et al., (2008). The oxytocin and 
the placebo spray only differed in the absence of oxytocin in the placebo. Both sprays had the 
formulation of Syntocinon Spray (Sigma Tau, Rome, Italy). Participants self-administered the 
nasal spray under supervision by a physician, according to recommendations by Guastella et al. 
(2013). Testing began after a waiting period of 40 minutes, consistent with the expected peak 
CSF concentration of nasally applied neuropeptides (Born et al., 2002). During the waiting 
period, participants completed questionnaires and were given standardized instructions for the 
following testing procedures. Then, thermal thresholding according to the QST protocol 
(20 min) was performed outside of the MRI scanner, followed by two fMRI runs. At debriefing, 
the occurrence and severity of 18 typical side effects was recorded on a 5-point numeric rating 
scale ranging from 0 (side effect absent) to 4 (severe). Additionally, each participant was asked to 
guess if he received placebo or oxytocin. 
Monitoring mood 
The Profile of Mood States (POMS, Pollock, Cho, Reker, & Volavka, 1979), an adjective rating 
scale instrument with 65 items, was used to monitor mood changes over the course of the 
experiment. The POMS total score reflects mood disturbance in general, while sub-scales allow 
for the monitoring of “tension-anxiety”, “depression-dejection”, “anger-hostility”, “fatigue-
inertia”, “vigor-activity”, and “confusion-bewilderment”. The POMS was administered three 
times: At the beginning of each session, after nasal spray application (near the end of the waiting 
period), and at the end of each session. At each time-point the participants were asked to rate 
their “momentary” state. 
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Quantitative sensory testing (QST) 
Participants were seated in upright position outside the MRI chamber with their arms 
comfortably resting on a cushioned tabletop. Thermal thresholding was performed on the volar 
surface of the left lower arm, 5 cm proximal from the wrist crease. Thermal stimuli were applied 
using a Thermosensory Analyzer II (Medoc, Israel) and a MR-safe 30 x 30 mm thermode, kept in 
place by an elastic strap. All thresholding procedures were performed in the presence of the same 
experimenter (MZ), with no other person or distractors present. Visual, auditory, or social clues 
indicating the onset of stimulation were precluded by the experimental setup. Written 
instructions were read aloud to the participant at each session. Cold (CDT) and warmth (WDT) 
detection thresholds, as well as cold (CPT) and heat (HPT) pain thresholds were retrieved in this 
order, according to the established QST protocol (Magerl et al., 2010; Rolke et al., 2006). For 
each measure five repetitions were obtained. The first stimulus of each measure was defined as a 
trial stimulus and discarded from analysis; thresholds were defined as the mean of the last four 
stimuli. 
fMRI—general information: 
After QST, participants underwent two separate fMRI experiments. Again, stimulation was 
applied to the volar surface of the left lower arm. Now the thermode location was 10 cm, 
or 15 cm proximal from the wrist crease. The thermode was moved in-between the fMRI runs to 
avoid skin damage. The order of fMRI runs and the order of thermode locations were balanced 
across participants and medication conditions. Only one of the two fMRI experiments was part 
of the present study, the other experiment will be reported elsewhere (Zunhammer et al., 
unpublished observations). 
A 3-Tesla Allegra Head Scanner (Siemens, Germany) equipped with a single channel head coil 
was used for MRI. Functional volumes were obtained with a T2*-weighted Echo-Planar 
Imaging (EPI) sequence (TR = 2000 ms, TE = 30 ms, interleaved slicing, flip angle = 90 º, 
3 × 3 x  3.5 mm voxel size, including a 16 % slice-gap, FoV = 192 × 192 mm), covering the full 
brain in 34 horizontal slices co-planar to the anterior and posterior commissure. The first five 
volumes of each run were discarded to account for T1-saturation effects. In addition a 
T1-weighted high-resolution structural head volume with 160 sagittal slices was obtained at 
Visit 1, using a Magnetization Prepared Rapid Gradient Echo (MP-RAGE) sequence 
(TR = 2250 ms, TE = 2.6 ms, flip angle = 9 º, 1 x 1 x 1 mm voxel size, FoV = 256 × 256 mm). 
Presentation 14.9 for Windows (Neurobehavioral Systems Inc., USA) was used to display stimuli, 
retrieve ratings, and log events. Visual stimuli were presented at a resolution of 1024 x 768 pixels 
and a frame-rate of 60 Hz on a screen attached to the head-end of the coil. Participant could see 
the entire display via a mirror attached to the head coil. The thermal stimulation equipment was 
the same as for the QST. 
MR images were pre-processed and analyzed with SPM 8. Volumes were corrected for slice-
timing differences using the middle slice as a reference; event onsets were adjusted accordingly. 
Volume time series were re-aligned and re-sliced to the first volume to account for head motion, 
using SPM’s rigid body transformation with 4th degree B-spline interpolation. Time series were 
screened for excessive head motion events using ArtRepair (Mazaika, Hoeft, Glover, & Reiss, 
2009). Anatomical images were co-registered to the mean realigned functional image, segmented 
using SPM’s MNI (Montreal Neurological Institute) tissue probability maps, and re-sampled at 
2 x 2 x 2 mm. Realigned functional images were normalized to MNI space using the parameters 
retrieved from the segmentation procedure, preserving signal concentrations (“unmodulated”). 
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All co-registration and segmentation results underwent visual quality control and were corrected 
if necessary. Images were spatially smoothed with a Gaussian full-width at half 
maximum (FWHM) kernel of 8 mm to improve signal-to-noise ratio. 
fMRI—experimental procedure: 
The fMRI experiment aimed to test if oxytocin induced changes in BOLD activity in response to 
tonic heat in the brain. Further, it aimed to obtain VAS ratings of heat intensity and/or 
unpleasantness. For these purposes, a parametric block design (Büchel, Holmes, Rees, & Friston, 
1998) with 24 repetitions and a total duration of 14.6 to 17.2 minutes was employed. A block-
outline is provided in Figure 1.1 (lower row). Block length varied between 36.5 and 43 s. Each 
block started with a visual cue: a red, iconic thermometer was shown on-screen for 1 s to indicate 
the imminent onset of thermal stimulation, followed by a fixation cross. After 0.5 s the thermode 
temperature increased rapidly (10 ºC / s) from baseline (35 ºC) to one of eight target 
temperatures. These target temperatures ranged from 44.7 ºC to 47.5 ºC in steps of 0.4 °C and 
were selected in order to cover the non-painful and painful (but tolerable) spectrum in the 
majority of male participants. Temperatures were selected by interpolating rating data obtained in 
a previous study (Zunhammer, Eichhammer, & Busch, 2013). Each target temperature was kept 
at a constant plateau for 14 s, before it returned to baseline (10 ºC / s). The duration of ramp-up 
and ramp-down varied between 1.3 s for 44.7 ºC to 1.5 s for 47.5 ºC. Over the course of a run, 
each target temperature was repeated four times in pseudo-randomized order. Each of the eight 
temperatures had to be presented once before being repeated, to achieve an even temperature 
distribution within runs. 
Thermal stimulation was followed by 3 to 6 s of rest. Then, a rating phase started: Participants 
were prompted to use a cursor to rate the preceding stimulus on consecutive displays for 
perceived “intensity” and “unpleasantness”. Intensity and unpleasantness were rated on two 
VASs occupying 70 % of the width of the display. The VASs were not ticked or numbered. 
Endpoints were labeled “no stimulus perceived” and “maximally intense” for the intensity rating 
and “not unpleasant” to “maximally unpleasant” for the unpleasantness rating. Ratings were 
recorded as integers ranging from 0 to 100, resulting in a 101-point scale. Ratings were entered 
with a LUMItouch keypad (Photon Control, Canada) held in the right hand. The cursor started at 
0 or 100 randomly and could be moved continuously by sustained button press of the index (left) 
and the middle (right) finger button. Selected ratings could be submitted by pressing the thumb 
button. Participants were required to submit ratings within 14 s, otherwise the next trial started 
and the block was discarded. When ratings were submitted in less than 14 s, a fixation cross was 
displayed for the remaining time. Thus, participants had no influence over the pace of the 
experiment. The next block followed after another resting interval of 3 to 6 s at fixation. 
Before each run, participants were given standardized instructions. Participants were asked to rate 
“How hot was the stimulus?” on the intensity scale and “How unpleasant was the stimulus?” on 
the unpleasantness scale. The difference between stimulus intensity and unpleasantness was 
illustrated by an analogy according to Price et al. (Price, McGrath, Rafii, & Buckingham, 1983). 
The analogy was adapted by replacing every occurrence of the word “pain” by “heat”, to account 
for the fact that we intended to measure (non-nociceptive) stimulus intensity, not (nociceptive) 
pain intensity, as in the original protocol. Before the start of the actual fMRI run, two training 
trials were performed to reduce novelty effects and to reduce sensitization/desensitization 
effects. Two stimuli with 44.7 and 47.1 ºC were presented for this purpose. 
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fMRI—whole brain analysis 
The first part of fMRI analysis aimed at identifying brain regions where oxytocin alters the 
processing of noxious temperatures. Emphasis was put on separating processes related to 
stimulation in general and pain-related processes. A standard two-step statistical parametric 
mapping (SPM) approach was used. In first level analysis a general linear model (GLM) was 
created for each participant in order to obtain voxel-wise beta estimates of within-subject effects. 
The thermal stimulation period was modeled as a boxcar regressor with blocks of 14 s duration, 
corresponding to the plateau phase of thermal stimulation. Stimulus temperature was added onto 
the stimulation period as a linear parametric modulator, maintaining SPM’s default 
orthogonalization procedure. The stimulation regressor therefore represented activity related to 
stimulation per-se, whereas the temperature regressor detected activity linearly related to stimulus 
temperature. Regressors were convolved with SPM’s canonical hemodynamic response function. 
Rating period, the six translational, and the rotational motion parameters were added to the 
model as nuisance regressors. An autoregressive (AR1) co-variance matrix was used to account 
for serial correlations. A temporal high-pass filter with a width of 400 s was applied. The eye 
regions and extra-cerebral tissue were excluded from analysis by using SPM’s a-priori brain mask. 
The beta contrast maps Stimulation > Baseline, Temperature > Baseline, (Oxytocin > Placebo, 
Stimulation > Baseline), (Oxytocin > Placebo, Temperature > Baseline), as well as the 
corresponding reverse contrasts, were obtained for each participant. 
In order to identify activations at group-level, a second level analysis was performed. Voxel-wise 
one-sample t-tests were used to test the single-subject contrast maps against the null hypothesis 
of no effect. The statistical threshold for activation at whole brain level was defined as p < .05, 
applying SPM 8’s family-wise error (FWE) correction for multiple comparisons. Regions were 
labeled with the Harvard-Oxford atlas for cortical (Desikan et al., 2006) and subcortical regions 
(Frazier et al., 2005), as included in the FSL analysis software (FMRIBs Software Library, 
www.fmrib.ox.ac.uk/fsl). Common structural names were added where appropriate. Clusters are 
overlaid for display on the mean structural image. Graphical artwork was prepared using 
MRIcron 6/2013 for Mac and arranged in panels using gimp. 
fMRI—region of interest analysis of the amygdala 
The second part of fMRI analysis aimed at quantifying the effects of oxytocin on the processing 
of noxious temperatures within the amygdala. ROIs for right and left amygdala were defined 
anatomically by the tissue probability maps from the sub-cortical Harvard-Oxford atlas (Frazier 
et al., 2005), binarized at a threshold of 50 %. 
The SPM-toolbox marsbar (Brett, Anton, Valabregue, & Poline, 2002) was used to obtain 
percent signal change estimates for each temperature and medication (placebo vs. oxytocin) 
condition within the ROIs. In order to estimate peri-stimulus activity for each temperature 
separately, the model for fMRI analysis described above had to be adapted: The eight different 
temperature stimuli were modeled as eight different boxcar regressors, split into 13 time bins 
of 2 s duration in a finite impulse response (FIR) model (Ollinger, Shulman, & Corbetta, 2001). 
Time bins started at the onset of temperature plateau (0 s) and ended 24 s post-stimulus onset, 
covering stimulus-offset (14 s), plus the subsequent resting period (> 3 s), plus the canonical 
delay of the HRF (6 s) (Henson & Friston, 2007). 
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Statistics 
Statistics were processed with SPSS 21.0.0.0 for Mac. A repeated-measures MANOVA was used 
to test effects of oxytocin on QST thresholds. POMS-scores, VAS-ratings, and percent signal 
changes within amygdala ROIs were analyzed using linear mixed models with maximum 
likelihood estimation. Sum-of-squares F-tests were performed at a two-tailed  < 0.05. For the 
POMS total score and all sub-scales, the main and interaction effects of the factors oxytocin 
(oxytocin, placebo) and within-session time-points (before session, before testing, after 
session) were tested. For the VAS results, the effect of oxytocin was tested, while the non-linear 
relationship between stimulation temperature and ratings of stimulus intensity and 
unpleasantness was modeled as a second-order polynomial: Mean-centered cofactors 
Temperature and Temperature2, as well as the interaction-terms Oxytocin * Temperature and 
Oxytocin * Temperature2 were included in the model. For amygdala activity, effect of the factor 
oxytocin was tested including factor time bin, as well as the linear cofactors temperature, intensity 
ratings, or unpleasantness ratings (and the respective interaction terms with oxytocin). Within-
participant dependencies were modeled by including individual random intercepts and random 
effects for all factors, cofactors, and interactions, to obtain a maximal random effects structure 
(Barr, 2013). A “variance components” co-variance matrix was used. 
Means are reported ± 1 standard deviation, if not denoted otherwise. Error bars in all figures 
represent standard errors of the mean (SEM) corrected for repeated measures (Bakeman & 
Mcarthur, 1996). Graphs were created using GraphPad Prism 5.0 for Windows.  
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Results 
Sample description and medication 
Thirty participants successfully completed the study and were eligible for analysis. A detailed 
participant flow according to the CONSORT criteria is available online, as Appendix 1.1. No 
adverse event related to oxytocin occurred. Investigators and participants were blinded until all 
measures were completed, after which the trial was concluded regularly. 
Mean age at study inclusion was 24.9 years (range: 19 to 30). Participants were assigned to 
Group A and B in 50.0 % of cases. After Visit 1, 77.4 % of participants indicated that they 
believed to have received oxytocin, compared to 53.3 % after Visit 2. Some participants guessed 
to have received oxytocin twice, despite being reminded that oxytocin was only given at one of 
the two visits. Nevertheless, participants guessed the right medication in 50.0 % of cases and as 
such did not differ from chance level. The mean side-effect score was 3.2 ± 2.8 for placebo and 
2.9 ± 1.7 for oxytocin and these values did not differ significantly (p = .82) according to a paired 
t-test. 
Mood 
The POMS total score indicated that participants were generally in good mood before and after 
the experiment (Nyenhuis, Yamamoto, Luchetta, Terrien, & Parmentier, 1999). Participants 
showed significant mood changes over the course of the experiment: They described themselves 
as significantly more fatigued, confused, and less invigorated after the experiment, compared to 
the two time-points before. Tension, anger, and depression sub-scales did not change 
significantly. There was a significant interaction-effect of Oxytocin*Time-Points for the POMS 
total score (F[2, 60.3] = 4.34, p = .017) and the confusion sub-scale (F[2, 60.1] = 5.91, p = .005). 
Post-hoc-test indicated that participants showed a non-significant tendency towards better mood 
(-4.36 ± 14.96, t(27) = 1.54, p = .135) and were significantly less confused (-1.75 ± 2.50, t(27) = 
3.67, p = .001) at the post-session time point, after having received oxytocin, as compared to 
placebo. Tables with full results for the POMS and its sub-scales are provided in Appendix 1.2. 
Quantitative sensory testing (QST) 
QST testing started 42 ± 2 min after nasal spray administration, at mean. There were no missing 
values for the QST procedure. No significant differences between oxytocin and placebo 
conditions could be found for any thermal thresholding procedure according to repeated-
measures MANOVA (F[4, 26] = 0.64, p = .64). Results are detailed in Table 1. 
 
Measure  Placebo Oxytocin Statistics df (1, 29) 
Cold detection threshold (CDT) 30.98 ± 0.47 30.90 ± 0.41 F = 0.68, p = .414 
Warmth detection threshold (WDT) 33.75± 0.79 33.99± 1.01 F = 2.22, p = .147 
Cold pain threshold (CPT) 18.37± 7.59 18.79± 7.68 F = 0.24, p = .627 
Heat pain threshold (HPT) 44.39± 3.15 44.59± 2.89 F = 0.29, p = .592 
Table 1.1: No significant effects of oxytocin on thermal detection and pain thresholds. All means and 
differences in °C. F-statistics were obtained performing a repeated-measures MANOVA (n = 30, two 
observations/variable/participant). 
fMRI—dataset 
On average, fMRI testing started 76 ± 6 min and ended 130 ± 10 min after nasal spray 
administration. The last three trials of one session were lost due to a technical failure, however 
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the remaining data from that participant were retained in analysis. At mean, participants 
completed their ratings within 7.50 ± 1.43 s. Two trials had to be excluded from analysis because 
ratings were not submitted within 14 s. Overall analysis was based on 1435 trials over 
30 participants. 
fMRI—ratings 
Mean results for intensity and unpleasantness ratings obtained during fMRI scanning are shown 
in Figure 1.2 a, and b, respectively; dashed lines show the curve of best-fit. Mixed model analysis 
indicated that the factor oxytocin explained a significant amount of variance in intensity 
(F[1, 41.9] = 4.23, p = .046), but not in unpleasantness ratings (F[1, 41.2] = 1.87, p = .18). As 
expected, cofactors temperature and temperature2 were significant predictors of intensity and 
unpleasantness ratings (all: p < .001). None of the interaction terms showed a significant effect 
(p > .16). We therefore conclude that oxytocin decreased intensity ratings after adjusting for 
repeated measures and the non-linear effects of temperature. 
 
  
Figure 1.2 a and b: Oxytocin effects on visual analog scale ratings of heat. Parameter estimates indicated 
that intensity ratings (β = -3.46, 95% CI [-6.86, -0.07], t = -2.06, p = .046) significantly decreased during 
oxytocin sessions, compared to placebo sessions. A similar, but non-significant trend was apparent for 
unpleasantness ratings (β = -2.77, 95% CI [-6.97, -1.42], t = -1.37, p = .18). The mean ratings shown were 
shifted slightly along the x-axis (± 0.02 °C) for the sake of illustration. Error bars represent SEM corrected for 
repeated measures. n = 30, with 48 observations per variable and participant. 
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fMRI—whole brain analysis 
The contrasts Temperature > Baseline and Stimulation > Baseline were assessed to confirm that 
our fMRI paradigm was effectively identifying regions of pain processing. Significant activations 
were found in the bilateral insula, somatosensory cortex II (SII), cingulate cortex, dorsolateral 
prefrontal cortex (DLPFC), and caudate nucleus. Results of this control analysis are provided in 
Figure 1.3 and in tabular form in Appendix 1.3. 
 
 
Figure 1.3: Clusters showing increased activity during stimulation period (contrast: Stimulation > Baseline, 
gold) and brain regions showing a linear activity increase with heat (contrast: Temperature > Baseline, red). 
The threshold of significance was p < .05, corrected for Family-Wise-Error (FWE), with a minimum size of 
5 voxels. Left hemisphere is shown left. Regions are labeled according to the Harvard-Oxford Atlas. 
Abbreviations: DLPFC: Dorsolateral prefrontal cortex, SII: somatosensory cortex II. For coordinates and 
tabular results see: Appendix 1.3. n = 30 with 48 trials of 14 s duration per variable and participant. 
 
The Oxytocin > Placebo and reverse contrasts were analyzed with respect to the effects of the 
temperature and the stimulation regressor. No significant effects of oxytocin were found on 
whole brain level for any of these comparisons at the statistical threshold of p < .05 when 
applying FWE correction. Using a liberal threshold of p < .001, uncorrected for multiple 
comparisons (minimal cluster size 5 voxel), several clusters were identified, which showed 
decreased activation during the oxytocin sessions. These preliminary results are provided in 
Figure 1.4 and in tabular form in Appendix 1.4. 
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Figure 1.4: Clusters showing decreased stimulus-related activity (green) and decreased temperature related 
activity (blue) during oxytocin compared to placebo sessions. The statistical threshold was set at p < .001, 
uncorrected for multiple comparisons, with a minimal cluster size of 5 voxel. No significant clusters were found 
showing increased activation under oxytocin. No significant effects were found when using a threshold of p < 0.05 
with family-wise-error (FWE) correction for multiple comparisons. Left hemisphere is shown left. Regions are 
labeled according to the Harvard-Oxford Atlas, with tissue probabilities in %. For coordinates and tabular results 
see: Appendix 1.4. n = 30 with 48 trials of 14 s duration per variable and participant. 
 
 
fMRI—region of interest analysis of the amygdala 
The percent signal change estimates for right and left amygdala activity are displayed in 
Figure 1.5. Main effects and interactions between factors oxytocin, time bin, and (mean centered) 
temperature were tested using mixed model analysis. Oxytocin was found to explain a significant 
amount of variance in BOLD signal in the left (F[1, 30.0] = 4.77, p = .037) and right 
(F[1, 30.0] = 7.89, p = .009) amygdala. As expected, the time bins explained a significant 
proportion of variance in both amygdalae (both: p < .001). The cofactor temperature did not 
explain a significant proportion of variance; neither in the left (F[1, 30.1] = 0.66, p = .42), nor 
right (F[1, 32.2] = 1.41, p = .24) amygdala. All interaction terms were non-significant. Intensity- 
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and unpleasantness-ratings did not explain a significant proportion of variance in amygdala 
activity, when used as a cofactor in mixed model analysis instead of temperature (p > .79 for 
both variables and hemispheres). 
Left Amygdala  Right Amygdala 
  
Figure 1.5: Mean time-course of bilateral amygdala activity during stimulation and effects of oxytocin. 
Parameter estimates indicated that left (β = -0.045, 95% CI [-0.087, -0.003], t = -2.19, p = .037) and right 
(β = -0.051, 95% CI [-0.088, -0.014], t = -2.82, p = .008) amygdala activity was significantly decreased in 
oxytocin, compared to placebo sessions. Temperature was not found to significantly predict amygdala 
activity, the depicted mean % signal changes were therefore pooled across temperatures. Error bars 
represent SEMs corrected for repeated measures. n = 30 with 48 trials of 14 s duration per variable and 
participant. 
Post-hoc analyses 
Oxytocin induced differences in intensity ratings (mean change in ratings) did not correlate with 
oxytocin induced difference POMS total score (mean change in score, Kendall’s tau-b = -.170, 
p = .21). Oxytocin induced differences in amygdala activity (mean change in signal) did not 
correlate with oxytocin induced difference in POMS total score (mean change in score, Kendall’s 
tau-b = -.099, p = .62). Similarly, there were no significant correlations between mean changes in 
intensity- or unpleasantness ratings and mean changes in amygdala activity (all variables and 
hemispheres: p > .79). Mean heat intensity (Kendall’s tau-b = .434, p = .001) and mean heat 
unpleasantness (Kendall’s tau-b = .407, p = .001) ratings correlated significantly with HPT (data 
aggregated across sessions), but not with HDT, CDT, and CPT (all: p > .11). 
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Discussion 
Overview 
The present neuroimaging study is the first to test the effects of intranasal oxytocin on human 
heat pain processing with a representative sample size. Oxytocin did not significantly affect 
thermal thresholds before fMRI (Hypothesis A), but significantly reduced subjects’ heat intensity 
ratings during fMRI (Hypotheses B). A similar, but non-significant trend towards reduced 
unpleasantness ratings could also be observed. The effects of oxytocin on VAS ratings had a 
modest (~4 % of the VAS) effect size. No effect of oxytocin on temperature-related cerebral 
processing was found at whole-brain level using a robust statistical threshold. (Hypotheses C). A 
ROI analysis showed that oxytocin significantly reduced BOLD responses within the bilateral 
amygdala (Hypothesis D). Oxytocin induced changes in mood, subjective heat intensity ratings, 
and amygdala activity did not correlate significantly. 
The amygdala, oxytocin, and pain 
By showing that oxytocin reduces the hemodynamic response within the amygdala during heat 
stimulation (see: Figure 1.5), our results point to the established effect of intranasal oxytocin on 
amygdala activity (for review see: Bethlehem et al., 2013). We could therefore consolidate 
preliminary evidence by Singer et al. (2008), who found reduced amygdala reactivity in response 
to painful stimulation in a sub-group of participants, while studying oxytocin effects on empathy. 
Contrary to our expectations, whole-brain analysis was unable to identify the amygdala among 
the regions showing significant stimulus- or temperature-related activity (see: Figure 1.3). Owing 
to its increased power, a ROI analysis could confirm that both amygdalae were active during 
stimulation and showed a typical hemodynamic response (see: Figure 1.5). Considering that the 
canonical delay of the hemodynamic response is ~5 s (Henson, 2006), the observed amygdala 
activation peak (12-16 s) was related to the second half of the heat stimulus plateau. This time-
course suggests that amygdala activity was linked to features of heat stimulus perception, rather 
than threat evaluation. The latter would be expected to occur earlier, corresponding to the 
stimulus onset, or to the preceding visual cue, i.e. at a time when the painfulness of the upcoming 
stimulus is still uncertain. Nevertheless, the amygdala response and the oxytocin effect were not 
significantly related to temperature, intensity ratings, or unpleasantness ratings. Therefore, general 
stimulus-related, rather than pain-specific processes might underlie the observed effects. Our 
results thus provide additional evidence for an effect of oxytocin on stimulus processing in the 
amygdala, but do not necessarily support the hypothesis of a specific anti-nociceptive effect. 
Our fMRI paradigm detected significant, robust, positive linear associations between noxious 
temperature and BOLD signal in the insula, SII, cingulate cortex, DLPFC and caudate nucleus 
(see: Figure 1.3). These results are in agreement with previous results for heat pain (Duerden & 
Albanese, 2013) and verify that our fMRI paradigm was capable of detecting pain-related cerebral 
processing. 
Despite these positive results, no effect of oxytocin on stimulus-, or temperature-related activity 
could be found with a threshold of p < 0.05, after correction for multiple comparisons with the 
conservative FWE procedure. Clusters of inhibitory oxytocin effects in the posterior 
hippocampus, the supra-marginal gyrus, as well as several prefrontal, fusiform and occipital 
regions (see: Figure 1.4) could be found with a more liberal statistical threshold of p < .001, voxel 
size > 5, uncorrected for multiple comparisons. However, we think that strict correction for 
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multiple comparisons is vital for fMRI research (Vul, Harris, Winkielman, & Pashler, 2009). 
Therefore, we consider these results preliminary and recommend that they be interpreted with 
caution. 
Rating results 
Similar to the amygdala results, our behavioral results do not provide unequivocal support of an 
analgesic effect of oxytocin. The small oxytocin effect on VAS-ratings was not found to be 
temperature dependent. In addition intensity, and less so unpleasantness ratings were affected — 
the opposite would be expected for a clear analgesic effect. We therefore conclude that changes 
in somatosensory perception and/or changes in other general cognitive states, such as attention, 
anxiety, or vigilance, may account for the observed oxytocin effects. Our results are in accord 
with recent findings of Rash and colleagues (2014), who found that intranasal oxytocin reduces 
pain intensity ratings, pain unpleasantness ratings, and descriptive ratings of cold-pressor pain. 
Although Kessner et al. (2013) found no effect of oxytocin on heat pain ratings, our results are 
compatible with the finding that oxytocin enhances the placebo effect. Our participants guessed 
to have received oxytocin in 77.4 % of cases at Visit 1 and in 53.3 % of cases at Visit 2. This high 
prevalence of placebo-beliefs in our sample may have driven the effect. 
Social interaction was limited in the present experiment, especially within the MR environment 
and no social stimulus material was involved in the present study. These circumstance may have 
limited the efficacy of oxytocin in comparison to previous studies, as the effects of oxytocin have 
repeatedly been shown to depend on social context and associated beliefs (Bartz, Zaki, Bolger, & 
Ochsner, 2011). The discrepancy between our positive results for the VAS-ratings and our 
negative results for the thermal thresholding procedure might be explained by a number of 
points: The rating procedure involved six times more stimulus repetitions than the thresholding 
procedure, thus entailing more statistical power. Further, the thresholding and the rating 
procedures differed in timing, thermode location, stimulus dynamics, stimulus intensity, and 
response type—all of which may have made a difference. Of note, oxytocin may have exerted an 
effect on pain perception in the anxiogenic environment of the MR-scanner, consistent with the 
hypothesis of oxytocin as an anxiolytic agent (Bethlehem et al., 2014). 
Oxytocin was found to ameliorate negative mood changes occurring over the course of the 
experimental sessions. Participants described themselves as less confused after the oxytocin 
session, in comparison to the placebo session. However, these changes in mood were not 
significantly correlated with changes in intensity ratings or amygdala activity, and therefore may 
be of limited relevance for the main aim of our study. Of note, the “tension-anxiety” sub-scale of 
the POMS, a measure related to stress and anxiety, was not significantly affected by oxytocin. 
Limitations 
The present study was limited to healthy males. The present results might therefore not 
generalize to the female population, to patient populations, or to clinical forms of pain, We 
limited our sample to males, because the summary of medical product characteristics for 
Syntocinon Spray listed uterine contractions as a potential side effect in females (Novartis, 2006), 
which was deemed a potential source of confound for the testing of pain processing. However, a 
large review on the safety of intranasal oxytocin indicated that female study participants are not 
reported to experience more side-effects than their male counterparts (MacDonald et al., 2011). 
Therefore our concerns might have been unsubstantiated and we encourage future studies on the 
effects of intranasal oxytocin on heat pain in females. 
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Thermal stimulation of the skin was the main method of sensory stimulation used in the present 
study. The present results may therefore not generalize to other forms of (noxious) 
somatosensory stimulation. In addition, the stimulus protocol used in our fMRI paradigm 
involved the same heat stimulus intensities for all participants. Individualized stimulus intensities 
may have increased the power to detect effects of oxytocin by reducing between-subject 
variability. 
The pathway of intranasal oxytocin into the brain its still unknown. Its peak and retention times 
in the brain, as well as its bioavailability and metabolism are incompletely understood. Born et al. 
(Born et al., 2002) found that 40 IU of intranasal vasopressin (a structural sibling of oxytocin) 
increased concentrations in human cerebrospinal fluid 40 and 80 min after application; no 
measurements were obtained beyond 80 min, prohibiting the estimation of retention times. A 
small study assessing oxytocin levels in the human cerebrospinal fluid (Striepens et al., 2013) 
found elevated oxytocin levels 75 min after intranasal application; again, no measurements were 
obtained beyond this time point. Oxytocin concentrations in human saliva have been reported to 
remain elevated for 7 hours after nasal spray application (Ijzendoorn, Bhandari, Veen, & Grewen, 
2012). Oxytocin levels were found to peak between 30 and 60 min and return to baseline 
between 90 and 120 min after nasal application in in-vivo micro-dialysates of rat and mouse brain 
tissues (Neumann et al., 2013). According to these studies our thresholding procedure (40-60 min 
post application) might have started too early (Striepens et al., 2013), or too late (Neumann et al., 
2013), and our fMRI experiments might have taken too long (130 minutes). The present results 
may therefore be limited to specific time frames, i.e. 40-60 min for the QST:, and 75-130 min for 
the rating and fMRI results. Further, no optimal dose of intranasal oxytocin for eliciting 
behavioral effects has been determined, yet. Since the present study did not include different 
dosing conditions, it cannot provide information on a probable dose-response relationship. The 
present findings are therefore limited to the specific oxytocin dose of 32 IU, which may be too 
low, or even too high (Cardoso, Ellenbogen, Orlando, Bacon, & Joober, 2013; Ijzendoorn et al., 
2012). These issues may have obscured further oxytocin effects from detection and may have 
resulted in an underestimation of actual effect sizes. 
Finally, we want to raise awareness for a limitation underappreciated in human intranasal 
oxytocin research: Oxytocin has repeatedly shown to affect social behavior (Guastella & 
MacLeod, 2012) and there is no reason why this should not apply to experimental settings, where 
participants usually interact with experimenters. “Good-participant” behavior might 
systematically increase under oxytocin, although there is no positive evidence for an oxytocin 
effect on demand characteristics (Weber & Cook, 1972), yet. Such an oxytocin-induced response 
bias might confound any behavioral measurement in oxytocin studies — even when a double-
blind placebo-control is employed, as in the present study. 
Conclusion 
In conclusion, our results provide further evidence for a significant, but subtle effect of oxytocin 
on heat stimulus perception and/or appraisal. They further provide evidence for a significant 
effect of oxytocin on heat stimulus processing in the amygdala. Preliminary evidence for activity 
decreases in the hippocampus, prefrontal cortex, parietal cortex, and occipital cortex could be 
obtained. These regions pose potential targets for further investigations on pain-related oxytocin 
effects. However, the present study could not support the hypothesis of an anti-nociceptive 
effect of oxytocin, since the oxytocin induced changes in VAS-ratings and amygdala activity were 
not found to be temperature-dependent and oxytocin affected intensity, rather than 
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unpleasantness ratings. Future studies are needed to unravel the effects of intranasal oxytocin on 
pain-related processes. 
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Appendix 1.1 
CONSORT Flowchart 
 
 
Assessed for eligibility (n=46) 
Excluded (n=10) 
♦ Not meeting inclusion criteria (n=10) 
♦ Declined to participate (n=0) 
♦ Other reasons (n=0) 
Analysed (n=15) 
 
Discontinued (compliance, n=2) 
Discontinued (technical failure, n=1) 
Allocated to Group A (placebo first, n=18) 
♦ Received allocated intervention (n=18) 
Discontinued (compliance, n=1) 
Allocated to Group B (oxytocin first, n=18) 
♦ Received allocated intervention (n=17) 
♦ Did not receive allocated intervention 
(voluntary drop-out, n=1) 
Analysed (n=15) 
Partial data for one participant (technical 
failure, no fMRI data, n=1) 
Allocation 
Analysis (N=30) 
Follow-Up 
Randomized (n=36) Enrollment 
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Appendix 1.2 
Time-Point Before Session Before Testing After Session 
Medication Placebo Oxytocin Placebo Oxytocin Placebo Oxytocin 
n 30 30 30 29 29 29 
POMS-Subscale       
Tension 3.3 ± 3.3 3.7 ± 3.3 3.1 ± 3.8 3.6 ± 2.8 4.4 ± 4.5 3.4 ± 2.8 
Depression 1.7 ± 2.7 1.5 ± 2.8 1.6 ± 2.6 1.1 ± 2 1.9 ± 3.8 1.0 ± 1.9 
Anger 1.6 ± 1.9 2.1 ± 2.2 1.7 ± 1.9 2.2 ± 2.4 1.9 ± 2.8 1.6 ± 2 
Vigor 19.6 ± 6.1 18.3 ± 4.8 17.6 ± 5.8 17.7 ± 4.9 15.5 ± 6.3 16.0 ± 5.8 
Fatigue 2.5 ± 2.8 3.3 ± 3.1 2.7 ± 2.9 3.3 ± 2.9 7.0 ± 4.7 6.7 ± 5 
Confusion 3.5 ± 2.3 3.3 ± 1.7 3.7 ± 2.7 3.5 ± 1.9 5.1 ± 3.3 3.9 ± 2.1 
Total -7.0 ± 13.5 -4.5 ± 11.6 -4.8 ± 15.2 -3.9 ± 11 4.2 ± 18.8 0.1 ± 14.2 
Appendix 1.2a: Results for the Profile of Mood States (POMS) and its sub-scales (n = 30), with three data-
points missing. Mean scores ± SD. Three data-points missing. Lower POMS total scores indicate better 
mood. 
 
 
Factor Time-Point Medication Time-Point* Medication 
 F(2) df2 p F(1) df2 p F(2) df2 p 
Tension 0.91 60.0 .407 0.02 30.1 .883 2.12 59.2 .129 
Depression 0.47 60.4 .627 1.32 30.2 .260 0.75 60.7 .478 
Anger 0.12 59.6 .884 0.72 27.8 .404 1.03 58.5 .365 
Vigor 15.44 60.5 < .001 0.09 29.7 .763 1.22 60.3 .303 
Fatigue 36.03 60.7 < .001 0.32 30.2 .575 1.76 58.8 .182 
Confusion 8.16 60.9 .001 3.23 30.1 .082 5.91 60.1 .005 
Total 15.46 61.0 < .001 0.06 30.1 .809 4.34 60.3 .017 
Appendix Table 1.2b: Mixed model results for the Profile of Mood States (POMS) and its sub-scales. 
n = 30, with three data-points missing. All mixed models included a random intercept term, as well as 
random slope terms for time-point and medication. 
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Appendix 1.3 
Region Hemis-
phere 
Size 
(voxel) 
Peak 
coordinates 
Peak voxel 
statistic: 
   x y z Z pFWE 
Stimulation > Baseline 
SII, central (51%)/parietal (12%) operculum R 2695 38 -16 20 6.92 < .001 
White matter (76%)/lat. ventricle (23%)/ R 81 12 -32 22 5.77 < .001 
White matter (79%)/lat. ventricle (20%)/ L 210 -14 -40 20 5.65 < .001 
Central (43%) operculum L 30 -36 6 14 5.02 .006 
Insula (58%) L 129 -34 18 0 5.01 .006 
White matter (47%)/lat. ventricle (47%)/ R 19 28 -48 12 4.91 .009 
Heschl’s gyrus (32%), planum polare (26%) L 46 -46 -16 0 4.88 .010 
DLPFC, Frontal pole (71%) R 9 40 42 6 4.67 .024 
Temperature > Baseline 
Insula (33%) R 4341 34 -16 18 7.76 < .001 
Insula (36%) L 2294 -30 16 4 6.45 < .001 
Insula (30%), central operculum (12%) L 96 -34 -18 20 5.91 < .001 
Post. supramarginal (61%), angular gyrus (15%) R 74 64 -42 34 5.58 .001 
Ant. supramarginal (43%), postcentral gyrus (20%) L 53 -58 -26 26 5.58 .001 
DLPFC, Frontal pole (80%) R 102 38 48 22 5.44 .002 
Supplementary motor cortex (46%) R 82 6 8 64 5.19 .006 
Lat. Ventricle (67%), caudate (30%) L 51 -8 12 14 5.11 .008 
SII, Parietal (41%), ant. supramarginal Gyrus (19%) R 39 54 -28 24 4.99 .014 
Ant. cingulate gyrus (26%) R 8 12 12 34 4.96 .016 
Ant. cingulate gyrus (86%) L/R 18 2 14 26 4.94 .018 
DLPFC, Frontal pole (89%) L 9 -34 48 24 4.90 .020 
DLPFC, Frontal pole (67%) R 27 40 46 4 4.89 .021 
Ant. (55%) and post. (18%) supramarginal gyrus L 8 -60 -44 32 4.84 .026 
Appendix 1.3: Whole brain-activity explained by Stimulation > Baseline and a Temperature > Baseline 
contrasts. Names with tissue probabilities in % are provided according to the Harvard-Oxford Atlas. All p-
values were family-wise-error corrected. Only clusters with a minimum size of 5 voxels are reported. 
Abbreviations: Ant.: anterior, DLPFC: Dorsolateral prefrontal cortex, lat.: lateral L: left, post.: posterior, R: 
right, SII: somatosensory cortex II. 
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Appendix 1.4 
Region Hemis-
phere 
Size 
(voxel) 
Peak 
Coordinates 
Peak voxel 
statistic: 
   x y z Z pFWE 
Stimulation Regressor: Decreases under oxytocin 
Angular (22%)/supramarginal (14%) gyrus  R 86 40 -48 38 3.88 .410 
Frontal Pole (2%) L 10 -30 38 6 3.62 .684 
White matter (80%) near postcentral gyrus (0%) L 14 -28 -28 40 3.61 .696 
Temperature Regressor: Decreases under oxytocin 
Hippocampus (20%) R 15 34 -38 -6 3.58 .892 
Frontal pole (46%)/orbitofrontal (13%) cortex  L 13 -22 38 -8 3.55 .913 
Precuneus (37%)/cuneal (22%) cortex L 15 -16 -70 26 3.49 .945 
Calcarine cortex (11%) L 10 -16 -88 8 3.45 .961 
Lingual gyrus (23%) R 16 18 -74 -2 3.38 .980 
Appendix 1.4: Exploratory whole brain-effects of oxytocin on processing of stimulation in general (green) 
and a linear temperature predictor (blue). Names with tissue probabilities in % are provided according to 
the Harvard-Oxford Atlas. The statistical threshold was set to p < .001, uncorrected for multiple 
comparisons and a minimal cluster size of 5 voxel. No regions were found which showed increased 
activation under oxytocin. No significant effects were found when using FWE correction for multiple 
comparisons. Left hemisphere is shown left in the picture. 
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Abstract 
BACKGROUND: The etiology of somatization is incompletely understood, but could be elucidated 
by models of psychosocial stress. Academic exam stress has effectively been applied as a 
naturalistic stress model, however its effect on somatization symptoms according to ICD-10 and 
DSM-IV criteria has not been reported so far. Baseline associations between somatization and 
personality traits, such as alexithymia, have been studied exhaustively. Nevertheless, it is largely 
unknown if personality traits have an explanatory value for stress induced somatization. 
METHODS: This longitudinal, quasi-experimental study assessed the effects of university exams 
on somatization—and the reversal of effects after an exam-free period. Repeated-observations 
were obtained within 150 students, measuring symptom intensity before, during, and after an 
exam period, according to the Screening for Somatoform Symptoms 7-day (SOMS-7d). 
Additionally, self-reports on health status were used to differentiate between medically explained 
and medically unexplained symptoms. Alexithymia, neuroticism, trait-anxiety, and baseline 
depression were surveyed using the Toronto-Alexithymia Scale (TAS-20), the Big-Five 
Personality Interview (NEO-FFI), the State Trait Anxiety Inventory (STAI), and Beck’s 
Depression Inventory (BDI-II). These traits were competitively tested for their ability to explain 
somatization increases under exam stress. 
RESULTS: Somatization significantly increased across a wide range of symptoms under exam 
stress, while health reports pointed towards a reduction in acute infections and injuries. 
Neuroticism, alexithymia, trait anxiety, and depression explained variance in somatization at 
baseline, but only neuroticism was associated with symptom increases under exam stress. 
CONCLUSION: Exam stress is an effective psychosocial stress model inducing somatization. A 
comprehensive quantitative description of bodily symptoms under exam stress is supplied. The 
results do not support the stress-alexithymia hypothesis, but favor neuroticism as a personality 
trait of importance for somatization. 
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Introduction 
Somatization has been defined as the “tendency to experience and communicate somatic distress 
in response to psychosocial stress and to seek medical help for it” (Lipowski, 1988). Although the 
re-definition of somatization as a clinical concept and its classification under the psychiatric 
category “somatic symptom disorders” is a matter of ongoing debate (Dimsdale & Creed, 2009) 
there is consensus that medically unexplained symptoms (MUS) and a stress-related etiology 
belong to its core features. 
Somatization and personality traits—is alexithymia the key concept? 
The causes of somatization have been hypothesized to be multifactorial, involving several 
mechanisms (for review see: Kellner, 1990; Lipowski, 1988; Rief & Broadbent, 2007). Evidence 
suggests co-occurrence and shared mechanisms with negative affect, anxiety (De Gucht, Fischler, 
& Heiser, 2004), neuroticism (Costa & McCrae, 1980; Wise & Mann, 1994), and alexithymia 
(Mattila et al., 2008). Especially alexithymia, the inability to identify, describe and differentiate 
emotions, has attracted considerable attention as a potential predisposing factor for somatization 
(for review see: De Gucht & Heiser, 2003). However, the belief that alexithymia causes or 
contributes to somatization is mainly based on cross-sectional studies, which do not allow causal 
inferences (De Gucht & Heiser, 2003; Mattila et al., 2008). Several authors therefore underlined 
the need for more longitudinal studies (Bailey & Henry, 2007; De Gucht & Heiser, 2003; Mattila 
et al., 2008). Mechanistically, alexithymia has been hypothesized to affect somatization by 
modulating physiological responses to stress (Martin & Pihl, 1985). Although this “stress-
alexithymia hypothesis” has been experimentally tested on measures of autonomic reactivity 
(Connelly & Denney, 2007; de Timary, Roy, Luminet, Fillée, & Mikolajczak, 2008), its relevance 
for somatization induced by a naturalistic psychosocial stressor has, to our knowledge, not been 
tested to date. 
The effects of exam stress on somatization are unknown 
The effectiveness of exam stress as a model of psychosocial stress has repeatedly been shown on 
immunological (Borella et al., 1999; Johannsen, Bjurshammar, & Gustafsson, 2010; Weik & 
Deinzer, 2010), neuroendocrine (Sherman, Bunyan, Creswell, & Jaremka, 2009; Weik & Deinzer, 
2010), physiological, and psychological (Koh, Choe, Song, & Lee, 2006; Loft et al., 2007; Šimić & 
Manenica, 2012; Spangler, 1997) parameters. Despite these associations, exam stress has not been 
used to investigate predisposing factors of somatization so far. To our knowledge only Koh and 
colleagues (2006) determined the effects of exam stress on somatization, showing a significant 
positive relationship in 38 participants. Still, no quantitative description of somatization 
symptoms under exam stress is available, although the somatic symptoms of acute exam anxiety 
have been assessed systematically (Pitts, Winokur, & Stewart, 1961; Ree, French, MacLeod, & 
Locke, 2008). 
The present study investigated somatization by exploring increases in MUS as a reaction to 
naturalistic psychosocial stress and by competitively testing the explanatory value of several 
personality traits including alexithymia. 
Our first aim was to provide a quantitative description of somatic symptom increases under exam 
stress including all 53 physical symptoms from the somatization symptom lists of ICD-10 and 
DSM-IV. It was hypothesized that an exam period affects total symptom scores, as well as 
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distinct symptoms. Both were expected to increase under exam stress and return to baseline after 
a period without exams. 
Our second aim was to test the predictive value of alexithymia and such related concepts as 
neuroticism, trait anxiety, and depression for increases in somatization under exam stress. It was 
hypothesized that alexithymia correlates positively with somatic symptom increases during exam 
stress, according to the stress-alexithymia hypothesis, and show a stronger association with these 
increases than neuroticism, state anxiety, or depression. 
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Methods 
The study was approved by the ethics committee of the University of Regensburg and conforms 
to the Declaration of Helsinki. Informed consent was obtained. Data were collected and analyzed 
pseudonymously. Written informed consents were obtained. 
Study design: 
We conducted a longitudinal, quasi-experimental study with a natural event, a reversal period and 
several control variables. The natural, predictive event was defined as a major university exam. 
Since exam types vary between academic disciplines, this was specified as an exam being 
prerequisite for graduation, or contributing to the university degree. Because exams are often 
clustered the most fearsome and/or distressing exam according to participants’ choice was 
selected. The intervention reversal period was defined as a subsequent exam-free period of 30 
days. Repeated observations were obtained at three times within participants: before 
(Pre-Baseline) and immediately after the predictive exam (Exam Period), as well as after reversal 
period (Post-Baseline). To guarantee that exam stress did not affect baselines, data was only 
included when participants reported no exam within the last and next 30 days. Moreover, to 
assure that the effect of the exam was maximal, data for Exam Period was excluded when 
participants failed to submit their survey within 3 days. Figure 2.1 provides an overview of the 
study’s time course. 
To increase internal validity, additional control measures were recorded: acute infections, injuries, 
or exacerbations of pre-existing conditions, i.e. medically explained symptoms (MES), pose an 
obvious alternative explanation for increases in symptom reports. Therefore, descriptive 
participant reports of current health status were surveyed, categorized, and subsequently tested 
for effects of Exam Period. Additional measures of stress, state-anxiety, and negative mood were 
taken to reassure that Exam Period was an effective psychosocial stressor. 
 
Figure 2.1: Timeline 
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Participants: 
For the present study 150 students of the University of Regensburg and the Regensburg 
University of Applied Sciences were recruited systematically across all faculties by advertisement 
via bulletins, flyers, and personal appeal at academic lectures. Investigators’ relatives, friends, and 
colleagues were excluded from participation. Past or present internal, neurological, hormonal, or 
psychiatric disorders were evaluated in a structured interview at study inclusion. Participants with 
acute conditions and in medical treatment were excluded from participation. Individuals with 
past or chronic disorders in stable remission were included, but their status was addressed as a 
potential confound in analysis. Participants received a compensation of 8 Euros per hour. 
Procedure: 
The only study visit was scheduled at least 30 days before the first major exam. Written informed 
consent, medical history, and exam dates were obtained. If necessary, exam dates were followed 
up by telephone interview and participants were advised to report any exams that had to be re-
scheduled. In addition, exam dates were retrieved at the end of the Post-Baseline session. All 
questionnaires were obtained using online forms. Each participant received an e-mail containing 
a web-link to an online platform and instructions on the day of study visit one (Pre-Baseline), the 
day of the selected exam (Exam Period) and one month after the last exam according to the 
participant’s specifications (Post-Baseline, see Figure 2.1). All online-questionnaires were identical 
to the paper versions, with the exception that missing items were prohibited by forced-choice 
settings. 
First aim—state questionnaires: 
Symptom intensities of 53 physical symptoms from the somatization symptom lists of ICD-10 
and DSM-IV were measured according to the Screening for Somatoform Symptoms 7-day 
version (SOMS-7d, Hiller, Rief, & Brähler, 2006; Rief & Hiller, 2003), with the difference that 
instructions asked participants to report perceived impairment for all symptoms, without 
requesting participants to differentiate between MUS and MES. The SOMS-7d was designed to 
measures impairment by 53 typical somatization symptoms, such as “headache”, “bloating”, or 
“back ache” on a 5-point Likert-scale within the last seven days: Scores are 0 (symptom absent or 
not impairing), 1 (mild), 2 (medium), 3 (severe), and 4 (very severe). SOMS-7d “Symptom Index” 
was the main outcome measure, calculated by summation of all items (Hiller et al., 2006; Rief & 
Hiller, 2003, 2008). 
Four custom items surveying current health status within the last seven days were used to 
differentiate between MES and MUS: Item one asked if the participant was feeling healthy today. 
Item two asked if medical treatment or counsel had recently been taken. Item three asked for the 
occurrence of any disease or injury and item four for exacerbations of pre-existing conditions. If 
any item was answered with “yes”, participants were required to enter a detailed description of 
their condition and symptoms into an open form field. Based on these items and responses, three 
of the authors (M.Z., H.E., V.B.) independently categorized sessions as “evidence for MES” 
(yesMES), or “no evidence for MES” (noMES). Where raters’ categorization did not match, 
sessions were classified as yesMES. This approach to differentiate between MES and MUS was 
chosen to preclude that the causal attribution of participants could bias somatization scores. 
The Perceived Stress Questionnaire (PSQ-20, Fliege et al., 2005) was used to confirm that the 
Exam Period was perceived as stressful. The PSQ-20 is a shortened, German adaptation of the 
original PSQ-30 (Levenstein et al., 1993), with good reliability (Cronbach’s α > .80). Perceived 
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stress is measured using 20 negatively and positively worded items, such as “Your problems seem 
to be piling up“, “You have trouble relaxing“, or „You have enough time for yourself“. Items are 
rated on a 4-point Likert scale (1 “almost never“, 2 “somtimes“, 3 “often“, 4 “usually“). 
The German versions of the State-Trait Anxiety Inventory–State Form (STAI-G-X1, Laux, 
Glanzmann, Schaffner, & Spielberger, 1981) and Beck’s Depression Inventory II (BDI-II, Beck, 
Steer, Ball, & Ranieri, 1996), were used to survey state anxiety and depression levels at all time-
points as an intervention check. For consistency, the BDI-II was adapted to a time-span of seven 
days. 
Second aim—trait questionnaires: 
Alexithymia and three competing explanatory personality traits were examined for their 
explanatory value for SOMS-7d scores: The 20-item version of the Toronto-Alexithymia Scale 
(TAS-20, Bagby, Parker, & Taylor, 1994; Bagby, Taylor, & Parker, 1994; Franz et al., 2008) was 
the primary measure of alexithymia with respect to our second aim. The TAS-20 surveys 
alexithymia on the three dimensions “Difficulty identifying feelings”, “Difficulty describing 
feelings”, and “Externally oriented thinking style”. It uses negatively and positively worded items 
such as: “I’m often confused about what emotion I am feeling”, “I am able to describe my 
feelings easily”, and “Being in touch with emotions is essential”. Items are rated on a five-point 
Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). From the perspective of test- 
and measurement-theory the 20-item version of the TAS-20 is the most robust and time-
economic instrument to measure Alexithymia currently available. However it has been criticized 
for its lack of discriminative validity and the fact that it requires a self-evaluation—the very 
feature alexithymia individuals are impaired in by definition (Kooiman, Spinhoven, & Trijsburg, 
2002; Rief, Heuser, & Fichter, 1996; Suslow, Donges, Kersting, & Arolt, 2000). Although defined 
as a trait measure, we collected the TAS-20 at all three time-points, to follow up reports on its 
doubtful temporal stability as a side-aim (De Gucht, Fontaine, & Fischler, 2004). For all other 
analyses the Post-Baseline score of the TAS-20 was used. 
Trait-anxiety was surveyed using the State-Trait Anxiety Inventory – Trait Form (STAI-G-X2, 
Laux et al., 1981). Trait neuroticism was measured by using the Big Five Personality Inventory 
NEO-FFI (Körner et al., 2008). Trait depression was defined as the mean BDI-II score of both 
baselines. Although the BDI-II is mostly used as a measure of state depression it has been 
reported to accurately assess trait-like characteristics (Spielberger, Brunner, Ritterband, & 
Reheiser, 2003). 
Statistics 
Statistics were processed with SPSS 21.0.0.0 for Mac OS (Statistical Product and Service 
Solutions Inc., Chicago, IL, USA), graphs were created using GraphPad Prism 5.0 (GraphPad 
Software, Inc, La Jolla, CA, USA). Statistical tests were performed at a two-tailed α < .05. Means 
are given ± standard deviation if not denoted otherwise. 
For aim one, a mixed linear model was used to estimate the effect of fixed factor time with the 
levels Pre-Baseline, Exam Period, and Post-Baseline on SOMS-7d Symptom Index, using SPSS’s 
genlinmixed function. To control for potential confounds, fixed factors MES with the levels 
yesMES and noMES, as well as factor disorder with levels yesDIS (i.e. stable past or chronic 
disorders) and noDIS (i.e. no disorders reported) were included into the model. To account for 
individual differences in SOMS-7d intensity score, a random intercept was added for each 
participant. An autoregressive covariance matrix (AR1) was used to model repeated covariance 
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within sessions. Robust estimation options and Satterthwaite-approximation were used to 
account for potential violations of model assumptions and correction of the estimated degrees of 
freedom for unequal sample sizes. The mixed model allows analyzing repeated-measures data 
without list-wise exclusion of missing values. Therefore all sessions meeting the deadlines in 
respect to past/upcoming exams were included in the analysis, even when a participant missed 
one or two sessions or deadlines. All other control variables besides MES were tested for effects 
of time analog to the linear mixed model for somatization scores. 
For MES, a chi-square test was used to determine if the proportion of reported 
infections/injuries during Exam Period differed from baselines. Further the mixed model 
described above was applied to address the question if the TAS-20 is a stable trait measure over 
time. In addition inter- (Pearson’s correlation coefficient) and intra-class correlations (ICC) for 
the TAS-20 were computed. Friedman’s tests were used for an item-by-item analysis of the 
SOMS-7d in order to identify symptoms increasing during Exam Period. For this item analysis an 
adapted α-level of < .001 was used to control for multiple-comparisons, and post-hoc 
Wilcoxon’s paired rank tests were performed to confirm increases between Exam Period and at 
least one baseline. 
Aim two was to identify the best explanatory trait variable for somatic symptoms at baseline and 
symptom increase under exam stress. Traits were alexithymia (TAS-20), neuroticism (NEO-FFI), 
trait anxiety (STAI-X-2), and trait depression (BDI-II). First, a correlation table using 
Kendall’s τ-b was created to explore monotonous relationships. Kendall’s τ-b is the non-
parametric correlation coefficient of choice for symptom rating scales, especially when 
comparisons are made between (sub-) samples of different size (Arndt, Turvey, & Andreasen, 
1999). For correlational analysis, Symptom Index at baseline was defined as the mean of both 
baseline sessions and somatization increase was defined as Symptom Index during the Exam 
Period minus Baseline. Correlation analysis was followed by a modeling approach to determine 
the best trait predictor of somatization symptoms. Eight variants of the basic model described 
above (Time, MES, and Disorder [df1=4]) were compared: Four models were created by adding 
one of the trait variates: Alexithymia, Neuroticism, Anxiety, or Depression (df1=5). Four further 
models included the respective first-degree trait-by-time interaction (df1=7) in addition. An 
individual random slope parameter for each trait variate was added to each model to keep the 
random effects structure of the model “maximal” (Barr, Levy, Scheepers, & Tily, 2013). Finally, 
Akaike’s Information Criterion for finite sample sizes (AICc) and Akaike Weights (Wagenmakers 
& Farrell, 2004) were used to determine the best-fitting model. 
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Results 
Sample description 
Figure 2.2 gives an overview of participant flow. Analysis was based on 142 participants (71 
female), of which 107 contributed three, 26 two, and 9 one valid session(s). Mean age at study 
inclusion was 22.2 ± 2.5 years (range: 18-33). Participants with past or chronic internal, 
neurological, and psychiatric disorders in stable remission constituted 11 % (8 male, 8 female) of 
the sample. The mean number of exams reported was 4.9 ± 2.1, ranging from 1 to 12. At mean, 
the Exam Period survey was submitted 1.0 ± 1.6 days after the exam defined as the intervention. 
For additional sample information see Appendix 2.1. 
Effects of exam stress on somatization 
 Pre-Baseline  Exam Period  Post-Baseline  
 n = 141 n = 123 n = 118 
Primary variable: 
SOMS-7d  11.1 ± 8.9 18.2 ± 14.5 9.7 ± 9.0 
Control variables: 
PSQ-20 33.6 ± 17.5 54.0 ± 19.3 29.8 ± 18.3 
BDI-II 6.6 ± 6.4 11.5 ± 7.0 5.2 ± 5.4 
STAI-G-X1 state 36.9 ± 8.1 42.74 ± 12.3 37.1 ± 10.3 
Side aim: temporal stability of the TAS-20 
TAS-20 45.3 ± 9.7 45.9 ± 10.1 44.6 ± 10.2 
Table 2.1: The effects of Exam Period on measures of somatic symptoms and stress: Descriptive results. All 
values represent mean ± SD. Abbreviations: BDI-II: Beck’s Depression Inventory; PSQ-20: Perceived Stress 
Questionnaire; SOMS-7d: Screening for Somatoform Symptoms 7-day version; STAI-G-X1 state: State-Trait 
Anxiety Inventory – State Form; TAS-20: Toronto Alexithymia Scale. 
In summary, the Symptom Index and all intervention check variables assessing stress, depression, 
and state anxiety were found to significantly increase during the Exam Period compared to both 
Pre and Post Baseline. Inclusion of the factors MES and disorder significantly improved model 
fit for the prediction of Symptom Index (Δdf1 = +2, ΔAICc = -20.29) and most control variables. 
Descriptive results are shown in Table 2.1, the corresponding mixed model results are shown in 
Table 2.2. 
 
Figure 2.2: Participant flow 
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 Model  Coefficient estimates (β ± SEM) 
Primary variable: 
SOMS-7d F(4, 6) = 18.92, p < .001 βExam = 8.89 ± 1.06, t = 8.42, p = .009 
  βpreBL = 1.77 ± 0.69, t = 2.553, p = .012 
  βMESyes = 2.44 ± 1.11, t = 2.20, p = .032 
  βyesDIS = 7.63 ± 3.15, t = 2.42, p = .076 
Control variables: 
PSQ-20 F(4, 168) = 55.68, p < .001 βExam = 24.22 ± 1.95, t = 12.45, p < .001 
  βpreBL = 3.98 ± 1.65, t = 2.410, p = .017 
  βyesMES = 0.27 ± 2.12, t = 0.13, p = .899 
  βyesDIS = 15.20 ± 4.25, t = 3.58 p = .001 
BDI-II F(4, 63) = 37.02, p < .001 βExam = 6.60 ± 0.61, t = 10.80, p < .001 
  βpreBL = 1.69 ± 0.50, t = 3.17, p = .003 
  βyesMES = 1.04 ± 0.67, t = 1.55, p = .124 
  βyesDIS = 4.49 ± 1.54, t = 2.92, p = .005 
STAI-G-X1 state F(4, 68) = 10.34, p < .001 βExam = 5.86 ± 1.19, t = 4.92, p < .001 
  βpreBL = 0.79 ± 0.90, t = 0.88, p = .930 
  βyesMES = 0.69 ± 1.20, t = 0.58, p = .566 
  βyesDIS = 6.32 ± 2.40, t = 2.63, p = .011 
Side aim: Temporal stability of the TAS-20 
TAS-20 F(4, 377) = 2.71, p = .030 βExam = 1.80 ± 0.60, t = 3.00, p < .003 
  βpreBL = 0.79 ± 0.56, t = 1.41, p = .164 
  βyesMES = 0.46 ± 0.93, t = 0.49, p = .623 
  βyesDIS = 4.14 ± 3.18, t = 1.30, p = .359 
Table 2: The effects of Exam Period on measures of somatic symptoms and stress: mixed model 
results. All linear mixed models included factors time (Pre-Baseline, Exam Period, Post-Baseline), MES 
(yesMES, noMES) and disorder (yesDIS, noDIS). Degrees of freedom (df2) may vary due to inequal sample 
sizes and the Satterthwaite correction used. All analyses were based on 142 subjects contributing 382 data-
points. Abbreviations: BDI-II: Beck’s Depression Inventory; GLM: Generalized Linear Model; MES: Medically 
Explained Symptoms; preBL: Pre-Baseline; PSQ-20: Perceived Stress Questionnaire; SOMS-7d: Screening for 
Somatoform Symptoms 7-day version; STAI-G-X1: State-Trait Anxiety Inventory – State Form; TAS-20: 
Toronto Alexithymia Scale; yesDIS: with stable past/chronic disorders; yesMES: evidence for MES. 
A chi-square test indicated that the proportion of participants reporting acute infections and/or 
injuries (evidence for MES) during Exam Period (8.1 %) was significantly lower (df = 2, χ2 = 7.45, 
p = .024) than at Pre- (19.1 %) and Post- (18.6 %) Baseline. 
Almost all participants (95.0 %) reported at least one symptom causing mild impairment 
according to the combined ICD-10 and DSM-IV list at baseline. The cumulative proportions of 
participants reporting at least one moderate, severe, or very severe symptom were 64.9 %, 
28.6 %, and 2.7 % respectively. These proportions increased under exam stress (mild: 97.6 %, 
medium: 80.5 %, severe: 51.2 %, very severe: 16.3 %). The eleven SOMS-7d items listed in 
Table 2.3 were found to be significantly elevated under exam stress according to Friedman’s-tests 
and post-hoc tests at α ≤ .001. A full description of results for all SOMS-7d items is available in 
Appendix 2.2. 
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Item Symptom Pre-
Baseline 
Exam 
Period 
Post-
Baseline 
Relative 
increase in 
prevalence 
Exam 
effect 
     any severe  
  n = 141 n = 123 n = 117  df = 2 
  Mean ± SD % of baseline Χ2F, sig 
1 Headache 
 
0.82 ± 0.92 1.33 ± 1.11 0.71 ± 0.78 30.7 258.8 26.70, **** 
2 Abdominal pain 
 
0.65 ± 0.89 0.93 ± 0.98 0.64 ± 0.79 30.7 123.1 14.91, *** 
3 Back pain 
 
0.71 ± 0.86 1.24 ± 1.12 0.75 ± 0.84 29.0 474.3 26.85, **** 
4 Joint pain 
 
0.33 ± 0.69 0.59 ± 0.88 0.34 ± 0.64 53.2 76.5 14.17, *** 
10 Nausea 
 
0.45 ± 0.71 0.76 ± 0.90 0.41 ± 0.66 53.8 317.8 23.64, **** 
12 Discomfort around 
stomach 
0.72 ± 0.94 1.24 ± 1.10 0.54 ± 0.83 79.8 199.5 43.44, **** 
17 Loss of appetite 
 
0.30 ± 0.68 0.67 ± 0.97 0.22 ± 0.59 136.2 222.9 26.36, **** 
20 Frequent diarrhea 
 
0.22 ± 0.60 0.50 ± 0.91 0.19 ± 0.53 105.3 227.9 14.24, *** 
30 Excessive tiredness 
after mild exertion 
0.50 ± 0.85 1.03 ± 1.21 0.37 ± 0.62 66.7 487.5 29.88, **** 
32 Sexual indifference 
 
0.35 ± 0.69 0.57 ± 0.83 0.23 ± 0.55 80.9 164.8 16.08, *** 
Table 2.3: Results for somatization items significantly increasing under exam stress. Symptoms were 
surveyed according to the Screening for Somatoform Symptoms 7-day version (SOMS-7d). Effects of Exam 
Period were tested using Friedman’s test (Χ2F). The alpha-Level was set to p ≤ .001 to correct for multiple 
comparisons. Significant results are depicted as **** p ≤ .0001, *** p ≤ .001. All post-hoc differences 
between baselines and Exam Period were significant as tested with Wilcoxon’s paired rank tests (results not 
shown). Increases in symptom prevalence are shown in % of valid cases for any severity (score ≥ 1) and 
severe/very severe only (score ≥ 3) at baseline. 
The explanatory value of personality traits on stress induced somatization 
Mean TAS-20 baseline score was 44.9 ± 9.5 and therefore roughly 4 units below norm values for 
the German population (Franz et al., 2008). Accordingly, only 8.9 %, or 19.3 %, of participants 
reached a TAS-20 score of 61 or 52.5—cut-off values suggested for the diagnosis of 
“alexithymic” (Franz et al., 2008). The significant differences in mean response found for TAS-20 
sum scores over time (see Table 2.2) were followed up by computing Pearson’s coefficient and 
the intra-class correlation coefficient (ICC): Correlations were r = .788 for Survey 1 and 2, 
r = .804 for Survey 2 and 3, and r = .787 (all p < .001) for Survey 1 and 3. Single ICC was .786, 
mean ICC .917. 
NEO-FFI-neuroticism scores (Körner et al., 2008) were close to normal values with a mean of 
21.0 ± 7.2 points. Mean BDI-II score was 6.0 ± 5.2 and therefore 4 units below a normal student 
sample (Storch, Roberti, & Roth, 2004). STAI-G-X2 trait anxiety scores were at 39.2 ± 8.7 points 
and therefore 4 units above a normal student sample (Laux et al., 1981). 
Correlations between somatic symptoms and trait variables according to Kendall’s τ-b are shown 
in Table 2.4. NEO-FFI-neuroticism was the only significant trait that correlated with somatic 
symptom increase during Exam Period, showing a positive monotonous relationship. All trait 
variables correlated with Symptom Index at baseline. All trait variables were considerably inter-
correlated. 
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 SOMS-7d baseline 
SOMS-7d 
increase 
TAS-20 
alexithymia 
NEO-FFI 
neuroticism 
STAI-G-X2 
trait anxiety 
SOMS-7d 
increase 
n = 134 
τ = .074 
p = .212 
   
 
TAS-20 
alexithymia 
n = 132 
τ = .228 
p < .001 
n = 131 
τ = -.050 
p = .412 
  
 
NEO-FFI 
neuroticism 
n = 132 
τ = .359 
p < .001 
n = 131 
τ = .152 
p = .012 
n = 132 
τ = .270 
p < .001 
 
 
STAI-G-X2 trait -
anxiety 
n = 142 
τ = .295 
p < .001 
n = 134 
τ = .074 
p = .212 
n = 132 
τ = .319 
p < .001 
n = 132 
τ = .514 
p < .001 
 
BDI-II baseline 
depression 
n = 142 
τ = .413 
p < .001 
n = 134 
τ = .066 
p = .271 
n = 132 
τ = .327 
p < .001 
n = 132 
τ = .470 
p < .001 
n = 142 
τ = .482 
p < .001 
Table 2.4: Correlations between somatic symptoms (SOMS-7d Symptom Index) at baseline, somatic 
symptom increase during an Exam Period and personality traits. All tests were performed using Kendall’s τ-
b. Abbreviations: BDI-II: Beck’s Depression Inventory; NEO-FFI: Big Five Personality Inventory, Neuroticism 
Subscale; SOMS-7d: Screening for Somatoform Symptoms 7 day version; STAI-G-X2: State-Trait Anxiety 
Inventory – Trait Form; TAS-20: Toronto Alexithymia Scale, 20-item version. 
An information theory driven model selection approach was applied to determine the best 
explanatory trait variable for the obtained somatization scores. AICc weights indicated that the 
basic model plus Neuroticism and Neuroticism x Time (df1 = 7) was the best-fitting model, with 
a probability of .97 relative to all equal or smaller models according to Akaike weights. The 
second-best model was the basic model plus the main effect of neuroticism only, with a 
probability of only .03. The competing models with TAS-20 and TAS-20 x Time 
(ΔAICc = +31.59), STAI-G-X2 and STAI-G-X2 x Time (ΔAICc = +105.22), and BDI-II and 
BDI-II x Time (ΔAICc = +81.93) had only marginal likelihoods of being the best-fitting model. 
The final model showed a significant main effect of Neuroticism (β = 0.44 ± 0.10[SEM], 
t = 4.34, p < .001) and MES (β = 2.55 ± 1.20[SEM], t = 2.10, p = .039), as well as a positive 
interaction between Neuroticism and Time F(2, 10) = 5.54, , p = .025, driven by a significant 
interaction of coefficients Neuroticism x Exam Period (β = 0.42 ± 0.13[SEM], t = 3.30, 
p = .020). The factor Disorder fell short of the criterion of significance (p = .128), which was also 
missed by all other coefficients. A graphical display of the relationship between Symptom Index, 
Neuroticism, and Time is given in Figure 2.3. 
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The models including TAS-20 (F[7, 3] = 16.39, p < .017), STAI-G-X2 (F[7, 7] = 15.01, p < .001), 
and BDI-II (F[7, 8] = 16.76, p < .001) were all explaining a significant amount of variance, 
however the coefficients TAS-20 x Exam Period (β = 0.101 ± 0.12[SEM], t = 0.86, p = .553), 
STAI-G-X2 x Exam Period (β = 0.31 ± 0.13[SEM], t = 2.46, p = .147) and BDI-II x Exam 
Period ( = 0.41 ± 0.23[SEM], t = 1.78, p = .183) failed to do so. 
Original data for the present results have been made publicly available as a download. However, 
the following changes to the raw data file were made: Birthdate, exam date, date of study 
inclusion, information on illicit drug use, subject of study, original description of medical history 
and original description of current illness/injuries were deleted and/or replaced by summary 
variables to ensure participant’s privacy. 
 
Figure 2.3: The relationship between trait neuroticism, somatic symptoms at baseline, and somatic 
symptoms under exam stress. There was a significant interaction between neuroticism and exam period 
(β = 0.42 ± 0.13[SEM], t = 3.30, p = .020), even when accounting for medically explained symptoms and 
pre-existing disorders. Raw data are shown and simple linear interpolation lines were added for illustrative 
purposes. To reduce overlap, data points for Pre- and Post-Baseline were shifted by -0.5 and +0.5 points 
along the x-axis, respectively, 
 S T U D Y  2 :  E X A M  S T R E S S  A N D  S O M A T I C  S Y M P T O M S  
54 
Discussion 
This quasi-experimental study was conducted to provide a comprehensive quantification of 
somatic symptoms under exam stress in healthy students and to evaluate whether personality 
traits such as alexithymia can explain their occurrence. 
Exam stress increases somatization—typical symptoms 
During an exam period, symptom scores showed highly significant increases compared to Pre- 
and Post-Baselines, even when accounting for participant reports of infections/injuries and pre-
existing disorders statistically. This was paralleled by increases in perceived stress, depression, and 
anxiety. These findings confirm that academic exam periods represent an effective model for 
psychosocial stress, with a significant impact on somatization. Bodily complaints increased across 
several domains encompassing pain, gastro-intestinal, and autonomic symptoms. Significant 
increases during the Exam Period were mainly found for symptoms with a high prevalence at 
baseline, e.g: headache, back pain, abdominal pain, and nausea. An exception of this trend was 
bloating, which did not significantly increase although being one of the most common 
symptoms. The symptom with the highest absolute increase in prevalence across all severities was 
discomfort/churning around the stomach, which is synonymous to the proverbial “butterflies in 
the stomach” commonly associated with exams. However, the symptoms with the highest 
relative increases in prevalence were loss of appetite, frequent diarrhea, and sexual indifference. 
These can therefore be recommended as the most target specific symptoms of exam stress for 
future studies. Finally, the symptoms with the strongest relative increases when counting 
severe/very severe ratings only, were excessive tiredness after mild exertion, back pain, nausea, 
and headache, indicating that these are the exam stress-related symptoms perceived as the most 
impairing.  
The differentiation of MES and MUS poses a challenging problem in the study of somatization 
(Klaus et al., 2013). Reports of infections and injuries were obtained in the present study to 
account for the effects of MES statistically. In addition these reports were found to significantly 
decline during Exam Period by about half, while predicting increased somatization symptom 
scores across all sessions. This decrease in MES may be explained by the well-known temporary 
immune-enhancing effects of acute stressors (Dhabhar, 2009), as well as reductions in social 
and/or physical activity during the exam preparation period. 
Neuroticism is associated with somatization increases under stress 
Neuroticism was found to explain a significant amount of variance in somatization under exam 
stress. Participants with high trait neuroticism scores showed higher symptom scores in general 
and higher symptom increases under exam stress. This finding replicates previous reports of 
baseline correlations between neuroticism and somatic symptoms (De Gucht, Fischler, et al., 
2004; Lane, Carmichael, & Reis, 2011; Noyes et al., 2001; Wise & Mann, 1994) and extends them 
by showing that neuroticism can explain stress-induced somatization. Neuroticism has been 
investigated as personality trait moderating stress reactivity since a long time. It has been linked 
to differences in the appraisal of a stressor, as well as the reactivity to a stressor. Further it has 
been discussed in conjunction with differences in stress coping behaviors and even differences in 
exposure to stressors. (Bolger & Zuckerman, 1995; Gunthert, Cohen, & Armeli, 1999). All of 
these influences might account for the observed relationship. 
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No support for the stress-alexithymia hypothesis 
Although the present study could replicate findings that TAS-alexithymia (for review see: De 
Gucht & Heiser, 2003), trait anxiety, and baseline depression (De Gucht, Fischler, et al., 2004) 
are positively associated with somatization at baseline, no such relationship could be found for 
increases in somatization under exam stress. Compared to neuroticism, TAS-alexithymia, anxiety, 
and baseline depression had only a marginal likelihood of being the best explanatory variable for 
the observed variance in Symptom Index. These results do not support our second hypothesis, 
which claimed that alexithymia was a significant and superior explanatory variable for exam stress 
induced somatization. This finding is in agreement with experimental studies, which reported that 
alexithymia was not associated with an increased reactivity to physiological measures of stress (de 
Timary et al., 2008; Pedrosa Gil et al., 2008). Further our results are in line with a longitudinal 
study, which could not find a predictive value of alexithymia for the persistence of unexplained 
physical symptoms in general medical outpatients (C. G. Kooiman, 2004). In accord with earlier 
conclusions (Lumley, Stettner, & Wehmer, 1996), our results point out that alexithymia and 
somatization might not be linked by a difference in reactivity to acute stress in the general 
population. It must be emphasized that exam stress is only one specific form of psychosocial 
stress. The link between alexithymia and stress reactivity might be different for other forms of 
psychosocial stress, such as long-term interpersonal stress. Moreover, the role of alexithymia 
might be different in patient samples, or highly alexithymic sub-populations. 
On the temporal stability of the TAS-20 
The temporal stability of the TAS-20, especially in clinical samples and under conditions of 
psychological distress, has been a matter of discussion (De Gucht, Fontaine, et al., 2004). In the 
present study, significant differences in TAS-20 between Session 2 and 3, but not 2 and 1 could 
be found. This result somewhat confirms reports of a state and probably stress dependent 
proportion of TAS-20 scores (De Gucht, Fontaine, et al., 2004; Fukunishi, Kikuchi, Wogan, & 
Takubo, 1997). However, the small size of session-to-session differences during a period of 
increased stress leads us to the conclusion that the TAS-20 is a reliable trait measure with only 
minor state confounds. Pearson’s correlation coefficients computed and a ICC computed for all 
three survey time-points confirm this notion by indicating an acceptable re-tests reliability 
of r > .75. 
Limitations 
Two baselines, before and after Exam Period, were included in the present study. Since all 
psychometric scores returned to normal at Post-Baseline, it can be ruled out that the observed 
increases reflect simple time effects. A number of control variables showed parallel effects for 
measures of distress (stress, depression, and anxiety) and a reduction in infection and/or injuries, 
which confirms that the observed effects are due to exam stress. MES were surveyed and 
categorized to control for participant bias. Nevertheless, several limitations apply to the present 
study and its interpretation: 
The main limitation of the present study is that response bias, driven by social desirability might 
have confounded all measures. Participants were aware of the study’s focus on the effects of 
exam stress; otherwise exact exam dates could not have been obtained. This might have in- or 
deflated somatization reports during the Exam Period, especially since it is known that students 
tend to bias retrospective ratings of pre-exam distress in the direction that maximizes self-esteem 
(Dewhurst & Marlborough, 2003). 
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In addition, our sample size decreased with each survey. This might have biased results towards a 
healthier student sample. Differences between Pre- and Post-Baselines are therefore not 
discussed, since these might be explained by drifts in sample characteristics and reduced stress 
levels alike. 
Finally, the trait measures NEO-FFI and STAI-G-X2 have been recorded at Pre- or Post-
Baseline only, to reduce participant’s timely efforts. Despite the high temporal stability of the 
STAI-G-X2 (Laux et al., 1981), its comparability with the other trait variables might be 
confounded by subtle state-differences between the baselines and the mentioned change in 
sample size. 
Conclusion 
Here we could show that somatization significantly increased under exam stress across a range of 
symptom dimensions in healthy university students. The present results verify that transient 
increases in somatization can be evoked by psychosocial stress. The dataset constitutes a valuable 
basis for future studies on bodily symptoms under psychosocial stress. Further the present 
findings could not support the stress-alexithymia hypothesis. This highlights that studies in 
search of personality factors predisposing for somatization should always consider alternative 
explanatory concepts. Neuroticism was identified as a better correlate of somatization induced by 
acute exam stress than TAS-alexithymia, trait anxiety, or depression. Perceptions or behaviors 
related to neuroticism might be of etiological importance for somatization under psychosocial 
stress and pose interesting targets for future studies. 
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Appendix 2.1 
Additional sample information 
SAMPLING: The sample size of 150 participants was selected a-priori, based on the resources 
available for recruiting and testing. Of the 142 participants passed to analysis, 90 participants 
were recruited during academic winter term 2011/2012 and 52 during summer term 2012. A 
mean of 126.1 ± 48.3 days passed between study inclusion (Pre-Baseline) and study exclusion 
(Post-Baseline). Mean exam phase duration (last, minus first exam date) was 19.7 ± 20.0 days, 
ranging from 0 to 122. Data for all variables was checked for outliers by visual examination of 
histograms, scatterplots, and by comparison with the available reference sample distributions. No 
unambiguous outliers were identified. 
EXCLUDED FROM STUDY: Eight (6 male, 2 female) participants were excluded from the study due 
to the following reasons: 
Acute disorder or injury (n = 3); Lost to follow up (n = 3); University drop out (n = 1). 
Voluntary drop out (n = 1). No reason was given for the withdrawal of consent for the voluntary 
drop out. 
PAST/CHRONIC DISORDERS: Sixteen (8 male, 8 female) participants had a history of major 
internal, or psychiatric disorders, or stable chronic disorders. These were: migraine (n = 5); 
chronic back pain (n = 3); chronic Joint pain (n = 2); depression (n = 2); tinnitus, urticaria, 
orofacial pain, social anxiety (each n = 1). 
PARTICIPANTS’ FIELDS OF STUDY (IN % OF VALID CASES.): Psychology/medicine 26.8 %; 
Humanities 27.5 %; Natural sciences, engineering, mathematics, or informatics 22.5 %; 
Economics 5.6 %; others in 17.6 %. 
PARTICIPANTS’ DRUG HABITS (IN % OF VALID CASES): Regular alcohol consumption: 83.7 %; 
regular nicotine consumption: 22.7 %; regular caffeine consumption: 66.7 %; regular 
consumption of cannabis/illicit drugs: 0.7 % 
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Appendix 2.2 
Item 
No Symptom 
Pre-Baseline 
n = 141 (f = 70, m = 71) 
Exam Period 
n = 123 (f = 61, m = 62) 
Post-Baseline 
n = 117 (f = 59, m = 58) 
Relative 
Increase  
Exam 
Effect 
  Symptom Index 
% 
Prevalence 
Symptom 
Index 
% 
Prevalence 
Symptom 
Index 
% 
Prevalence 
% 
Baseline 
Prevalence 
Χ2F Sig. 
  Mean±SD Any/Severe Mean±SD Any/Severe Mean±SD Any/Severe Any/Severe   
1 Headache 0.82±0.92 53.2 5.7 1.33±1.11 70.7 16.3 0.71±0.78 55.1 3.4 30.7 258.8 26.70 **** 
2 Abdominal pain 0.65±0.89 42.6 4.3 0.93±0.98 57.7 5.7 0.64±0.79 45.8 0.8 30.7 123.1 14.91 *** 
3 Back pain 0.71±0.86 50.4 2.8 1.24±1.12 67.5 15.4 0.75±0.84 54.2 2.5 29.0 474.3 26.85 **** 
4 Joint pain 0.33±0.69 23.4 2.8 0.59±0.88 37.4 3.3 0.34±0.64 25.4 0.8 53.2 76.5 14.17 *** 
5 Pain in legs/ arms 0.29±0.54 25.5 0.7 0.51±0.80 36.6 1.6 0.43±0.71 33.1 0.8     
6 Chest pain 0.09±0.35 7.1 0.7 0.21±0.62 13.8 1.6 0.19±0.51 14.4 0.8     
7 Rectal pain 0.11±0.35 9.2 0.0 0.15±0.54 8.9 1.6 0.06±0.33 4.2 0.8     
8 Pain during sexual intercourse 0.06±0.31 4.3 0.7 0.07±0.25 6.5 0.0 0.08±0.32 5.9 0.0     
9 Pain during urination 0.06±0.34 4.3 0.7 0.08±0.35 6.5 0.8 0.03±0.18 3.4 0.0     
10 Nausea 0.45±0.71 33.3 0.7 0.76±0.90 50.4 3.3 0.41±0.66 32.2 0.8 53.8 317.8 23.64 **** 
11 Bloating 0.89±0.93 57.4 6.4 0.91±0.91 60.2 4.9 0.75±0.97 46.6 8.5     
12 Discomfort/ churning around stomach 0.72±0.94 44.0 6.4 1.24±1.10 71.5 14.6 0.54±0.83 35.6 3.4 79.8 199.5 43.44 **** 
13 Vomiting (excluding pregnancy) 0.04±0.26 2.8 0.0 0.03±0.28 1.6 0.8 0.05±0.29 3.4 0.0     
14 Regurgitation 0.20±0.50 16.3 0.7 0.36±0.77 22.8 3.3 0.11±0.31 11.0 0.0     
15 Hiccup or heartburn 0.18±0.49 14.9 0.7 0.17±0.47 13.0 0.0 0.17±0.42 15.3 0.0     
16 Food intolerance 0.23±0.58 16.3 1.4 0.33±0.76 19.5 3.3 0.24±0.62 16.1 2.5     
17 Loss of appetite 0.30±0.68 19.9 2.8 0.67±0.97 41.5 7.3 0.22±0.59 15.3 1.7 136.2 222.9 26.36 **** 
18 Bad taste in mouth or coated tongue 0.45±0.76 31.9 3.5 0.49±0.79 33.3 3.3 0.32±0.64 24.6 1.7     
19 Dry mouth 0.24±0.57 17.7 0.7 0.38±0.75 26.0 4.1 0.27±0.59 20.3 0.8     
20 Frequent diarrhea 0.22±0.60 14.9 2.1 0.50±0.91 30.1 4.9 0.19±0.53 14.4 0.8 105.3 227.9 14.24 *** 
21 Discharge of fluid from anus 0.05±0.28 3.5 0.0 0.07±0.34 4.9 0.0 0.02±0.13 1.7 0.0     
22 Frequent urination 0.33±0.62 27.0 1.4 0.60±0.94 36.6 6.5 0.24±0.60 16.9 1.7     
23 Frequent defecation 0.25±0.58 18.4 0.7 0.44±0.80 27.6 3.3 0.15±0.48 11.0 0.8     
24 Palpitations 0.13±0.42 10.6 0.0 0.33±0.70 23.6 3.3 0.11±0.41 8.5 0.8     
25 Feelings of pressure around precordium 0.09±0.31 8.5 0.0 0.24±0.61 18.7 1.6 0.13±0.44 9.3 0.8     
26 Sweating 0.23±0.51 19.1 0.7 0.44±0.84 26.8 4.1 0.22±0.53 16.9 0.0     
27 Flushing or blushing 0.23±0.56 17.7 0.7 0.45±0.78 29.3 2.4 0.19±0.44 17.8 0.0     
28 Breathlessness without exertion 0.08±0.36 5.7 0.7 0.15±0.57 9.8 2.4 0.08±0.36 5.9 0.0     
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Item 
No Symptom 
Pre-Baseline 
n = 141 (f = 70, m = 71) 
Exam Period 
n = 123 (f = 61, m = 62) 
Post-Baseline 
n = 117 (f = 59, m = 58) 
Relative 
Increase  
Exam 
Effect 
  Symptom Index 
% 
Prevalence 
Symptom 
Index 
% 
Prevalence 
Symptom 
Index 
% 
Prevalence 
% 
Baseline 
Prevalence 
Χ2F Sig. 
  Mean±SD Any/Severe Mean±SD Any/Severe Mean±SD Any/Severe Any/Severe   
29 Hyperventilation 0.11±0.43 8.5 1.4 0.21±0.62 13.8 3.3 0.07±0.31 5.1 0.0     
30 Excessive tiredness on mild exertion 0.50±0.85 31.9 5.0 1.03±1.21 52.0 17.1 0.37±0.62 30.5 0.8 66.7 487.5 29.88 **** 
31 Blotchiness or discoloration of skin 0.10±0.40 6.4 0.0 0.31±0.73 19.5 2.4 0.09±0.39 6.8 0.8     
32 Sexual indifference 0.35±0.69 26.2 2.8 0.57±0.83 39.8 4.9 0.23±0.55 17.8 0.8 80.9 164.8 16.08 *** 
33 Unpleasant sensations around genitals 0.11±0.39 8.5 0.7 0.14±0.50 9.8 0.8 0.04±0.20 4.2 0.0     
34 Impaired coordination or balance 0.13±0.39 10.6 0.0 0.28±0.63 20.3 1.6 0.08±0.30 6.8 0.0     
35 Paralysis or myasthenia 0.01±0.12 1.4 0.0 0.07±0.34 4.9 0.0 0.03±0.16 2.5 0.0     
36 Difficulty swallowing or lump in throat 0.18±0.55 11.3 1.4 0.16±0.55 10.6 2.4 0.08±0.27 7.6 0.0     
37 Loss of voice 0.11±0.40 9.2 0.7 0.07±0.32 5.7 0.0 0.07±0.31 5.1 0.0     
38 Urinary retention 0.01±0.08 0.7 0.0 0.04±0.24 3.3 0.0 0.03±0.21 1.7 0.0     
39 Hallucinations 0.06±0.23 5.7 0.0 0.10±0.32 8.9 0.0 0.04±0.24 3.4 0.0     
40 Loss of touch or pain sensation 0.01±0.08 0.7 0.0 0.04±0.24 3.3 0.0 0.04±0.20 4.2 0.0     
41 Paresthesias 0.14±0.41 12.1 0.0 0.25±0.64 17.1 2.4 0.11±0.34 10.2 0.0     
42 Double vision 0.05±0.30 3.5 0.7 0.07±0.31 4.9 0.0 0.01±0.09 0.8 0.0     
43 Blindness 0.01±0.08 0.7 0.0 0.01±0.09 0.8 0.0 - - 0.0     
44 Deafness 0.03±0.17 2.8 0.0 0.01±0.09 0.8 0.0 0.03±0.16 2.5 0.0     
45 Seizures 0.01±0.12 1.4 0.0 0.07±0.34 4.9 0.0 0.04±0.24 3.4 0.0     
46 Amnesia 0.06±0.30 5.0 0.0 0.11±0.40 7.3 0.0 0.05±0.26 4.2 0.0     
47 Fainting 0.01±0.08 0.7 0.0 - - 0.0 0.01±0.09 0.8 0.0     
48 Painful menstruation 0.51±0.96 27.1 5.7 0.56±0.99 29.5 6.6 0.47±0.91 25.0 6.7     
49 Irregular menstruation 0.41±0.96 20.0 5.7 0.67±1.22 31.1 13.1 0.33±0.84 18.3 5.0     
50 Excessive menstrual bleeding 0.17±0.54 11.4 1.4 0.20±0.65 9.8 3.3 0.15±0.49 10.2 0.0     
51 Vomiting during pregnancy - - - - - - - - -     
52 Unusual/excessive vaginal discharge 0.24±0.52 20.0 0.0 0.48±0.81 31.1 3.3 0.31±0.65 22.0 1.7     
53 Erectile or ejaculatory dysfunction 0.06±0.37 2.8 1.4 0.02±0.13 1.6 0.0 0.05±0.22 5.2 0.0     
Appendix 2.2: SOMS items under exam stress: Full results. Symptoms were surveyed according to the Screening for Somatoform Symptoms 7 day (SOMS-7d). Effects of 
Exam Period were tested using Friedman’s test (Χ2F). The alpha-Level was set to ≤ 0.001 to correct for multiple comparisons. Significant results are depicted as **** p ≤ 
0.0001, *** p ≤ 0.001. All post-hoc differences between baselines and Exam Period were significant as tested with Wilcoxon’s paired rank tests (results not shown). 
Increases in symptom prevalence are shown in %of valid cases for any severity (score ≥ 1) and severe/very severe only (score ≥ 3) at baseline. 
 
 S T U D Y  3 :  B R E A T H I N G  E X E R C I S E S  A N D  P A I N  
60 
S T U D Y  3  
Do cardiorespiratory variables predict the antinociceptive 
effects of deep and slow breathing? 
Matthias Zunhammer, Peter Eichhammer, Volker Busch 
This is a pre-copy-editing, author-produced version of an article published 2013 in Pain Medicine (14:843–854) 
following peer review. The definitive publisher-authenticated version is available at: 
http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291526-4637 
© 2013 Wiley periodicals Inc.: Reprinted with permission. 
Abstract 
Deep and slow breathing (DSB) is a central part of behavioral exercises used for acute and 
chronic pain management. Its mechanisms of action are incompletely understood. 
OBJECTIVES: 1) To test the effects of breathing frequency on experimental pain perception in a 
dose dependent fashion. 2) To test the effects of breathing frequency on cardiorespiratory 
variables hypothesized to mediate DSB analgesia. 3) To determine the potential of the 
cardiorespiratory variables to mediate antinociceptive DSB effects by regression analysis. 
DESIGN: Single-blind, randomized, crossover trial. 
SUBJECTS: Twenty healthy participants. 
INTERVENTIONS: Visually paced breathing at 0.14 Hz, 0.10 Hz, 0.06 Hz, and resting frequency. 
OUTCOME MEASURES: Cardiorespiratory variables: RR-interval (= 60 s/heart rate), standard 
deviation of the RR-interval (SDRR), and respiratory CO2. Experimental pain measures: Heat 
pain thresholds, cold pain thresholds, pain intensity ratings, and pain unpleasantness ratings. 
RESULTS: 1) There was no significant effect of DSB frequency on experimental pain perception. 
2) SDRR and respiratory CO2 were significantly modulated by DSB frequency, while RR-interval 
was not. 3) Baseline-to-DSB and session-to-session differences in RR-interval significantly 
predicted pain perception within participants: Prolonged RR-intervals predicted lower pain 
ratings and shortened RR-intervals predicted higher pain ratings. SDRR and respiratory CO2 
were not found to predict pain perception. 
CONCLUSION: The present study could not confirm hypotheses that the antinociceptive effects 
of DSB are related to changes in breathing frequency, heart rate variability, or 
hypoventilation/hyperventilation when applied as a short-term intervention. It could confirm the 
notion that increased cardiac parasympathetic activity is associated with reduced pain perception. 
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Introduction 
Deep and slow breathing (DSB) techniques are used in the multimodal therapy of chronic pain as 
a behavioral method of pain management (Morone & Greco, 2007). Most DSB techniques are 
characterized by a reduction of breathing frequency and a diaphragmal emphasis of breathing 
with a long exhalation phase. In clinical practice, biofeedback techniques often pace the 
frequency of DSB, i.e., the patient is instructed to inhale/exhale according to a moving bar 
shown on a screen (Lehrer, Vaschillo, & Vaschillo, 2000). Despite the widespread popularity and 
some evidence of its effectiveness in painful conditions (Chambers, Taddio, Uman, & McMurtry, 
2009; Friesner, Curry, & Moddeman, 2005; Hassett et al., 2007) and experimental settings (Busch 
et al., 2012; Cogan & Kluthe, 1981; Zautra, Fasman, Davis, & Craig, 2010), the mechanisms of 
action of DSB are still not fully understood. 
The majority of studies have suggested that the antinociceptive effects of DSB are mediated by 
psychological mechanisms, such as facilitation of emotional regulation (Zautra et al., 2010), 
relaxation (Busch et al., 2012; Cogan & Kluthe, 1981) or distraction (Chambers et al., 2009). In 
addition, expectancy and placebo effects have to be considered (Buhle, Stevens, Friedman, & 
Wager, 2012; Subotnik & Shapiro, 1984). However, there is a body of evidence suggesting that 
DSB has elementary physiological consequences that may directly or indirectly moderate 
antinociceptive effects: Slow breathing frequencies have been reported to prolong RR-intervals 
(= 60[beats]/heart rate [beats/s] by definition; Pöyhönen, Syväoja, Hartikainen, Ruokonen, & 
Takala, 2004) and studies using heart rate biofeedback found that prolonged RR-intervals are 
associated with diminished pain perception (Reeves & Shapiro, 1982; Victor, Mainardi, & 
Shapiro, 1978). Further, DSB is likely to influence pulmonary gas exchange. Faster breathing 
frequencies may lead to hypocapnia and very slow breathing frequencies may lead to hypercapnia. 
The latter has been shown to cause antinociceptive effects (Stokes III., Chapman, & Smith, 
1948). Moreover, increases in heart rate variability (HRV) depend on breathing frequency. It is 
known that HRV reaches its maximum at a breathing frequency of approximately 0.10 Hz 
(6 breaths/min), the so-called “resonant frequency” (Lehrer et al., 2003; Vaschillo, Vaschillo, & 
Lehrer, 2006; Vaschillo, Vaschillo, Pandina, & Bates, 2011). Based on this observation, it has 
been hypothesized in the field of HRV biofeedback that DSB may modulate autonomic nervous 
system (ANS) activity and pain perception most efficiently at the resonant frequency (Chalaye, 
Goffaux, Lafrenaye, & Marchand, 2009). 
In summary, depending on the breathing frequency, DSB might affect a number of 
cardiorespiratory variables that might in turn mediate changes in pain perception. To our 
knowledge, the impact of DSB frequency on pain perception has not been studied so far in a 
dose-dependent fashion. It is further unclear, which of the mentioned cardiorespiratory variables 
are influenced by DSB frequency and at the same time able to predict antinociceptive effects. 
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Therefore, the first objective of the present study was to test experimentally if pain perception 
was significantly affected by four different paced DSB frequencies. Pain perception was 
measured using thermal pain thresholds and by retrieving ratings of tonic heat stimuli. The 
second study objective was to test the effects of four paced breathing frequencies on the 
cardiorespiratory variables RR-interval, standard deviation of the RR-interval (SDRR), and 
respiratory CO2. Finally, the third study objective was to determine if DSB-initiated changes in 
the measured cardiorespiratory variables could predict changes in nociception. Based on the 
studies mentioned earlier, it was expected that increases in RR-interval, SDRR, and respiratory 
CO2 predict anti-nociception. 
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Methods 
Participants: 
Twenty healthy volunteers (50 % male) were recruited by advertisement among university 
students. Absence of acute infections, obesity, internal, neurological, or psychiatric disorders, 
acute or chronic pain, as well as absence of analgesic, psychoactive, cardiovascular, or anti-allergic 
medication was ascertained in a structured clinical inter-view with a certified specialist. Written 
informed consent was obtained from all participants. The study was approved by the local ethics 
committee and is conform to the Declaration of Helsinki (59th WMA General Assembly, 2009). 
Participants were informed that the study aim was to determine the effect of “several breathing 
exercises” on pain perception, but it was not explicated that the study focused on breathing 
frequency and that one session involved paced breathing at their own baseline frequency. 
Participants were not given any suggestion that a certain breathing condition may be more 
effective than the others. 
Procedure: 
The present study was designed as a randomized, repeated-measures, single-blind trial with four 
sessions per participant. The experimental conditions were paced breathing at:  
1) 0.14 Hz (8.4 breaths/min), 
2) 0.10 Hz (6 breaths/min), 
3) 0.06 Hz (3.6 breaths/min), and 
4) the individual’s resting frequency. 
The breathing conditions were arranged in 20 different intervention sequences balanced for first 
session. Participants were randomly assigned to these intervention sequences using a free online 
tool (Urbaniak & Plous, 2011). To get accustomed to the laboratory setting, all participants 
completed an additional training session before the first testing session, where paced breathing 
was exercised at different breathing frequencies and pain measurement procedures were 
practiced. Sessions were scheduled at least 7 days apart, to rule out carryover effects between the 
experimental conditions. Sessions were held always at the same time of day (± 1 hour) to control 
for circadian effects. All testing was performed in a quiet room, with participants sitting in a 
comfortable reclining chair in a semi-supine position. Participants were sitting for at least 10 min 
before any measurement was started. A full timeline of the procedures is shown in Table 3.1. 
 
0 min 10 min 20 min 30 min 40 min 50 min 60 min 70 min 80 min End 
Exclusion criteria 
 
Vital Signs 
 
Electrode Setup 
ECG Measures 
CO2 Measures 
Thermal 
Thresholding Tonic Heat Testing 
Vital 
Signs 7 min 7 min 30 min 30 min 
Rest Paced Breathing (at 0.14, 0.10, or 0.06 Hz, or at Resting Frequency) 
Table 3.1: Timeline of experimental procedures, ECG=electrocardiogram. 
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For baseline resting period, participants were asked to relax, breathe normally, and sit quietly for 
7 min. For the rest of the session, breathing was paced visually, with a vertically moving bar 
presented on-screen using EZ-Air Plus (BFE, retrieved from http://www.bfe.org/ 
breathpacer.htm). The inspiration-to-expiration ratio was set to 1:2 for all frequencies (Eckberg, 
Kifle, & Roberts, 1980; Strauss-Blasche et al., 2000). In each session, participants were instructed 
to pace their breathing according to a script adapted from Lehrer et al. (Lehrer et al., 2000) 
focusing on a “constant diaphragmal breathing rhythm, while using pursed lips to control 
exhalation volume”, emphasizing that they should “breathe in a relaxed way” and “not try too 
hard.” They were further instructed to maintain paced breathing during and between all 
measurements. For the resting frequency condition, the breath pacer was set to the individual’s 
mean resting frequency of that day’s 5 min of rest. 
R-R intervals and heart rate variability measures: 
The “EXG” module of a “Biofeedback Expert 2000” system (Schuhfried, Mödling, Austria) was 
used to obtain a standard three lead setup electrocardiograms (ECGs). ECGs were recorded 
during 7 min of rest and 7 min of paced breathing at a sampling frequency of 1 kHz with 
instantaneous R-R interval detection. An ECG dataset was defined as the last 5 min of a given 
measuring period. Recording and data processing was performed following the appropriate 
guidelines (Malik et al., 1996). 
SDRR was defined as the only outcome measure of HRV for the present study. Frequency 
domain measures of HRV, such as low- (LF) and high-frequency power (HF) were included for 
descriptive purposes, but excluded from further analysis, as they are only valid indices of ANS 
function, when breathing frequency is constant between experimental conditions (Ritz & Dahme, 
2006). LF and HF represent the spectral power of HRV in frequency bands of 0.04–0.15 Hz and 
0.15–40 Hz, respectively. Respiratory sinus arrhythmia (RSA) usually is the main source of HF 
power under resting conditions with a peak around 0.20 Hz. Paced breathing according to our 
experimental conditions switches RSA power below 0.15 Hz and therefore from HF to LF. The 
subsequent increase in LF and decrease in HF would therefore reflect the filter properties 
inherent to these measures instead of meaningful changes in vagal activity. The time domain 
measure root mean square successive difference (RMSSD) was dismissed from further analysis 
due to similar reasons (Berntson, Lozano, & Chen, 2005). 
All HRV variables were calculated using the software Kubios-HRV (Niskanen, Tarvainen, Ranta-
Aho, & Karjalainen, 2004). All recordings were inspected visually and artifacts corrected with the 
software’s built-in filter function. Recordings with more than three artifacts were to be excluded 
from analysis. 
Respiratory measures and CO2: 
Respiratory amplitude was recorded using the “RESP” module of the biofeedback equipment. 
The module equals a strain gauge with a resolution of 0.2 mm and a sampling-rate of 200 Hz. 
Recordings were visually checked and artifacts corrected. Analysis was performed using an 
adapted version of the open-source algorithm “peakdet” (Billauer, 2007) in combination with a 
moving-average low-pass filter with a window size of 0.5 s. End-tidal partial pressure of 
respiratory CO2 was measured at the end of the resting and breathing intervals using a tight-
fitting anatomic mask, in combination with a CO2 sensor connected to a Sirecust (SC) 9000XL 
(Siemens, Erlangen, Germany) health monitor. The CO2 values of five subsequent breaths were 
recorded and averaged. 
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Testing of Pain Perception 
Temperature stimuli were applied to the volar surface of the left lower arm with a 30 x 30 mm 
thermode connected to a Thermosensory Analyzer II (Medoc, Ramat Yishai, Israel). The 
thermode was kept in place by an elastic strap, while the arm comfortably rested on a tablet 
attached to the chair. The experimenter relocated the thermode once after the thresholding 
procedure and once after half of the tonic heat rating procedure. The three sites of stimulation 
were 3 cm, 9 cm, and 15 cm above the wrist, used in balanced sequence. 
Heat and cold pain thresholds were determined using the method of limits according to 
established protocols (Busch et al., 2012). Nociceptive perception was measured using cold pain 
threshold (CPT) and heat pain threshold (HPT). In short, five stimuli were presented as 
decreasing (CPT) or increasing (HTP) temperatures starting from a baseline of 32 °C. 
Participants were instructed to press a stop button at pain threshold defined according to a read-
aloud script (Rolke et al., 2006). Stimuli were separated by jittered interstimulus intervals of 
11 ± 1 s. The first stimulus was defined as a trial stimulus and discarded from analysis. 
Thresholds were defined as the mean of the four other stimuli. 
As a second measure of pain perception, a rating procedure (Geuze et al., 2007) was employed: 
18 heat stimuli with temperature levels of 43, 44, 45, 46, 47, and 48 °C were applied. Each level 
was presented three times. All stimuli were applied in pseudorandomized sequences, ensuring 
that no temperature occurred twice in a row. Sequences were randomly assigned across 
participants and conditions. All heat stimuli were applied for 20 s duration, oscillating ± 1 °C 
around the temperature levels at 0.5 Hz (speed: 2 °C/s) to reduce adaption/sensitization effects 
(Schmahl et al., 2006). Thermode temperature ramp-up was set to 2 °C/s, the interstimulus 
interval was 30 s. After nine stimuli, thermode location was switched. Before the procedure and 
after changing thermode location, two preconditioning stimuli of 43 and 47 °C were applied to 
reduce adaption/sensitization effects. Participants could stop a stimulus if deemed unbearable at 
any time by pressing a button. In this case, the following interstimulus interval was automatically 
prolonged to keep testing duration constant. During the interstimulus intervals, participants were 
asked to enter ratings of pain intensity and unpleasantness on two visual analog scales (VASs) 
shown on-screen using a mouse. The VASs that ranged from “0” to “100”, were ticked and 
labeled in steps of 10, and the cursor always started at “0.” Instructions were provided to the 
participant before the procedure by a read-aloud script. The distinction between pain intensity 
and pain unpleasantness was illustrated according to established protocols (Price, McGrath, Rafii, 
& Buckingham, 1983) and resulted in two variables: pain intensity ratings and pain 
unpleasantness ratings. Both were calculated as the mean individual rating response to 
temperature steps 45, 46, 47, and 48°C. Ratings for 43 and 44°C were excluded from analysis as 
preliminary results indicated that ratings did not significantly differ from 0. 
Statistics 
SPSS 19.0.0.2 for Mac OS X (IBM, Armonk, New York) was used for statistical analysis. All 
statistical tests were performed using SPSS’s GENLINMIXED procedure for generalized linear 
model (GLM) analysis with robust covariance estimation to correct for potential violations of the 
model assumptions. Before analysis, all variables were z-transformed to ensure grand mean 
centering and to standardize results. Further unstructured autoregressive covariance matrixes (no 
assumptions on repeated covariance structure are made) were used to model repeated covariance 
within participants across time and sessions for objectives one and three. For objective two, a 
first-order autoregressive covariance matrix (measures closer in time are expected to show 
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stronger covariance) was used due to the limited degrees of freedom available. Within each study 
objective, Bonferroni correction was used to account for multiple comparisons. 
For objective one, the effects of the factor “breathing frequency” on the dependent variables 
CPT, HPT, pain intensity ratings, and pain unpleasantness ratings were tested using four separate 
one-way mixed analyses of variance (ANOVAs). For objective two, the effects of the fixed 
factors “time” (two levels: 5 min of baseline vs 5 min of paced breathing), “breathing frequency” 
(four levels: paced baseline frequency, 0.14 Hz, 0.10 Hz, and 0.06 Hz), and the interaction term 
“time x breathing frequency” on the dependent variables RR-interval, SDRR, and respiratory 
CO2 were tested with three separate 2 x 4 mixed ANOVAs. Significant effects were followed up 
using planned contrasts (Bonferroni corrected), testing all differences between baseline and paced 
breathing, as well as all differences between the four paced breathing conditions. For objective 
three, within-session changes from resting period to paced breathing (paced breathing minus 
resting period) and resting period measures of RR-interval, SDRR, and CO2 were defined as 
predictive scalar factors for the dependent variables CPT, HPT, pain intensity ratings, and pain 
unpleasantness ratings in 12 separate GLMs. Pearson’s standardized residuals were examined for 
all models to guarantee robustness of the results. As a rule of thumb, 5% of cases can be 
expected to show an absolute value greater than 2.0 (Field, 2009). So for the present sample size 
of 74 sessions, 3.7 sessions were expected to show an absolute value above this limit. Therefore, 
models with four values above 2.0 were to be reexamined, excluding these particular cases. 
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Results 
General: 
The mean age of the sample was 24.4 (range: 20.7–28.6) years. Two participants reported side 
effects: One participant experienced paresthesias in the upper limbs, as well as hiccups during 
three sessions. He was excluded from analysis as only one valid session remained. Another 
participant reported dizziness after the resting frequency condition. All data from this session 
were excluded from analysis except for the baseline measures. For another participant’s session 
respiratory belt, RR-interval, and SDRR data were lost due to equipment failure. Inspection of 
respiratory belt data indicated that all participants were able to maintain a stable breathing pattern 
throughout the HRV measurements, except for one participant who showed a respiratory rate of 
0.89 Hz during the 0.06 Hz breathing frequency condition. Data from this session were excluded 
from analysis except for baseline measures. In total, the sample included 74 sessions within 19 
participants, with one additional missing session for breathing frequency, RR, and SDRR, and no 
missing sessions for respiratory CO2. 
 
Condition 
 
Breathing Frequency 
(breaths/min) 
RR-interval 
(ms) 
SDRR 
(ms) 
Respiratory CO2 
(% vol) 
 Baseline Paced Baseline Paced Baseline Paced Baseline Paced 
0.06 Hz 
(3.6 breaths/min) 14.3 ± 4.2 3.7 ± 0.2 
813.6 
± 124.4 
819.5 
± 107.8 
59.3 
± 21.9 
98.0 
± 27.2 
5.1 
± 0.4 
5.4 
± 0.7 
0.10 Hz 
(6.0 breaths/min) 14.2 ± 3.4 6.0 ± 0.2 
839.2 
± 122.4 
853.2 
± 105.0 
70.5 
± 22.7 
109.2 
± 33.0 
4.9 
± 0.4 
4.9 
± 0.6 
0.14 Hz 
(8.4 breaths/min) 14.0 ± 3.5 8.5 ± 0.3 
816.3 
± 132.4 
829.7 
± 114.2 
63.1 
± 21.8 
84.8 
± 20.9 
4.9 
± 0.5 
4.9 
± 0.7 
Paced resting 
frequency 14.0 ± 4.1 14.4 ± 4.0 
847.7 
± 131.9 
858.1 
± 120.6 
62.7 
± 20.1 
62.1 
± 20.7 
4.9 
± 0.5 
4.6 
± 0.7 
Table 3.2: Descriptive results for the cardiorespiratory variables: Means ± standard deviation. n=19 (74 
sessions). Baseline data was recorded during 5 min at rest. Subsequently, 5 min of paced breathing 
according to the experimental conditions were recorded. SDRR = standard deviation of the RR-interval 
Descriptive results for cardiorespiratory variables are shown in Table 3.2, and additional HRV 
results including frequency domain measures are shown in Appendix 3.1. Descriptive results for 
variables of pain perception are shown in Table 3.3. Shapiro–Wilk’s test for normality performed 
on within-subject centered variables indicated a non-normal distribution of within-participant 
differences for breathing frequency (p < .001), HTP (p = .032), and RR-interval (p = .012). Intra-
individual differences in CPT, pain intensity ratings, pain unpleasantness ratings, CO2, and SDRR 
were normally distributed. 
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Condition 
Cold Pain  
Thresholds 
(ºC) 
Heat Pain  
Thresholds 
(ºC) 
Heat Intensity  
Ratings 
(Points) 
Heat Unpleasantness 
Ratings 
(Points) 
0.06 Hz (3.6 breaths/min) 12.3 ± 9.5 46.8 ± 2.0 42.4 ± 17.4 41.4 ± 18.2 
0.10 Hz (6.0 breaths /min) 10.6 ± 9.1 46.5 ± 2.5 43.9 ± 19.5 43.3 ± 19.2 
0.14 Hz (8.4 breaths /min) 12.3 ± 8.0 46.6 ± 1.8 42.1 ± 19.6 41.1 ± 19.6 
Paced resting frequency 9.2 ± 8.0 46.9 ± 1.8 44.6 ± 19.5 41.5 ± 20.4 
Table 3.3: Descriptive results for the somatosensory variables: Means ± standard deviation, n=19 (74 
sessions) Somatosensory variables were recorded during constant paced breathing following the 
cardiorespiratory recordings. Intensity- and Unpleasantness-Ratings are shown as participants’ mean ratings 
for stimuli with 45, 46, 47, and 48 ºC of thermode temperature on a 0-100 point visual analog scale. 
Objective 1: Effects of different paced breathing frequencies on pain perception 
No measure of pain perception was found significantly affected by the experimental condition. 
There were no significant differences in the effect of different slow-paced breathing frequencies 
on four variables on pain perception (see Table 3.4). 
 
Variable F(3, 70) p pBonf 
Cold Pain Threshold 2.599 .059 .236 
Heat Pain Threshold 0.263 .852 1 
Pain Intensity Ratings 1.242 .301 1 
Pain Unpleasantness Ratings 0.568 .638 1 
Table 3.4: General Linear Model results for the effects of breathing frequency on pain perception. 
Breathing conditions were: paced baseline frequency, 0.14 Hz, 0.10 Hz, and 0.06 Hz. n=19 (74 sessions). 
pBonf = Bonferroni corrected p-Value. 
Objective 2: Effects of different paced breathing frequencies on physiological 
variables 
RR-interval was not found significantly affected by factors Time or Breathing Frequency, but 
significant Time x Breathing Frequency interactions were found for SDRR and CO2 (see 
Table 3.5). 
 
Variable df2 Model Term F p pBonf 
RR-interval 141 
Time 0.02 .889 1 
Breathing Frequency 0.63 .595 1 
Time x Breathing Frequency 1.66 .178 .534 
SDRR 141 
Time 38.82 <.001 <.001 
Breathing Frequency 22.22 <.001 <.001 
Time x Breathing Frequency 16.69 <.001 <.001 
Respiratory CO2 142 
Time 0.78 .379 1 
Breathing Frequency 5.28 .002 .006 
Time x Breathing Frequency 5.01 .002 .006 
Table 3.5: General Linear Models testing the effects of slow paced breathing frequency on 
cardiorespiratory variables. df1 = 7. Significant effects are marked bold. Abbreviations: SDRR, standard 
deviation of the RR-interval; pBonf, Bonferroni corrected p-Value. 
For SDRR, planned comparisons revealed that all breathing exercises with the exception of paced 
resting frequency significantly increased mean SDRR compared with baseline. Further, mean 
SDRR significantly increased with decreasing breathing frequencies until the 0.1 Hz condition. 
The 0.06 Hz condition did not significantly increase SDRR in comparison to the 0.1 Hz 
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condition and the 0.14 Hz condition. Significant changes from baseline were only found for 
paced resting frequency, which decreased CO2. However, respiratory CO2 during the 0.06 Hz 
breathing condition was significantly elevated compared to resting frequency, 0.10 Hz, and 
0.14 Hz conditions. Results for planned comparisons are shown in Table 3.6. 
 
 SDRR Respiratory CO2 
Planned Contrast t p pBonf t p pBonf 
Resting compared to Breathing Period (within-session) 
0.06 Hz, rest vs 0.06 Hz, paced -8.37 <.001 <.001 -2.49 .023 .233 
0.10 Hz, rest vs 0.10 Hz, paced -6.33 <.001 <.001 0.41 .685 1 
0.14 Hz, rest vs 0.14 Hz, paced 0.23 <.001 <.001 0.82 .422 1 
Resting frequency, rest vs Resting frequency, paced -2.14 .820 1 3.88 .001 .012 
Between-session comparisons of Breathing Period 
0.06 Hz, paced vs 0.10 Hz, paced 1.88 .048 .475 3.90 .001 .012 
0.06 Hz, paced vs 0.14 Hz, paced 5.04 .077 .773 3.91 .001 .011 
0.06 Hz, paced vs Resting frequency, paced 4.04 <.001 .001 4.11 .001 .008 
0.10 Hz, paced vs 0.14 Hz, paced 8.47 .001 .007 -0.01 .993 1 
0.10 Hz, paced vs Resting frequency, paced 5.56 <.001 <.001 2.02 .060 .595 
0.14 Hz, paced vs Resting frequency, paced -8.37 <.001 <.001 2.02 .059 .594 
Table 3.6: Planned paired contrasts following up significant effects of slow paced breathing frequency on 
cardiorespiratory variables n=19 (74 sessions), Significant effects are marked bold. Abbreviations: SDRR, 
standard deviation of the RR-interval; pBonf, Bonferroni corrected p-Value. 
Objective 3: Predicting pain perception by DSB-induced cardiorespiratory 
changes 
Table 3.7 shows the results of twelve regression analyses testing the relationships between the 
cardiorespiratory and nociceptive variables. Including RR-interval change and RR-interval at 
baseline improved model fit for pain intensity ratings and pain unpleasantness ratings compared 
to an intercept-only model. Changes in RR-interval and baseline RR-interval both were highly 
significant predictors of pain unpleasantness ratings. For pain intensity ratings, change in RR-
interval was a predictor of borderline significance and RR-interval at baseline was a highly 
significant predictor. Beta-coefficients indicated that in sessions where the RR-interval increased 
by 10ms from baseline, pain unpleasantness ratings decreased by -0.23 ± 0.07 points. Beta-
coefficients further indicated that in sessions where RR-interval was elevated by 10 ms at 
baseline, pain intensity ratings were -0.53 ± 0.11 points lower and pain unpleasantness ratings 
were -0.56 ± 0.12 points lower2. Change in RR-interval and baseline RR-interval could not 
explain significant proportions of variance for CPT or HPT and could not improve model fit. 
The same held true for, changes in SDRR and respiratory CO2. Examination of Pearson’s 
residuals indicated that six cases were z > 2.0 for pain unpleasantness ratings, (the largest case 
being -2.328). Re-analysis excluding the particular cases did not change the results in respect to 
model fit, direction of effect, and the criterion of significance. Further, a visual examination of 
the results indicated that one session could represent an outlier with undue influence on the 
linear results. Excluding this session did not change the results in respect to model fit, direction 
of effect, or the criterion of significance. All pairs of somatosensory variables were re-examined 
                                                
2An increase by 10 ms of RR-interval corresponds to an increase in heart rate by 0.9 beats/minute at mean 
breathing frequency. A decrease by 10 ms of RR-interval corresponds to a decrease in heart rate by 
0.8 beats/minute at mean breathing frequency. 
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using one cardiorespiratory variable at a time for descriptive purposes and can be found in 
Appendix 3.2. 
Variable Cofactor Model Term 
Effect Coefficient 
F(4, 70) p pBonf beta ± (SE) ∆AICC 
Cold Pain 
Thresholds 
RR-interval 
Intercept 2.12 .128 1 0.083 ± 0.204 
5.710 RR-interval change 0.02 .894 1 -0.008 ± 0.058 
RR-interval baseline 3.97 .050 .600 -0.102 ± 0.051 
SDRR 
Intercept 1.35 .266 1 0.097 ± 0.205 
5.343 SDRR change 1.21 .275 1 0.078 ± 0.071 
SDRR baseline 1.27 .263 1 -0.062 ± 0.055 
Respiratory 
CO2 
Intercept 0.27 .762 1 0.105 ± 0.210 
7.081 CO2 change 0.48 .489 1 0.050 ± 0.073 
CO2 baseline 0.10 .757 1 0.022 ± 0.071 
Heat Pain 
Thresholds 
RR-interval 
Intercept 3.64 .031 .372 0.292 ± 0.123 
2.919 RR-interval change 0.80 .376 1 0.066 ± 0.074 
RR-interval baseline 4.74 .033 .396 0.150 ± 0.069 
SDRR 
Intercept 0.35 .709 1 0.309 ± 0.133 
5.522 SDRR change 0.22 .638 1 0.027 ± 0.056 
SDRR baseline 0.56 .456 1 0.037 ± 0.049 
Respiratory 
CO2 
Intercept 0.18 .839 1 0.281 ± 0.135 
7.293 CO2 change 0.09 .765 1 -0.018 ± 0.061 
CO2 baseline 0.31 .578 1 0.036 ± 0.064 
Intensity 
Ratings 
RR-interval 
Intercept 11.19 < .001 < .001 0.211 ± 0.204 
-4.796 RR-interval change 7.61 .007 .084 -0.120 ± 0.044 
RR-interval baseline 22.1 < .001 < .001 -0.310 ± 0.066 
SDRR 
Intercept 3.22 .046 .552 0.048 ± 0.206 
0.598 SDRR change 4.41 .039 .468 -0.074 ± 0.035 
SDRR baseline 0.03 .853 1 -0.014–0.075 
Respiratory 
CO2 
Intercept 1.04 .359 1 -0.008 ± 0.187 
0.534 CO2 change 2.02 .160 1 0.075 ± 0.053 
CO2 baseline 0.21 .650 1 0.020 ± 0.043 
Unplea-
santness 
Rating 
RR-interval 
Intercept 12.74 < .001 < .001 0.128 ± 0.183 
-5.080 RR-interval change 11.46 .001 .012 -0.134 ± 0.040 
RR-interval baseline 23.51 < .001 < .001 -0.324 ± 0.067 
SDRR 
Intercept 0.32 .731 1 -0.019 ± 0.192 
-1.798 SDRR change 0.60 .440 1 -0.039 ± 0.050 
SDRR baseline 0.12 .736 1 0.026 ± 0.075 
Respiratory 
CO2 
Intercept 0.76 .474 1 0.020 ± 0.181 
-2.629 CO2 change 0.01 .919 1 0.006 ± 0.063 
CO2 baseline 1.48 .227 1 0.072 ± 0.059 
Table 3.7: General Linear Models testing if changes in cardiorespiratory variables predict measures of pain 
perception. Cardiorespiratory variables at rest were included in analysis to account for session-to-session 
baseline differences. n = 19 (74 sessions). Significant effects are marked bold. 
∆AICC = AICCModel-AICCIntercept only (a lower AICC indicates increased model fit). Abbreviations: AICC: Akaike’s 
information criterion corrected for finite sample sizes; SDRR: standard deviation of the RR-interval. 
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Discussion 
Overview 
The present study tested effects of slow paced breathing frequencies on experimental pain 
perception (Objective 1), cardiorespiratory function (Objective 2), and examined the relationship 
between changes in cardiorespiratory variables and experimental measures of pain perception 
(Objective 3). Results indicated that breathing frequency had no significant effect on 
experimental pain perception and RR-interval. Only SDRR and respiratory pCO2 were 
significantly affected by different breathing frequencies. Nevertheless, neither SDRR nor 
respiratory CO2, could predict intra-individual changes in pain perception. In contrast, baseline-
to-breathing as well as session-to-session differences in RR-interval were found to predict 
changes in pain perception. Prolonged RR-intervals predicted lower pain unpleasantness ratings, 
while shortened RR-intervals predicted higher ratings. 
Breathing frequency was not found to determine antinociceptive effects 
The present study could not add evidence to the hypothesis that breathing frequency is the 
determining factor of DSB-induced hypoalgesia. This stands in contrast to two recent studies that 
could show an effect of slow-paced breathing on experimental pain perception using paced 
breathing at normal frequency as a control condition (Martin et al., 2012; Zautra et al., 2010). The 
best explanation for these conflicting results might be that the present study was the first to test 
the effects of slow breathing in a dose-dependent fashion, i.e., using several slow breathing 
frequencies. 
On the one hand, this approach might have diminished statistical power. On the other hand, the 
use of several slow breathing conditions might have reduced expectation effects. Finally, these 
results could point toward a third variable underlying DSB analgesia. Besides breathing 
frequency, the present study particularly aimed to follow up two other hypotheses on 
physiological phenomena accompanying DSB: modulation of cardiac autonomic function and 
modulation of respiratory gas concentrations. 
RR-Interval not found influenced by DSB, yet best predictor of pain ratings 
RR-interval was not influenced by DSB, yet the best predictor of pain ratings. ANS activity is 
closely linked to nociception (Craig, 2003; Schlereth & Birklein, 2008). RR-interval, heart rate, as 
well as HRV in general have been interpreted as measures of general ANS function in the past, 
“although inferences are clearly restricted to the level of the heart” (Ritz, 2009). Nevertheless, 
these measures of cardiac autonomic function have been shown to be interrelated with pain 
perception in different contexts (Appelhans & Luecken, 2008; Rainville, Bao, & Chrétien, 2005; 
Tousignant-Laflamme, Rainville, & Marchand, 2005). 
Accordingly, we found that pain unpleasantness ratings significantly decreased when RR-interval 
increased during DSB. Although this effect did not reach significance for CPT, HPT, and pain 
intensity ratings, the same direction of effect could be observed (see Table 3.7 and Appendix 3.2). 
Similarly, in sessions with elevated RR-interval at baseline, pain unpleasantness ratings, and pain 
intensity ratings were decreased significantly. As increases in RR-interval are commonly 
interpreted as increases in parasympathetic activity or sympathetic withdrawal, our results are in 
accord with earlier animal (Ren, Zhuo, Randich, & Gebhart, 1993) and human (Pereira et 
al., 2010) studies linking increases in cardiac parasympathetic tone and sympathetic withdrawal to 
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antinociceptive effects. However, it cannot be concluded that the DSB exercise was causally 
related to changes in cardiac ANS function and the associated effects on pain perception as 
breathing frequency was not found to significantly modulate RR-interval. Small but meaningful 
increases in RR-interval from baseline to DSB that remained undetected due to a lack of 
statistical power may have led to this outcome. The finding that paced DSB was insufficient to 
influence RR-interval stands in line with some earlier finding (Anderson, McNeely, & Windham, 
2010; Ritz, 2009; Song & Lehrer, 2003), but in contrast to others (Martin et al., 2012; Pöyhönen 
et al., 2004) and indicates that DSB alone might not be efficient for manipulating heart rate. 
Biofeedback procedures designed to increase RR-interval might be more successful in doing so 
(Reeves & Shapiro, 1982; Victor et al., 1978) and should be considered as an intervention in 
future studies. 
Hear rate variability during slow breathing was not found to predict anti-
nociception 
SDRR is the most general measure of HRV. It has been used as an indirect measure of cardiac 
ANS activity and used to infer on general ANS function (Malik et al., 1996; Thayer & Sternberg, 
2006; Zhong, Jan, Ju, & Chon, 2006). Increases in SDRR are commonly interpreted to reflect 
parasympathetic activation and/or sympathetic withdrawal referring to experiments using 
cholinergic and beta-adrenergic receptor blockade (Berntson, Cacioppo, & Quigley, 1994; Bittiner 
& Smith, 1986). However, it is long known that slow breathing frequencies and increases in 
respiratory volume lead to dramatic increases in measures of HRV by mechanisms that obscure 
the association between HRV measures and the psychophysiologically relevant portion of ANS 
activity (Billman, 2011; Ritz, 2009). Notwithstanding, HRV increases have been hypothesized to 
indicate resonance between the RSA mechanism and the baroceptor reflex (Vaschillo et al., 
2011), and proposed to be therapeutically beneficial when used to exercise parasympathetic 
function (Lehrer et al., 2000). Taking this hypotheses one step further, Chalaye et al. 2009 
postulated that “slow deep breathing and HR biofeedback would produce the largest cardiac 
changes and the strongest analgesic responses” on experimental pain in a one-session experiment 
with healthy participants. Based on their finding of coinciding differences in pain tolerance 
thresholds and SDRR amplitude between a distraction and a slow breathing condition, they 
concluded: “modulation of HR and pain share a common neurophysiological pathway”. 
Our present experiment followed up this hypothesis by testing if DSB induced intra-individual 
SDRR amplitude changes can predict antinociceptive DSB effects in a dose-dependent fashion. 
Indeed, we could replicate that DSB at frequencies of around 0.1 Hz (“the resonant frequency”) 
causes large increases in SDRR (Hirsch & Bishop, 1981; Vaschillo et al., 2006) and therefore 
general HRV. Consequently, SDRR should have been expected to predict a good degree of 
variation in experimental pain measures if a functional relationship between pain perception and 
general HRV existed. The fact that large DSB-induced changes in HRV did not predict any 
difference in pain perception is in accord with recent results by Martin et al. who could not find a 
relationship between breathing-induced changes in RMSSD and pain ratings (Martin et al., 2012). 
Together, these findings question if the “resonance” mechanism is relevant for DSB-induced 
antinociception, at least when applied without long-term training (Lehrer et al., 2000). It further 
underlines that HRV amplitude changes seen during slow breathing may reflect “mechanical 
effects of respiration” (Billman, 2011), rather than appropriate correlates of ANS function. The 
finding that RR-interval could predict differences in pain perception, while SDRR could not, 
supports the notion that RR-interval (or heart rate) at baseline is a better correlate of the 
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psychophysiologically relevant ANS portion than HRV (Grossman & Kollai, 1993; Paul 
Grossman & Taylor, 2007; Kollai & Mizsei, 1990). 
Paced breathing at baseline and very slow frequencies induced 
hyper/hypoventilation 
Hypercapnia-facilitated analgesia was the second candidate mechanism to be examined in the 
present study. Measures of respiratory CO2 were used to detect potential consequences of DSB 
on respiratory gas exchange as hypercapnia had been shown to modulate acute pain perception 
(Stokes III. et al., 1948). Indeed, significant differences in respiratory CO2 could be found, which 
indicated that participants tended to develop hypercapnia during the 3.6 breaths/min condition 
and hypocapnia during the paced resting frequency condition. These findings encourage the 
monitoring of hyperventilation/hypoventilation in the study of DSB exercises and replicate the 
finding that paced breathing at resting frequency is not just a simple “distraction” control 
condition, but has measurable consequences on respiratory gas exchange (Pinna, Maestri, La 
Rovere, Gobbi, & Fanfulla, 2006). Nevertheless, respiratory CO2 could not explain relevant 
differences in any experimental measure of nociception. The magnitude of 
hyperventilation/hypoventilation might have been too small to lead to significant somatosensory 
consequences. 
Limitations 
The present findings have to be considered in the context of the following limitations: DSB 
effects were studied using experimental pain in healthy participants and may not generalize to 
clinical forms of pain or patient populations with ANS dysregulation. Caution must be exercised 
when comparing the results of our DSB protocol with other studies using breathing, relaxation, 
or distraction exercises: e.g., participants maintained visually paced breathing during sensory 
measurements at any time and only received a single training session. Therefore, the whole 
procedure might have been too demanding to have a relaxing effect. The simultaneous execution 
of paced DSB and thermal thresholding might also have diminished the sensitivity of the CPT 
and HPT measurements, which are affected by reaction time (Yarnitsky & Ochoa, 1990). We 
particularly emphasize that prolonged DSB training might yield entirely different results. It might 
enhance the effect of DSB by several mechanisms, but particularly because association effects 
were suggested to play a role in pain appraisal (Hallman, Olsson, von Schéele, Melin, & Lyskov, 
2011). Lastly, the decision to exclude participants reporting side effects from analysis might have 
led to an underestimation of hyperventilation/hypoventilation effects. 
Conclusions: 
The present study supports the hypothesis that pain is as a homeostatic emotion (Craig, 2002; 
Zautra et al., 2010) depending on ANS function (Appelhans & Luecken, 2008) as inter-individual 
RR-interval differences at rest and changes in RR-interval were associated with measures of 
experimental pain perception. However, as the experimental conditions have neither influenced 
experimental pain perception directly, nor indirectly by altering RR-interval, we cannot conclude 
that breathing frequency is a determining factor of the proposed antinociceptive effects of DSB. 
Similarly, highly significant breathing induced changes in HRV and respiratory gas concentration 
could not predict antinociceptive DSB effects. 
The present results do not exclude the possibility that DSB therapies might be beneficial for 
chronic pain patients. DSB might have a different impact on patients with ANS dysfunction, and 
other mechanisms of action could account for its therapeutic efficacy. In this context, potential 
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long-term training effects of DSB on cardiorespiratory function and pain perception might be of 
particular interest for future studies. As mentioned earlier, psychophysiological mechanisms such 
as “facilitation of emotional regulation” (Zautra et al., 2010), “relaxation” (Busch et al., 2012; 
Cogan & Kluthe, 1981), or “distraction” (Chambers et al., 2009) pose relevant alternative 
mechanisms of action to be considered. Based on our results, we encourage further biofeedback 
studies to determine the relevant mechanisms of action of slow breathing exercises. 
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Appendix 3.1 
Condition 
 
SDRR 
(ms) 
RMSSD 
(ms) 
LF 
(ms2) 
HF 
(ms2) 
 Baseline Paced Baseline Paced Baseline Paced Baseline Paced 
0.06 Hz (3.6 breaths/min) 59.3 ± 21.9 
98.0 
± 27.2 
55.7 
± 29.6 
49.5 
± 18.2 
1438 
± 2150 
9812 
± 5423 
1735 
± 1753 
623 
± 525 
0.10 Hz (6.0 breaths/min) 70.5 ± 22.7 
109.2 
± 33.0 
69.9 
± 32.7 
79.8 
± 38.5 
1198 
± 1368 
9656 
± 5310 
2948 
± 2383 
1726 
± 1932 
0.14 Hz (8.4 breaths/min) 63.1 ± 21.8 
84.8 
± 20.9 
60.8 
± 31.0 
65.5 
± 24.6 
1554 
± 1890 
5644 
± 2243 
2242 
± 1798 
885 
± 1168 
Paced resting frequency 62.7 ± 20.1 
62.1 
± 20.7 
60.4 
± 26.9 
60.8 
± 23.7 
1167 
± 1433 
821 
± 747 
1919 
± 1473 
1916 
± 1263 
Appendix 3.1: Descriptive HRV Results—Frequency domain measures: Means ± standard deviation. n = 19 
(74 sessions). Baseline data was recorded during 5 min at rest. Subsequently, 5 min of paced breathing 
according to the experimental conditions were recorded. Abbreviations: SDRR, standard deviation of the 
RR-interval; RMSSD, root mean squared of successive difference; LF, low frequency power; HF, high 
frequency power. 
Appendix 3.2 
 RR-interval SDRR Respiratory CO2 
 Baseline Paced Baseline Paced Baseline Paced 
Cold pain 
thresholds 
-0.10 ± 0.05 
p = .066 
-0.10 ± 0.05 
p = .038 
-0.07 ± 0.06 
p = .271 
0.07 ± 0.07 
p = .362 
0.05 ± 0.07 
p = .533 
0.06 ± 0.08 
p = .489 
Heat pain 
thresholds 
0.11 ± 0.034 
p = .005 
0.13 ± 0.05 
p = .016 
0.05 ± 0.05 
p = .340 
0.03 ± 0.05 
p = .588 
0.03 ± 0.06 
p = .652 
0.00 ± 0.06 
p = .968 
Intensity 
Ratings 
-0.21 ± 0.06 
p = .001 
-0.28 ± 0.05 
p < .001 
-0.02 ± 0.08 
p = .792 
-0.04 ± 0.04 
p = .331 
0.03 ± 0.05 
p = .580 
0.09 ± 0.06 
p = .181 
Unpleasantness 
Ratings 
-0.24 ± 0.07 
p = .002 
-0.28 ± 0.05 
p < .001 
-0.03 ± 0.08 
p = .734 
-0.01 ± 0.05 
p = .804 
0.07 ± 0.06 
p = .228 
0.07 ± 0.07 
p = .282 
Appendix 3.2: Simple regressions between cardiorespiratory and somatosensory variables. Results of 
Robust General Linear Models depicting Beta ± (SE). Repeated-covariance from 74 sessions within 
19 participants was modeled using an unstructured covariance matrix. Significant effects are marked bold. 
“Baseline” data was recorded during a 5 min interval at rest. Paced data were recorded in 5 min interval 
while the participant was performing paced breathing according to the experimental condition. 
Abbreviations: SDRR, standard deviation of the RR-interval. 
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Abstract 
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) of motor and prefrontal 
cortex has been shown to modulate pain perception. Even though evidence suggests an 
involvement of cerebellar structures in pain processing, the effect of rTMS over the cerebellum 
on pain perception has not yet been investigated. 
OBJECTIVE/HYPOTHESIS: This study aimed to test the effects of rTMS over the cerebellum on 
sensory perception, particularly controlling for peripheral stimulation effects. Methods Sensory 
perception was determined as temperature detection and temperature pain thresholds. 
Experiment one explored the effects of four different rTMS protocols (flat figure-of-eight coil; 
120 % motor resting threshold; 1000 stimuli; 1 Hz and 10 Hz; medial and right lateral 
cerebellum) on sensory thresholds in 10 healthy volunteers using pairwise comparisons. The 
most efficient protocol of experiment one was compared in a second experiment with two 
control conditions (rTMS with a sham coil over the cerebellum [sham] and repetitive magnetic 
stimulation [rMS] of the neck) by using robust statistics (MANOVA). 
RESULTS: The first experiment demonstrated pronounced effects on sensory perception for 1Hz 
rTMS over the lateral cerebellum. The second experiment confirmed this result in comparison to 
sham. However, rMS over the neck had a similar effect like rTMS over the cerebellum. 
CONCLUSIONS: Our findings suggest that changes in sensory perception after rTMS over the 
cerebellum are largely due to stimulation effects on peripheral structures and support recent 
reports of analgesic effects of neck rMS. They advocate the critical review of the proposed 
analgesic effects of rTMS and encourage the future use of proper control conditions in rTMS 
research. 
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Introduction 
Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique 
that is currently examined as a treatment option for a large variety of neuropsychiatric disorders, 
including chronic pain (Leung et al., 2009). In rTMS neuronal discharges are repeatedly induced 
in superficial brain areas by magnetic pulses, delivered through the scalp by a magnetic coil 
(Hallett, 2000). rTMS of the primary motor cortex has been demonstrated to exert analgesic 
effects lasting from minutes to days in various chronic pain disorders (André-Obadia, Mertens, 
Gueguen, Peyron, & Garcia-Larrea, 2008; Khedr et al., 2005; Lefaucheur, Drouot, Ménard-
Lefaucheur, Keravel, & Nguyen, 2006; Lefaucheur, Drouot, & Nguyen, 2001; Passard et al., 
2007; Pleger et al., 2004). Analgesic effects of rTMS of the motor cortex (Johnson, Summers, & 
Pridmore, 2006; Lefaucheur et al., 2010; Summers, Johnson, Pridmore, & Oberoi, 2004; Tamura 
et al., 2004) and prefrontal areas (Borckardt et al., 2007) could further be evidenced for 
experimentally induced pain. Modulation of neuronal excitability in cortical and subcortical 
regions like the thalamus has been proposed as a putative mechanism of rTMS induced analgesic 
effects (Lefaucheur et al., 2001; Leo & Latif, 2007). This view is supported by evidence for 
altered cortico-spinal excitability in several forms of chronic pain (Mhalla, de Andrade, Baudic, 
Perrot, & Bouhassira, 2010; Strutton, Theodorou, Catley, McGregor, & Davey, 2005; Turgut & 
Altun, 2009) and studies demonstrating that the analgesic effects of rTMS correlate with 
normalization of cortical excitability in chronic pain patients (Lefaucheur et al., 2006; Schlaier et 
al., 2007). 
Apart from motor and prefrontal cortex no other brain regions have been investigated as targets 
for pain modulation. Among the regions ignored so far is the cerebellum, although several lines 
of evidence highlight it as a promising target. Both animal and human studies have demonstrated 
the involvement of the cerebellum in several aspects of pain processing (Moulton, Schmahmann, 
& Borsook, 2010). Moreover the cerebellum has strong connections with the motor cortex via 
the cerebello-thalamo-cortical pathway, which can be modulated by rTMS (Daskalakis et al., 
2004; Fierro et al., 2007; Langguth et al., 2008). Accordingly, rTMS over the cerebellum has been 
shown to have an impact on a variety of neurobiologic functions (Gironell et al., 2002; Oliveri et 
al., 2009). An important confounder in the investigation of cerebellar rTMS is the concomitant 
stimulation of peripheral structures such as neck muscles (Gerschlager, Christensen, Bestmann, 
& Rothwell, 2002; Ugawa et al., 1991). This is of special relevance in the investigation of pain 
thresholds, because magnetic stimulation of neck muscles is known to have analgesic effects 
(Smania et al., 2005). 
In this study, we performed two experiments to explore the effects of rTMS over the cerebellum 
on pain and temperature perception in healthy humans. In the first experiment, we screened 
several stimulation parameters for their effect on sensory thresholds. In the second experiment, 
the most promising rTMS protocol was retested and compared with two control conditions. 
Repetitive magnetic stimulation (rMS) of the neck was performed to control for effects of muscle 
stimulation. Sham rTMS over the cerebellum was applied as a further control condition, because 
measures of pain perception are known to be particularly susceptible to placebo effects 
(Krummenacher, Candia, Folkers, Schedlowski, & Schönbächler, 2010). Nociceptive and non- 
nociceptive sensation was assessed by quantitative sensory testing of temperature and pain 
detection thresholds. 
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Methods 
General information 
Study participants were recruited among students and hospital personnel through advertisement. 
They were free of analgesic or centrally active medication and free of any acute or chronic 
medical diagnosis. The study was approved by the local ethics committee and written informed 
consent was obtained from all participants. The study conformed to the most recent version of 
the Helsinki Declaration (59th WMA General Assembly, 2009). 
For rTMS, participants were seated in a comfortable chair. TMS was delivered by a Magstim 
super rapid stimulator (Magstim Co, Dyfed, UK) connected to a figure-of-eight coil (double-
circular 70 mm coil). Resting motor threshold (RMT) of the motor cortex was determined 
according to standard procedures before the first experimental session (Rossini et al., 1994). 
rTMS was performed at 120 % RMT or at 60 % maximum stimulator output (MSO) when RMT 
exceeded 50 % MSO. The limit of 60 % MSO was set due to safety considerations and as higher 
stimulation strengths were found to be hardly tolerable by the participants in a previous study 
(Langguth et al., 2008). Low frequency stimulation was applied at 1 Hz rTMS (1 train, 
1000 stimuli), high-frequency stimulation at 10 Hz (20 trains, 50 stimuli/train, inter-train interval 
of 20 s). The handle of the coil was pointed upward and held in place by a mechanical arm. The 
current in the coil was thus directed downward during the reversal phase of the biphasic stimulus, 
inducing an upward current in the region of interest (Ugawa, Uesaka, Terao, Hanajima, & 
Kanazawa, 1995). All used coils were precooled with ice packs to prevent overheating. Net 
duration of stimulation was about 17 min for the 1 Hz protocol and about 8 min for the 10 Hz 
protocol. 
Before and after rTMS treatment, sensory measurements were performed while participants were 
sitting in a comfortable chair. Changes in nociceptive and non-nociceptive sensation were 
determined as threshold temperatures, using an adapted version of the method of limits 
(Fruhstorfer, Lindblom, & Schmidt, 1976; Summers et al., 2004). Temperature stimuli were 
applied to the thenar of the right hand, using a 30 x 30 x 30 mm thermode connected to a 
sensory Analyzer II (Medoc, Ramat Yishai, Israel). Measurements were only retrieved from the 
right hand ipsilateral to the stimulation site, according to the ipsilateral motor representation of 
the cerebellum. Temperature stimuli were presented as ramping thermode temperatures starting 
from a baseline of 32 °C. For the temperature detection thresholds ‘‘cold detection threshold’’ 
(CT) and ‘‘warmth detection threshold’’ (WT) participants were requested to press a response 
button as soon as they perceived ”the slightest change in temperature”. Temperatures increased 
or decreased with a rate of 0.5 °C for detection thresholds. For pain thresholds ‘‘cold pain 
threshold’’ (CPT) and ‘‘heat pain threshold’’ (HPT), participants were requested to press a 
response button as soon as the perceived heat or cold started ‘‘to be accompanied by the slightest 
feeling of pain.’’ Temperatures increased or decreased with a rate of 1 °C for pain thresholds. On 
pressing the response button, the reached temperature was recorded and temperature 
automatically returned to baseline with 10 °C/s. Automatic safety temperature limits were set, so 
that whenever a temperature of 0 °C or 50.5 °C was reached, the thermode temperature rapidly 
returned to baseline. Participants could not see the operator screen and no visual or auditory cues 
were present to signal stimulus onset. Ramping stimuli were separated by automatically timed, 
jittered intervals of 10 ± 1 s at baseline temperature. 
 S T U D Y  4 :  C E R E B E L L A R  r T M S  A N D  P A I N  
79 
Statistics were processed with SPSS 17.0 (SPSS Inc, Chicago, IL). Graphs were processed with 
GraphPad Prism 5.0 (GraphPad Software, Inc, San Diego, CA). Significance levels for all 
statistical tests were α < .05 Shapiro-Wilk test for normality was used to test if the data was 
sampled from a Gaussian distribution. Means are displayed ± standard deviation if not denoted 
otherwise. 
 
Experiment 1 
 
Baseline measurements 
(15 min) 
Repetitive transcranial 
magnetic stimulation 
(20 min): 
Posttreatment measurements 
(15 min) 
Cold detection threshold (4x) and 1 Hz; lateral cerebellum or Cold detection threshold (4x) and 
Warm detection threshold (4x) and 10 Hz; lateral cerebellum or Warm detection threshold (4x) and 
Cold pain threshold (4x) and 1 Hz; medial cerebellum or Cold pain threshold (4x) and 
Heat pain threshold (4x). 10 Hz; medial cerebellum Heat pain threshold (4x). 
   
Experiment 2 
 
Baseline measurements 
(25 min) 
Repetitive (transcranial) 
magnetic stimulation 
(25min): 
Posttreatment measurements 
(25 min) 
Cold detection threshold (8x) and 1 Hz; lateral cerebellum or Cold detection threshold (8x) and 
Warm detection threshold (8x) and 1 Hz; lateral neck or Warm detection threshold (8x) and 
Cold pain threshold (6x) and 1 Hz; lateral cerebellum (sham) Cold pain threshold (6x) and 
Heat pain threshold (6x).  Heat pain threshold (6x). 
Table 4.1 Experimental protocol of Experiments 1 and 2 
Experiment 1 
The aim of the first experiment was to explore different rTMS protocols (medial and lateral 
cerebellum, low and high frequency) for their potential to alter sensory detection and pain 
thresholds. Ten volunteers (4 male, 6 female, mean age 24.4 years, range 22.2-25.8) were tested in 
four sessions, each time applying one of four rTMS stimulation protocols. Two stimulation 
frequencies, 1 Hz and 10 Hz, were tested at each of the two stimulation sites, which were located 
over the medial and the lateral cerebellum (Table 4.1). The order of treatment was randomly 
assigned. The stimulation targets were localized using a neuronavigation system (Brainvision, 
Brainlab, Munich, Germany) in combination with individual anatomical MRI scans, retrieved 
from each participant. Stimulation areas were chosen over lobule VII of the cerebellar vermis 
(medial) and over Crus II of the right lateral cerebellar hemisphere (lateral) as defined in previous 
experiments (Langguth et al., 2008). The neuronavigation system ensured correct localization of 
the coil over the target during the application of rTMS. Once the target area was found, the coil 
was held in place by a mechanical arm and the experimenter constantly monitored its position 
over the target region. Ramping temperature stimuli for CT, WT, CPT, and HPT were presented 
in blocks and in this given order (Summers et al., 2004; Verdugo & Ochoa, 1992). Temperature 
detection thresholds were assessed first, as they are known to be influenced by immediately 
antecedent temperature pain stimuli (Heldestad, Linder, Sellersjö, & Nordh, 2010; Quiton & 
Greenspan, 2008). A block consisted of four subsequent temperature stimuli for CT and WT and 
of three for CPT and HPT. The means of all thresholds in a given block were defined as CT, 
WT, CPT, and HPT, respectively.  
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In case of missing data at least two valid measurements per block had to be obtained to include 
the value. The sensory testing procedure took approximately 15 min of time (Table 4.1). CT, WT, 
CPT, and HPT were compared for pre- and post-rTMS differences by two-tailed repeated 
measures t-tests for each rTMS condition. No correction for multiple comparisons was applied in 
this experiment, because the purpose was to screen for potential effects of the different 
stimulation protocols. 
Experiment 2 
Based on the results of the first experiment, low-frequency rTMS stimulation over the lateral 
cerebellum was chosen as a treatment condition for the second experiment. The second 
experiment aimed to answer the question, whether 1 Hz rTMS over the lateral cerebellum 
significantly modulates warm and cold detection and pain thresholds in comparison to (1) sham 
TMS and (2) active rMS over neck muscles. rMS of the lateral neck was applied as control 
condition in addition to standard sham rTMS, to account for rTMS effects on cervical 
somatosensory afferents as a potential confounding factor.  
No participant of the first experiment was tested in the second experiment. Each of the twelve 
volunteers of the second experiment (5 males, 7 females, mean age 31.8 years, range 20.6-55.0) 
was tested three times under one of the following conditions: low-frequency active stimulation 
over the lateral cerebellum, low-frequency active stimulation of the lateral neck, and low-
frequency sham stimulation over the lateral cerebellum using a sham coil (Table 4.1). The order 
of the stimulation conditions was random. Neuro-navigated coil localization in the first 
experiment revealed only minimal inter-individual differences with respect to the stimulation site 
and indicated sufficient accuracy for coil positioning according to anatomic landmarks, as shown 
in previous studies (Herwig, Satrapi, & Schönfeldt-Lecuona, 2003; Langguth et al., 2006). Thus, 
in the second experiment, coil positioning was performed according to established standard 
procedures based on anatomic landmarks. For stimulation over the right lateral cerebellum the 
center of the coil was positioned 20 mm below the inion and 20 mm lateral from the mid-sagittal 
plane (Fierro et al., 2007). Stimulation of the neck was performed by placing the center of the coil 
100 mm below the inion and 20 mm lateral to the mid-sagittal plane resulting approximately at 
the level of the fifth cervical vertebra and thus in sufficient distance from cerebellum and 
brainstem. Once the target area was found, the coil was held in place by a mechanical arm and its 
position over the target region was constantly monitored by the experimenter. Sham rTMS was 
performed with a sham coil (Magstim Co) at 1 Hz over the lateral cerebellum. The sham coil 
does not emit magnetic pulses, but mimics the characteristic ‘‘clicking’’ sounds of rTMS. The 
temperature detection and pain measurement procedures were slightly modified for the second 
experiment with the aim to reduce data variability. Conformity of instructions was now ensured 
by reading the instructions to the participant from a script. Moreover, the number of temperature 
measurements underlying the threshold values was increased by performing the whole 
thresholding procedure twice, with a 3 min break in between. This was done to reduce the 
influence of missing data and to reduce intra-individual variability. Apart from these 
modifications, temperature and pain thresholds were assessed identically as in experiment 1. The 
sensory testing procedure took approximately 25 min of time (Table 4.1). Within-subject effects 
of the independent factors Time (pre-rTMS versus post-rTMS) and Treatment (cerebellum 
versus neck versus sham) were tested using a repeated-measures, multivariate analysis of variance 
(MANOVA) that included all thresholding variables (CT, WT, CPT, HPT). Repeated-measures t-
tests were used as planned comparisons to determine the directions of effect. To assess, if the 
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effect of verum rTMS over the cerebellum was significantly larger than the effect of neck or 
sham rTMS, the planned comparisons cerebellum versus neck (pre-rTMS versus post-rTMS), 
cerebellum versus sham (pre-rTMS versus post-rTMS), and neck versus sham (pre-rTMS versus 
post-rTMS) were performed for all variables. 
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Results 
Mild and transient muscle pain in the neck was experienced by most participants after rTMS over 
neck and cerebellum. Mild headache (after rMS of the neck) was reported by one and transient 
concentration problems (after active rTMS over the cerebellum) by another participant. 
Fortunately, no nausea, as previously reported for low frequency stimulation of the right lateral 
cerebellum was observed in any of the 22 participants as a side effect of rTMS (Satow 
et al., 2002). 
Experiment 1 
Shapiro-Wilk tests indicated that all but three measures were potentially sampled from a Gaussian 
distribution and thus the assumption of normality was maintained. Results indicated significant 
differences between before and after low-frequency stimulation over the lateral cerebellum for 
CT (n = 10, t = 2.34, p = .044), WT (n = 10, t = 2.91, p = .017), and HPT (n = 10, t = 3.27, 
p = .010). Significant differences were further found for the lateral (n = 10, t = 2.67, p = .026) 
and medial (n = 10, t = 2.59, p = .029) 10 Hz rTMS conditions for CT. Descriptive results are 
given in Table 4.2. Several participants reached machine safety limits during CTP testing pre-
rTMS. These measures were excluded from analysis. Based on these results with significant 
differences in three of four sensory parameters, low-frequency rTMS stimulation over the lateral 
cerebellum was chosen as the most promising stimulation protocol for the second experiment. 
rTMS Lateral, 10 Hz Medial, 10 Hz Lateral, 1Hz Medial, 1Hz 
 Pre Post Pre Post Pre Post Pre Post 
Cold detection 
thresholds 
30.93 
± 0.11 
30.25 
± 0.25 
30.99 
± 0.13 
30.36 
± 0.33 
31.01 
± 0.10 
30.57 
± 0.20 
31.02 
± 0.14 
30.87 
± 0.19 
Warmth detection 
thresholds 
32.91 
± 0.09 
33.15 
± 0.09 
33.05 
± 0.12 
33.18 
± 0.18 
32.80 
± 0.06 
33.15 
± 0.15 
32.92 
± 0.06 
32.94 
± 0.10 
Cold pain thresholds 12.97 
± 2.70 
10.18 
± 2.00 
14.70 
± 2.64 
12.75 
± 2.38 
13.79 
± 2.84 
14.52 
± 2.79 
14.38 
± 2.96 
15.89 
± 2.77 
Heat pain thresholds 46.62 
± 0.79 
47.61 
± 1.07 
46.60 
± 0.76 
46.58 
± 1.05 
44.93 
± 0.89 
46.08 
± 0.96 
43.85 
± 1.20 
44.12 
± 0.99 
Table 4.2: Descriptive results of the first experiment. Means ± SD. All values in ºC. Abbreviations: rTMS: 
repetitive transcranial magnetic stimulation. 
Experiment 2 
From 12 participants, 10 completed all study procedures. Two participants had to be excluded 
from the study, as they constantly reached the temperature safety limit of 50 °C pre-rTMS during 
HPT-testing. One participant’s HPT difference for the sham condition was identified as an 
outlier (net HTP change 15.17 C, ΔZ = 2.58) by using box plots and excluded from analysis. This 
reduced the total sample size for the repeated measures MANOVA to n = 9, because of case-
wise exclusion. Shapiro-Wilk tests indicated that all measures were potentially sampled from a 
Gaussian distribution and thus the assumption of normality was maintained. The repeated 
measures 2 x 3 MANOVA with the variables HPT, CPT, WT, CT, and within-subject factors 
Time (pre-rTMS versus post-rTMS) and Treatment (cerebellum versus neck versus sham) 
indicated a significant interaction between Treatment and Time (Wilk’s lambda = 0.265, 
F(8) = 3.059, p = .014). No significant main effects of Treatment or Time were found. This 
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suggested that temperature thresholds differed significantly in at least one mean vector pairing in 
one of the four measures. Mauchly’s test indicated that the assumption of sphericity had not been 
violated for any variable, still all results are reported applying Greenhouse-Geisser correction. 
Significant Time versus Treatment interactions were found for CT and HPT 
(Figures 3.1a and 3.1d), but not for WT or CPT (Figures 3.1b and 3.1c). There was a significant 
main effect of Time for WT (Figure 3.1b), and a near significant main effect of Time for CT and 
HPT. This suggests a general reduction in thermal sensitivity across all Treatment conditions, 
which is most likely a consequence of the repeated heat and cold pain measurements (Heldestad 
et al., 2010; Quiton & Greenspan, 2008). Descriptive results are given in Table 4.3. Planned 
comparisons for the Time x Treatment interactions between verum rTMS over the cerebellum 
and sham rTMS indicated no significant differences for WT or CPT and near significant 
differences for CT (n = 9, t = 1.93, p = .090). The increases in HPT (n = 9, t = 4.00, p = .004) 
were highly significant. Planned comparisons for the Time x Treatment interactions indicated no 
significant differences between rTMS over the cerebellum and rMS of the neck for CT, WT, 
CPT, or HPT, although the latter was nearly significant (n = 9, t = 2.84, p = .071). Planned 
comparisons for the Time x Treatment interactions between rMS of the neck and sham rTMS 
indicated no significant differences for WT and CPT, but for CT (n = 9, t = 2.82, p = .022) and 
HPT (n = 9, t = 3.53, p = .007). 
  
  
Figure 3.1a: Cold detection threshold (CT) before and after rTMS. There was a near significant main effect 
of Time F(1) = 4.70, partial η2 = 0.370, p = .062. The interaction between factors Time and Treatment was 
found significant: F(2; 1.62) = 4.65, partial η2 = 0.368, p = .036. 
Figure 3.1b: Warm detection threshold (WT) before and after rTMS. There was a significant main effect of 
Time F(1) = 5.40, partial η2 = 0.403, p = .049. 
Figure 3.1c: Cold pain threshold (CPT) before and after rTMS. There were no significant or near significant 
main effects or interactions. 
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Figure 3.1d: Heat pain threshold (HPT) before and after rTMS. There was a near significant main effect of 
Time F(1) = 3.73, partial η2 = 0.318, p = 0.089. The interaction between factors Time and Treatment was 
found significant F(2; 1.448) = 13.036, partial η2 = 0.620, p = .002. 
All means are displayed ± standard deviation. 
rTMS Cerebellum Neck Sham 
 Pre Post Pre Post Pre Post 
Cold detection 
thresholds 
31.15 
± 0.38 
30.90 
± 0.47 
31.10 
± 0.23 
30.77 
± 0.38 
30.95 
± 0.64 
31.06 
± 0.42 
Warmth detection 
thresholds 
32.88 
± 0.26 
33.10 
± 0.35 
32.93 
± 0.38 
33.15 
± 0.39 
33.14 
± 0.57 
33.18 
± 0.52 
Cold pain thresholds 17.09 
± 5.18 
16.28 
± 5.09 
16.79 
± 5.78 
17.62 
± 4.76 
15.58 
± 4.64 
15.66 
± 4.88 
Heat pain thresholds 42.58 
± 2.31 
44.21 
± 1.94 
42.61 
± 2.93 
43.54 
± 2.80 
44.11 
± 3.30 
43.31 
± 3.15 
Table 4.3: Descriptive results of the second experiment. Means ± SD, all values in ºC. Abbreviations: 
rTMS: repetitive transcranial magnetic stimulation. 
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Discussion 
This is the first study to examine the potential of rTMS over the cerebellum to modulate 
temperature and pain thresholds in humans. In two separate experiments, 1 Hz rTMS over the 
lateral cerebellum was consistently found to significantly increase HPT and to decrease CT by 
trend. However, main result of the study is that similar changes of CT and HPT occurred after 
the control condition, in which rMS was performed over the neck. Therefore, the observed 
effects of rTMS over the lateral cerebellum on thermal perception are most likely mediated via 
stimulation of peripheral structures and not via modulation of cerebellar activity. Though we 
cannot exclude a potential surplus effect of cerebellar rTMS over rMS of the neck on thermal 
sensation with the current sample size, our results suggest that such an effect might be smaller 
than the effect of magnetic stimulation of peripheral structures of the neck. 
The results of the current study indicate that the observed effects of rTMS over the cerebellum 
on thermal perception are rather mediated via stimulation of cervical muscles or afferents than 
via modulation of cerebellar activity. This is in accordance with studies on the effects of rMS of 
the neck, where 10 sessions of rMS of myofascial trigger points at the trapezius muscle resulted 
in pain relief outlasting the stimulation by several weeks (Smania et al., 2005). Also single sessions 
of rMS were shown to relief pain caused by localized musculoskeletal processes (Pujol et al., 
1998). The more pronounced analgesic effect of rMS as compared with transcutaneous electrical 
nerve stimulation (TENS) has been explained by the fact that magnetic stimulation achieves 
higher stimulation intensities than electrical stimulation without local patient discomfort (Smania 
et al., 2005). The higher stimulation intensities achieved with rMS result in stimulation induced 
rhythmic muscle contractions, which may trigger mechanisms similar to those underlying 
analgesia after isometric muscle contractions (Hoeger Bement, Dicapo, Rasiarmos, & Hunter, 
2008; Staud, Robinson, & Price, 2005). However, the exact peripheral mechanisms by which rMS 
of the neck and rTMS over the posterior skull modulate pain remain incompletely understood. 
Potential mechanisms of action include modulation of afferent fiber excitability, gate control 
mechanisms in dorsal horn and brainstem, counter irritation mechanisms similar to the ‘‘diffuse 
noxious inhibition controls’’ (DNIC), activation of the sympathetic nervous system, and central 
release of endogenous analgesic substances such as opioids, dopamine, or serotonin (Bragin, 
1986; Heldmann, Kerkhoff, Struppler, Havel, & Jahn, 2000; Melzack, 1999; Schlaier et al., 2007; 
Sluka & Walsh, 2003; Smania et al., 2005). Clarification of the underlying mechanisms will require 
further research. 
Nevertheless, the current pilot study provides additional evidence for a pain relieving effect of 
repetitive magnetic muscle stimulation, though replication in a larger sample is necessary before 
definite conclusions can be drawn. Several previous studies have found effects of TMS over the 
cerebellum using different stimulation protocols (Fierro et al., 2007; Fisher, Lai, Baker, & Baker, 
2009; Gironell et al., 2002; Koch et al., 2009; Langguth et al., 2008; Oliveri et al., 2009; Satow et 
al., 2002; Ugawa, Uesaka, Terao, Hanajima, & Kanazawa, 1994; Ugawa et al., 1995). Flat figure-
of-eight coils, as well as angled double-coned coils have been used in various orientations, with 
different stimulation intensities and at different locations. Just recently, (Ugawa, 2009) rightfully 
advocated a systematic reassessment of cerebellar stimulation thresholds to settle the inconsistent 
use of cerebellar stimulation protocols. 
The stimulation of superficial structures is well known as an important confounding factor in the 
investigation of rTMS (Mennemeier et al., 2009; Rossi et al., 2007). For rTMS over the 
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cerebellum, it has been shown that effects on cortico-spinal excitability are largely mediation via 
stimulation of peripheral structures such as muscles or afferent fibers (Gerschlager et al., 2002). 
These potent peripheral effects of rTMS at the posterior skull are further substantiated in the 
current study. 
A recent study also evidenced the risk of concomitant stimulation of deep brainstem structures 
with TMS over the cerebellum when using a double coned-coil (Fisher et al., 2009). However, the 
risk of concomitant stimulation of the brainstem or the dorsal columns seems negligible in the 
current study, as the magnetic pulse of a flat figure-of-eight Magstim coil as used in our study 
decays rapidly with increasing distance to the coil (Thielscher & Kammer, 2004). 
Our data further highlight, that results of rTMS studies in general may depend to a large extent 
on the adequate choice of the control condition. Being aware that all available control conditions 
have shortcomings, the best choice among the available options depends on the specific 
experimental context (Langguth et al., 2008). Along these lines, our results stress the importance 
to account for peripheral effects of rTMS, especially when the dependent variable is known to be 
influenced by somatosensory modulation. 
In conclusion, rTMS effects over the cerebellum did not differ significantly from those obtained 
by rMS over the lateral neck in the current study. A pain relieving effect via cerebellar modulation 
could not be demonstrated, yet these results are showing for the first time that rTMS over the 
neck can induce significant reductions in heat pain perception and non-noxious cold perception 
by recruiting peripheral mechanisms. With the given sample size, the current study can only serve 
as a pathfinder in the search for effects of cerebellar rTMS. Further studies will be needed to 
investigate to which extent the analgesic effect of muscle stimulation depends on stimulation 
parameters such as frequency, intensity, and localization. Relying on our results, we lastly argue 
for a critical examination of the proposed analgesic effects, which were reported for rTMS of 
various other cranial stimulation sites. Peripheral stimulation effects of rTMS might be 
underestimated in their impact on experimental, as well as clinical pain. 
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C O N C L U D I N G  D I S C U S S I O N  
On measuring pain 
The methods used to obtain information on pain perception for this dissertation stem from the 
domain of classic psychophysics. In the following section, an overview on available methods of 
pain measurement is provided, the challenges in studying pain are discussed, and potential future 
directions are presented. Finally, the pro and contra of the methods used for this dissertation are 
examined and the obtained results are summarized. 
Methods of measuring pain 
A multitude of attempts have been made to measure human pain. An overview of methods used 
in the past is provided in Table D.1 without claims of completeness. 
 
Domain Method Example reference 
Classic 
Psychophysics 
Thresholding: Method of constant stimuli (Strigo, Carli, & Bushnell, 2000) 
Thresholding: Method of limits (Rolke, Magerl, et al., 2006) 
Thresholding: Staircase method (Rolke, Magerl, et al., 2006) 
Thresholding: Method of adjustment (Horn, Blischke, Kunz, & Lautenbacher, 
2012) 
Descriptive scales (e.g. verbal, numeric or item 
based scales) 
(Melzack, 1975) 
Analog scales/cross-modality 
matching/magnitude estimation (e.g. visual 
analog scales, handgrip, finger-span) 
(Breivik, Björnsson, & Skovlund, 2000; 
Gracely, McGrath, & Dubner 1978) 
Modern 
Psychophysics  
Signal-detection theory designs (based on 
two-alternative or two interval forced choice 
tasks) 
(Lloyd & Appel, 1976) 
Behavioral Facial expressions (Prkachin, 2009) 
 Vocalization (infants only) (Mijović et al., 2010) 
 Observation of general behavior (e.g. activity, 
sleep, medication intake) 
(Keefe, Bradley, & Crisson, 1990) 
Physiological Microneurography (i.e. in-vivo afferent nerve 
recordings of peripheral nerves) 
(Mano, Iwase, & Toma, 2006) 
Reflex myography (e.g. Nociceptive flexion 
reflex, Eyeblink reflex) 
(Skljarevski & Ramadan, 2002; Holle et 
al., 2011) 
Electroencephalography (e.g. laser evoked 
potentials, contact heat evoked potentials, 
gamma band oscillations) 
(Handwerker & Kobal, 1993; Greffrath, 
Baumgärtner, & Treede, 2007) 
Pupillary dilation (Ellermeier & Westphal, 1995) 
Heart rate variability (as a measure of 
autonomic nervous system activity) 
(Tousignant-Laflamme, Rainville, & 
Marchand, 2005; Loggia, Juneau, & 
Bushnell, 2011) 
Galvanic skin response (as a measure of 
autonomic nervous system activity) 
(Loggia et al., 2011) 
Neuroimaging Functional magnetic resonance imaging 
(fMRI), positron emission tomography (PET), 
single photon emission computed 
tomography (SPECT) 
(Apkarian, Bushnell, Treede, & Zubieta, 
2005) 
Table D.1: Measures in human pain research. 
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Most of the methods listed in Table D.1 can only be used in combination with experimental pain 
stimulation; an overview on experimental methods of pain induction used in the past is given in 
Table D.2, again, without claims of completeness. 
 
Stimulus type Stimulus Example reference 
Heat Hot plate (Rolke, Magerl, et al., 2006) 
 Hot water bath (Verne, Himes, et al., 2003) 
 Hot light bulb (“Hardy-Wolff-Goodell 
Dolorimeter”) 
(Tousignant, 2011) 
 Laser (Bornhövd et al., 2002) 
Cold Cold plate (Rolke, Magerl, et al., 2006) 
 Water bath (“Cold pressor”) (Lovallo, 1975) 
 Thermal-grill illusion (Boettger, Schwier, & Bär, 2011) 
Mechanical Sharp force (Rolke, Magerl, et al., 2006) 
 Blunt force (e.g. on the nail bed) (Göbel, Heller, Nowak, & Westphal, 
1988; Woollard & Carmichael, 1933) 
 Incision pain (Reitz et al., 2012) 
 
 
Distension devices in gastrointestinal tract 
(esophageal/colonic/rectal distension) 
(Paine, Kishor, Worthen, Gregory, & 
Aziz, 2009; Verne, Robinson, Vase, & 
Price, 2003) 
Other Ischemia (cuff around arm) (Fillingim et al., 1997) 
 Capsaicin (paste, injection) (Tamura et al., 2004) 
 Ascorbic acid (Favilla et al., 2014) 
 Muscle pain (exercise induced, hypertonic 
saline injections) 
(Dannecker, Price, O’Connor, & 
Robinson, 2008; Owen, Clarke, 
Ganapathy, Prato, & St Lawrence, 
2010) 
 Electric shock (Rhudy, Williams, McCabe, Rambo, & 
Russell, 2006) 
Table D.2: Methods of experimental pain stimulation in human research. 
Difficulties in measuring pain 
How to measure pain? Despite all past efforts, this still is a central question of pain research and 
the field of psychophysics. All measures listed in Table D.1 can yield valuable information on 
pain-related processes. However, no single method has been established as a generally accepted, 
unbiased measure of perceived pain so far. All methods in Table D.1 are limited in the scope of 
application, reliability and validity. The shortcomings of the available pain measurements are 
based on a number of basic problems complicating the study of pain: 
• Problem 1.) Pain is still defined as a psychological, subjective phenomenon (International 
Association for the Study of Pain, 2002, p. 210). There currently is no objective criterion to 
determine if a given stimulus is perceived as painful with certainty. A participant’s rating of a 
stimulus as “painful” or “not painful” cannot be verified as “correct” and “incorrect”. 
Participants’ responses have to be relied on. 
Consequently, pain is mostly studied in so called “Type 2-experiments” and “appearance” 
rather than “performance” tasks, according to the classification of psychophysiological 
experiments by Kingdom & Prins (2010), pp. 18–24.3 
 
                                                
3 Signal detection theory designs have been suggested to circumvent Problem 1 in the past (Coppola & 
Gracely, 1983; Handwerker & Kobal, 1993), however this view has been challenged (see: Rollman, 1977). 
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• Problem 2.) Stimulus-related pain exists in a continuum with other somatosensory domains. 
For example low-dose heat, electric shocks, or capsaicin are perceived as warm, tingling, or 
itching before becoming painful with higher doses. To my knowledge there is no 
experimental method of pain induction where sub-threshold stimulation is not accompanied 
by any sensation (see: Table D.2). Therefore, non-nociceptive somatosensory perception has 
to be considered as a confounding factor. 
• Problem 3.) Response bias (see: Furnham, 1986) may affect any self-report measures of pain: 
Expectations, motivations, and the social context associated with an experiment (e.g. see: 
Aslaksen, Myrbakk, Høifødt, & Flaten, 2007) may all falsify participants’ responses in pain 
measurements. Nevertheless, these factors might also have a genuine influence on the 
perception of pain (for review see: Wiech, & Tracey, 2013). A notable example is the placebo 
effect; an expectation, which might both bias pain measurements (i.e. alter the nature of the 
measurement, causing a “deviation from the truth”, Hróbjartsson, Kaptchuk, & Miller, 2011) 
and influence the experience of pain (Wiech, & Tracey, 2013). 
• Problem 4.) Both habituation and sensitization may occur with prolonged or repeated pain 
stimulation; these effects can be peripherally and/or centrally mediated and add systematic 
variance to pain measurements (Breimhorst, Hondrich, Rebhorn, May, & Birklein, 2012; 
Vierck, Cannon, Fry, Maixner, & Whitsel, 1997; Werner, Lassen, Pedersen, & Kehlet, 2002). 
• Problem 5.) Ethical conduct in pain research is of primary importance. Restrictions apply 
(International Association for the Study of Pain, 2014) in addition to the standards of ethical 
conduct in human research (59th WMA General Assembly, 2009): For example the quality 
and duration of pain endured in research settings must be limited. 
Fortunately, an appropriate study design can compensate for the inevitable shortcomings of pain 
measures and problems listed above. Proper study design is the key feature of scientific 
experiments and the prerequisite for a meaningful interpretation of results. Three basic features 
(e.g. see: Ruxton & Colegrave, 2011) of experiments that help to make valid inferences are: 
• Blinding and control conditions 
• Random allocation of participants to the studied conditions 
• Replications of measurements within a representative and sufficient sample size 
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Discussion of methods and study designs used 
Study design: blinding and control conditions 
In Study 1 a double-blind, placebo controlled crossover design was used; participants received 
oxytocin at one study visit and a placebo at another. Neither the participants nor the 
experimenters knew the order in which the medication was given during testing. The double-
blind placebo design is the gold standard of experimental control; it effectively minimizes both 
experimenter bias and participant response bias (Ruxton & Colegrave, 2011). Crossover designs 
are superior in statistical power compared to parallel-group designs since every participant acts as 
his or her own control, greatly reducing random between-participant variability (Ruxton & 
Colegrave, 2011). The absence of carryover effects was assumed for Study 1, based on the 
known pharmacokinetics of oxytocin and the choice of an appropriate wash-out phase of ≥ 7 
days between study visits. Known sensitization and desensitization effects of repeated thermal 
stimulation were reduced by employing a training session and pre-conditioning stimuli (Quiton & 
Greenspan, 2008). 
Study 2 was not an experimental study, but a questionnaire survey. A “quasi-experimental” 
longitudinal design (for review see: Fife-Schaw, 2012) was employed to examine the effects of an 
exam period in university students. Again, participants acted as their own control. Two baseline 
measures were obtained as a control condition, one before and one after the exam period 
measurement. The choice of two baselines excluded that simple time effects explained the results. 
Further, control variables, such as perceived stress and current infections/injuries, were assessed 
to confirm that exam period was an effective psychosocial stressor and to rule out alternative 
explanations. Quasi-experimental study designs are often applied when “natural” treatments, 
interventions, or conditions cannot be controlled experimentally for practical or ethical purposes 
(Fife-Schaw, 2012). Effects of conditions can be observed under more “realistic” circumstances 
and thus entail higher external validity than in strictly controlled experimental settings (Fife-
Schaw, 2012). However, quasi-experimental approaches are less capable in controlling for the 
confounding effects of third variables (Fife-Schaw, 2012), which is a considerable threat to the 
internal validity of the results. A specific threat to the internal validity of the effects observed in 
Study 2 is that no blinding could be applied due to the longitudinal design. Therefore 
experimenter bias and participant response bias cannot be excluded, which considerably limits 
the interpretation of results. 
The choice of a valid placebo (also: sham) condition for behavioral (Study 3) and 
electrophysiological (Study 4) interventions is challenging. The nature of the verum- and 
placebo-conditions is difficult to conceal from participants and even more difficult to conceal 
from experimenters. Studies 3 and 4 both had single-blind crossover design, since it was not 
feasible to achieve double-blind conditions, e.g. by using different experimenters for treatment 
application and outcome measurement. 
Single-blind designs largely exclude participant response bias, but are susceptible to experimenter 
bias (Ruxton & Colegrave, 2011), which therefore cannot be excluded for Studies 3 and 4. To 
achieve blinding of participants for Study 3, no information was given about the explicit 
hypotheses before debriefing. A design with four different paced breathing conditions was 
chosen, in which the hypothesized effect was expected to show a non-linearly relationship with 
heart-rate variability. Since breathing frequency was the only discernible difference between 
sessions, and the range of breathing frequencies were not known a-priori, the explicit hypotheses 
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were hard to guess. To achieve blinding of participants in Study 4 a sham stimulation condition 
and an ectopic verum stimulation condition were used. Again, participants were not informed 
about the hypothesized effects of the different conditions before debriefing. 
Again, Studies 3 and 4 had designs with repeated visits, treatments, and measurements within 
participants. In both studies a wash-out phase of ≥ 7 days was observed to minimize carry-over 
effects of breathing exercises or rTMS from one study visit to the other. However, no training 
visit was used in the two studies. Therefore sensitization and desensitization effects (Quiton & 
Greenspan, 2008) may have added to the random variability within the data.  
Study design: randomization 
For Studies 1, 3, and 4 participants were randomly allocated to the treatment sequence. 
Treatment order was strictly balanced across participants to exclude a systematic impact of 
habituation, sensitization, or other time effects on the results. For Study 2, a random assignment 
to academic exams was not possible, of course—thus the quasi-experimental design. 
Study design: choice of sample  
Regarding the nature of replications, all four studies investigated pain in student samples: In 
Studies 1, 3, and 4 healthy students were tested. In Study 2 a naturalistic student sample was 
obtained. Therefore, all four studies suffer from a shortcoming in external validity that is 
common to the field of pain research: The results obtained might not generalize to the general 
population or sufferers of chronic pain. However, the use of “unnatural” model situations in pain 
research has two good reasons: First, studies on pain models are more resource efficient than 
trials in patient populations. Second, a basic understanding of the mechanisms in health is 
necessary to allow an understanding of the highly diverse mechanisms of pathological pain. The 
dilemma of bridging-the-gap between experimental pain research and clinical application can only 
be solved by developing refined methods, by translational research approaches, and by replication 
of findings. Additionally, the sample of Study 1 was restricted to male participants, since the 
effects of oxytocin are likely to be sex-specific (Theodoridou, Penton-Voak, & Rowe, 2013). Any 
conclusions drawn from Study 1 are therefore limited to the male population. 
Study design: replications 
A sufficient sample size allows generalizing findings to the population and to detect an existing 
effect with an acceptable probability. But how many replications have to be chosen for a sample 
size to be sufficient? The answer depends on several factors: E.g. the actual size of the effect in 
question, potential interaction effects, the reliability of the measurement, the natural variability 
within the sample, as well as the information available a-priori. 
The sample size of Study 1 was chosen based on a power-analysis for heat an cold pain 
thresholds: The smallest important absolute effect size of oxytocin compared to placebo was 
defined as +0.5 °C for heat and -1.5 °C for cold pain thresholds, as this approximates 50 % of 
the effect of a low dose (10 mg) of intravenous morphine (Pavlakovic, Tigges, & Crozier, 2009). 
Standard deviations and test-retest correlations for heat pain thresholds (SD = 1.42 °C, r = 0.88) 
and cold pain thresholds (SD = 7.44°C, r = 0.91) were estimated based on the results of 18 male 
participants from Studies 3 and 4. For a paired two-tailed t-test4 with a Bonferroni-corrected α-
error probability αBonf < .05 and a desired power (β-error probability) β > .80, a minimal sample 
                                                
4 The statistical models were simplified for the purposes of the power calculation. The general linear 
(mixed) model used for analysis was assumed to entail more power to detect an effect. 
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size of 21 (heat pain threshold) and 44 (cold pain threshold) participants was estimated. A sample 
size of 36 was chosen as a compromise between the two values. In regard to the fMRI measures 
and pain rating procedures such power calculations were not conducted due to the lack of a-
priori data. 
For Study 2 the sample size of 150 participants was based on the following calculation: For the 
SOMS-7d a re-test reliability of r = .76 and a population mean of 6.25 ± 8.65 points of the 
Symptom Index has been reported (Hiller, Rief, & Brähler, 2006; Rief & Hiller, 2008). A paired 
two-tailed t-test1 at an α-error probability α < .05 would require a sample size of 128, to detect a 
change of 1.5 points in the Symptom Index with a power of β > .80. This minimum sample size 
was rounded to 150 participants to account for the expected dropout rate. 
No a-priori sample size calculations were performed for Study 3, which certainly is a limitation. 
The aim was to achieve a statistical power comparable to the study generating the study 
hypothesis (Chalaye, Goffaux, Lafrenaye, & Marchand, 2009). 
For Study 4, no estimations of power were made due to the nature of the study: Two separate 
experiments were performed; the first identified potential hypotheses, while the second aimed to 
test and verify the hypotheses. Retrospectively, Type-II errors are a minor concern in Study 4, 
since effects of stimulation were found for most measures. 
Methods of psychophysics: thresholding 
Thresholding procedures according to the “method of limits” were used in Studies 1, 3, and 4 
to infer on pain perception: Slowly decreasing and increasing temperatures were applied to the 
skin by using an electrically heated/cooled plate (“thermode”). Participants were instructed to 
press a button when the temperature reached the heat or cold pain threshold. 
These thresholding procedures are fast, efficient, reliable, and established in the field (Rolke, 
Baron, et al., 2006). The automated, computerized execution of the protocol, the standardized, 
scripted definition of thresholds, and other precautions make the technique an acceptably 
objective measurement. Nevertheless, the procedure has shortcomings: First, thresholding cannot 
discern between changes in pain perception, pain appraisal, response criterion (i.e. the individual, 
internal definition of the pain threshold), and response speed. These confounding factors can 
only be compensated by appropriate experimental design, e.g. by blinding participants to the 
studied conditions (see above). Second, thresholding measures can be confounded by changes in 
non-nociceptive somatosensation, since the stimulus shifts from the non-nociceptive to the 
nociceptive range (see: Problem 2). Therefore, non-nociceptive warmth and cold detection 
thresholds always were assessed in parallel, as a control. Third, pain thresholding according to the 
method of limits involve transient and low pain intensities only, which reduces the face-validity 
of the measure. Moreover the low intensities might reduce the reliability of the measurement, 
since Quiton & Greenspan (2008) showed that higher pain intensities are judged more reliably 
within- and between-individuals. 
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Methods of psychophysics: visual analog scale ratings 
To account for the last-mentioned shortcoming of the thresholding procedure, Studies 1 and 3 
additionally included a pain-rating procedure: The VAS is an established and time-efficient 
method for obtaining ratings of perceived experimental and clinical pain (Breivik, Björnsson, & 
Skovlund, 2000; Quiton & Greenspan, 2008; Rosier, Iadarola, & Coghill, 2002). In 
Studies 1 and 3 participants were asked to rate tonic heat stimuli of 14 s duration on such a 
VAS. Although the VAS rating procedure shares almost all advantages and disadvantages of the 
thresholding procedure, considerably higher stimulation intensities could be used, which might 
have reduced variability and increased validity of the measurement (Quiton & Greenspan, 2008).  
Methods: self-assessment questionnaires 
Study 2 is the only study of this dissertation that investigated pain in its naturalistic form. A 
questionnaire was used to obtain self-report measures of pain and other bodily symptoms. The 
Screening for Somatoform Symptoms 7-day version (SOMS 7d) is not a classic pain scale, but 
was developed as a measure of somatization (Rief & Hiller, 2008). Nevertheless, the SOMS 7d 
includes the most common idiopathic forms of pain (headache, backache, intestinal pain, joint 
pain) and surveys a number of typical bodily symptoms occurring under stress. Furthermore, it is 
well established according to the quality criteria of test theory (Rief & Hiller, 2008). 
Questionnaires are a fast and efficient way to obtain detailed population estimates of disease 
prevalence and to identify potential causes. However, like all self-descriptions, questionnaires are 
highly susceptible to response bias (see: Furnham, 1986). 
Methods: functional magnetic resonance imaging (fMRI) 
Positron emission tomography (PET, e.g. Talbot et al., 1991), single photon emission computed 
tomography (SPECT, e.g. Krabbe, Henriksen, & Olesen, 1984), and functional magnetic 
resonance imaging (fMRI, e.g. Davis, Wood, Crawley, & Mikulis, 1995) have been adopted for 
the study of pain early after the advent of modern neuroimaging. Hundreds of neuroimaging 
experiments have since then been conducted to study various aspects of human pain (for review 
see: Duerden & Albanese, 2013). Like Study 1, many studies used fMRI, in combination with the 
analysis approach “statistical parametric mapping” (SPM, Friston et al., 1995). With fMRI and 
SPM, the cerebral correlates of human pain could successfully be identified (for review see: 
Apkarian, Bushnell, Treede, & Zubieta, 2005; Duerden & Albanese, 2013). Especially the insula, 
SI, SII, and the anterior cingulate cortex, have repeatedly been confirmed as correlates of human 
pain processing (Apkarian, Bushnell, Treede, & Zubieta, 2005; Duerden & Albanese, 2013). 
However, a number of limitations apply to these techniques: 
• Limitation a) The blood oxygenation level dependent (BOLD) signal measured by fMRI is a 
unitless metabolic correlate of neuronal mass activity (Logothetis, 2008). Its ability to qualify 
and quantify cerebral processes is constrained: 
The fMRI signal cannot easily differentiate between function-specific processing and 
neuromodulation, between bottom-up and top-down signals, and between excitation and 
inhibition. Moreover the magnitude of the fMRI signal is no accurate estimate of activity 
differences between brain regions, or even between different tasks within the same 
region. (Logothetis, 2008) 
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• Limitation b) The low signal-to-noise-ratio of fMRI leads to a low reliability and a high 
statistical uncertainty (Smith et al., 2005). This problem is aggravated by the fact that fMRI 
studies are costly and therefore their sample size is usually limited. Consequently, the regions 
found to be associated with pain vary considerably between fMRI studies of pain, despite 
similar experimental designs (Apkarian et al., 2005; Duerden & Albanese, 2013) 
• Limitation c) SPM involves the calculation of more than 100,000 regressions for a whole 
brain analysis. However, there is no generally accepted standard procedure to correct for 
multiple comparisons in SPM (compare: Vul, Harris, Winkielman, & Pashler, 2009 and 
Lieberman & Cunningham, 2009). 
• Limitation d) “The brain is never inactive” (Balduzzi, Riedner, & Tononi, 2008), therefore 
there is no „zero“ baseline condition in fMRI. Simple comparisons with an alleged 
“baseline”-activity, or deficient control condition, can easily lead to confounded results. As an 
example, many studies in pain research used subtractive designs with categorical predictors in 
the past, i.e. they simply compared painful stimulus conditions and with no stimulation 
(Duerden & Albanese, 2013). Non-nociceptive somatosensory processing almost certainly 
confounds such results (Tseng et al., 2009). 
The problem of selecting an adequate baseline conditions is part of a general problem in fMRI 
analysis: Inferences regarding the effects of a stimulation condition on brain activity are based on 
the assumption of “pure insertion”, i.e. that the stimulation condition of interest “inserts” only a 
single additional process compared to the baseline condition and that this additional process does 
not interact with other processes (Friston et al., 1996). However, this assumption has been 
identified as flawed from early on (Friston et al., 1996). One method to relax the assumption of 
pure insertion is the use of a parametric fMRI design (Büchel, Holmes, Rees, & Friston, 1998): In 
parametric fMRI designs, scalar, instead of categorial predictors are used to model the cerebral 
process in question. E.g. temperature intensities or rated pain intensities are employed as linear 
(or higher order) predictors of BOLD signal, instead of simply using a categorical predictor. The 
potential for contamination by nuisance processes is therefore reduced. Consequently, parametric 
designs have successfully been applied to discriminate between perceived pain processing and 
accompanying non-nociceptive processes (Büchel et al., 2002). 
Aim of the fMRI experiment in Study 1 was to test effects of intranasal oxytocin on cerebral heat 
pain processing. A parametric fMRI design was employed to address the issues mentioned above. 
Stimulus temperature was used as a linear predictor for brain activity related to noxious 
temperature processing. As a result, our approach could identify most canonical candidate 
regions of the pain matrix—despite using the conservative family-wise-error (FWE) correction 
for multiple comparisons. The VAS-intensity and -unpleasantness ratings acquired during fMRI 
indicated that the applied stimulus conditions had the desired effect. Further, by using the 
parametric design, the effects of oxytocin on temperature-related activity could be tested 
separately from oxytocin effects on stimulation-related activity. Nevertheless, no effect of 
oxytocin could be found in whole-brain analysis at a FWE corrected statistical threshold, 
although behavioral effects of oxytocin were found for the VAS-intensity ratings. 
A region of interest (ROI) analysis was the second type of fMRI analysis used in Study 1 
(Poldrack, 2007): In ROI analysis certain brain regions are pre-selected and treated as functional 
units. The BOLD-signal is estimated for the ROI as a whole, instead of making inferences on 
every single voxel separately. The ROI approach therefore reduces the multiple comparisons 
problem and greatly improves statistical power (Poldrack, 2007). Further, by applying a finite 
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impulse response (FIR) model (Ollinger, Shulman, & Corbetta, 2001), a ROI analysis allows to 
evaluate the time-course of the BOLD signal after stimulus presentation. Note that the selection 
of ROIs has to be performed independently from any paralleling whole-brain analysis; otherwise 
the rate of false-positive results is dramatically inflated (Vul, Harris, Winkielman, & Pashler, 
2009). The ROI analysis in Study 1 was used to test a-priori hypotheses regarding the effect of 
oxytocin on amygdala activity. Anatomic tissue probability maps were used to define the ROIs, 
independently from whole-brain analysis. With this approach, main effects of oxytocin could be 
found within the amygdala. 
Methods: outlook 
While the studies of this dissertation were being conducted, new methods were developed, which 
might solve some limitations of pain measurements listed above: 
The combined use of skin conductance and pupil dilation measures has recently been proposed 
as a reliable measure of pain (Geuter, Gamer, Onat, & Büchel, 2014). Although these findings 
have to be replicated independently, such a procedure may pose a resource-efficient alternative to 
neuroimaging experiments. 
As mentioned, the BOLD signal is no absolute measurement of cerebral blood flow. The 
obtained signal depends on sources of inter- and intra-individual physiological variance, such as 
cerebral blood flow, cerebral blood volume, tissue specific features, cardiac noise, and acquisition 
variance, such as scanner noise and field inhomogeneity (Bulte et al., 2012; Logothetis, 2008; 
Smith et al., 2005). Therefore, cerebral blood oxygenation in traditional fMRI can only be 
measured reliably in terms of relative, within-subject contrasts for stimulation conditions that 
vary within a session (Tracey & Johns, 2010). Conditions that cannot easily be manipulated 
within a session, such as chronic and recurrent pain, cannot be effectively studied with traditional 
fMRI. Two new techniques have recently been proposed to overcome this limitation: Arterial 
spin labeling (ASL) is a direct and quantitative measure of blood flow (Tracey & Johns, 2010) and 
might be useful to study chronic recurrent pain. Another new technique presented recently is 
respiratory calibrated fMRI (Bulte et al., 2012). Here, breathing gas concentrations are 
manipulated in a calibration scan to allow an absolute estimate of blood oxygenation levels. 
Further, new development in neuroimaging analysis might solve shortcomings of the SPM 
approach and advance neuroimaging towards becoming an objective measure of pain. Four 
variants of machine learning have been proposed to allow for a reliably prediction and/or 
quantification of perceived pain: “Gaussian process” modeling (Marquand et al., 2010), “support 
vector machine” modeling (Brodersen et al., 2012; Brown, Chatterjee, Younger, & Mackey, 
2011), “ν-method” modeling (Prato, Favilla, Zanni, Porro, & Baraldi, 2011), and “least absolute 
shrinkage and selection operator-regularized principal components regression” (LASSO-PCR, 
Wager et al., 2013). All of these techniques first estimate the spatio-temporal pattern of activity 
exhibited in fMRI volumes in response to an experimental condition (e.g. pain vs. no-pain) or a 
regressor (e.g. pain ratings) from a “training” dataset. The trained patterns are then used to 
classify (and/or quantify) activity within a second set of neuroimaging data as (more or less) 
painful. In contrast to the classical SPM techniques, which compute the relationship between 
conditions/regressors and fMRI signal for each brain-voxel separately, the patterns of machine 
learning are multi-dimensional, combining spatial and temporal patterns. The future will show the 
impact of these methods on pain research and clinical practice. It is worth noting that the data 
obtained in Study 1 might be suitable for an analysis with one of these strategies. 
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Discussion of results and outlook  
Study 1: The effects of intranasal oxytocin on pain perception and processing in 
healthy male—a randomized trial 
For Study 1, an effective sample size of 30 was obtained; the study was therefore considerably 
larger than almost all previous studies investigating experimental heat pain with fMRI (see: 
Duerden & Albanese, 2013). Study 1 could provide first evidence that intranasal oxytocin 
modulates ratings of heat intensity and amygdala activity in response to heat stimuli. However, 
the effects were independent of temperature (i.e. pain stimulus intensity) and therefore could not 
support the hypotheses that intranasal oxytocin has a specific effect on pain processing (Rash, 
Aguirre-Camacho, & Campbell, 2013). The observed effects might reflect changes in anxiety 
and/or reward sensitivity as suggested by Bethlehem, Baron-Cohen, van Honk, Auyeung, & Bos 
(2014), or an enhanced placebo responses as shown by Kessner, Sprenger, Wrobel, Wiech, & 
Bingel (2013). The mechanisms by which oxytocin modulates thermal stimulus processing, as 
well as the relevance of this modulatory effect for clinical applications, must be assessed in future 
studies. In particular, a repetition of the present study with a female sample is desirable, since the 
effects of oxytocin might be sex-specific (Theodoridou, Penton-Voak, & Rowe, 2013). 
There are several future directions for Study 1: A second fMRI experiment testing the effects of 
oxytocin on emotional modulation of pain (Rhudy, Williams, McCabe, Nguyen, & Rambo, 2005) 
was conducted in parallel to Study 1 and its results are currently under review. As mentioned 
above, another future direction of Study 1 is the re-analysis of the dataset with machine learning 
techniques (Marquand et al., 2010; Wager et al., 2013). These analyses might have an improved 
statistical power to detect effects of oxytocin. In addition, a side-project of Study 1 is waiting for 
analysis: Within a month of the last experimental session, participants were asked to recognize 
the pictures shown during the emotional modulation experiment amongst other distracting 
images. These data could shed light on the effects of oxytocin on emotional memory processes. 
Study 2: Somatic symptoms evoked by exam stress in university students: the role 
of alexithymia, neuroticism, anxiety, and depression. 
In Study 2, 150 university students provided a detailed, quantitative symptom-by-symptom 
description of their bodily reactions during a period of academic exam stress. Symptoms of pain 
were amongst the items showing the strongest increases. All control variables indicated that the 
observed symptoms were due to exam stress, rather than time effects, acute infections, or 
injuries. Moreover neuroticism could be identified as a significant explanatory personality trait for 
symptom increases under exam stress. No such relationship could be found for trait anxiety, trait 
depression, or alexithymia. The descriptive and quantitative results of Study 2 may help to 
establish academic exam stress as a model of psychosocial stress in the field of pain research; 
complementary to models of experimental stress induction (Kirschbaum, Pirke, & Hellhammer, 
1993) or diary studies (Bolger & Zuckerman, 1995). 
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In parallel to Study 2, data were retrieved to describe the effects of exam stress on sleep reports 
and drug-related behavior. This parallel study has been analyzed and is currently being revised 
after a first submission (Zunhammer, Eichhammer, & Busch, submitted for publication). 
Further, a follow-up to Study 2 is currently being conducted, which aims to disentangle the 
relative contributions of reporting behavior and actual symptom occurrence under exam stress 
using different participant instructions. 
Study 3: Do cardiorespiratory variables predict the antinociceptive effects of deep 
and slow breathing? 
Study 3 could not confirm the main hypotheses tested: Breathing exercises had no effect on pain 
perception, neither via breathing frequency, nor via cardiac parasympathetic activity, nor via 
hyperventilation. Nevertheless, baseline and within-session associations of pain perception and 
heart rate could be found. Study 3 therefore successfully replicated the finding that experimental 
pain perception is linked to ANS activity (Appelhans & Luecken, 2008), but could not elucidate 
the modulatory effects or mechanisms of breathing exercises. 
The results of Study 3 highlight an underrated limitation of heart rate variability (HRV) 
measurements, when used as a tool to infer on ANS activity: Breathing frequency is one of the 
strongest determinants of heart rate variability. Although this fact has been acknowledged since 
long (Hirsch & Bishop, 1981; Pinna, Maestri, La Rovere, Gobbi, & Fanfulla, 2006), the relevance 
of breathing induced changes in HRV for parasympathetic tone in general, and the 
psychophysiological consequences in particular, are a matter of debate (Grossman & Kollai, 
1993; Hirsch & Bishop, 1981; Kollai & Mizsei, 1990). Breathing induced changes in HRV might 
reflect peripheral, rather than central modulations of ANS activity and be irrelevant for the 
proposed antinociceptive effects of breathing exercises (Martin et al., 2012). In the light of the 
present results, the study by Chalaye et al. (2009) that contributed the main hypotheses might 
have been confounded by the lack of adequate control conditions and an incomplete 
randomization of treatment sequences. Study 3 demonstrates that the choice of proper control 
conditions in behavioral and alternative pain treatments is difficult, yet of central importance. No 
follow-up experiments or analyses on Study 3 are currently being planned. 
Study 4: rTMS over the cerebellum modulates temperature detection and pain 
thresholds through peripheral mechanisms 
Similar conclusions can be drawn from Study 4, which investigated the effects of cerebellar 
rTMS on pain perception: A first exploratory experiment identified 1Hz rTMS over the lateral 
cerebellum as an effective method of pain modulation. However, a second experiment including 
additional control conditions identified an important alternative explanation for the observed 
effects: Repetitive magnetic stimulation (rMS) of peripheral neck had similar effects as cerebellar 
rTMS. Two interpretations can be drawn from this result: a) the sham rTMS simulation currently 
used in TMS research is insufficient, especially since it does not simulate the obvious, unpleasant 
side effects of verum TMS, such as muscle twitches and pinching sensations. b) rMS stimulation 
of peripheral tissues might affect pain perception via peripheral pathways. 
In the meantime Albu et al., 2013 followed up Study 4 by testing local and distal effects of 1 Hz 
rMS over the neck. They replicated the effects of rMS on non-nociceptive thresholds, while 
effects on nociceptive thresholds were only apparent by trend. Furthermore our study has been 
cited in two reviews articles (Mylius, Borckardt, & Lefaucheur, 2012; Tomlinson, Davis, & 
Bracewell, 2013). No follow-up experiments or analyses on Study 4 are currently being planned. 
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